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Cancer is one of the major killers of human. Delivery systems for anti-cancer 
drugs and imaging agents play important roles in cancer treatment and 
diagnosis. For development of safe and efficient delivery systems, stimuli-
responsive polymers which undergo significant physical or chemical 
properties change in response to environmental variations including redox-
responsive polymers are becoming more and more important. Exploring the 
much more reductive environment in intracellular compartments compared to 
extracellular matrixes, redox-responsive polymers are promising to provide 
high efficacy with low side effects of drugs and imaging agents delivered. In 
this thesis, a category of redox-responsive poly(amido amine)s is developed 
with the following works being carried out.   
 An optimized condition is identified to prepare linear poly(amido amine)s 
via Michael Addition polymerization of trifunctional amine, 4-
(aminomethyl)piperidine (AMPD), with an equimolar diacrylamide, N,N-
cystaminebisacrylamide (BAC). Poly(ethylene glycol) (PEG) and 
cholesterol (CE) are conjugated to linear poly(BAC-AMPD) through the 
reactions with the 2
o
 amino groups in the backbone, respectively, to form 
poly(BAC-AMPD)-g-PEG-g-CE. Micelles with PEG shells and 
hydrophobic cores composed of poly(BAC-AMPD) and CE are formed via 
self-assembly of poly(BAC-AMPD)-g-PEG-g-CE in aqueous solution. 
The anti-cancer drug, doxorubicin (DOX), is loaded into the micelles, and 
DOX loaded micelles can deliver DOX into the cells and show a higher 





 Vinyl-terminated hyperbranched poly(BAC2-AMPD1) were produced by 
reacting AMPD with double molar of BAC under optimized condition. 
Under directed self-assembly, the PEGylated hyperbranched poly(BAC2-
AMPD1) were capable of forming micelles and encapsulating DOX with a 
higher capacity and efficiency than the micelles of poly(BAC-AMPD)-g-
PEG-g-CE. However, its capability to kill cancer cells is slightly poorer or 
comparable to free DOX-HCl. 
 Polydisulfide MRI contrast agent was obtained by grafting 
diethylenetriaminepentaacetic (DTPA) to disulfide containing poly(amido 
amine)s-g-poly(ethylene glycol) (PEG) and followed by complexation 
with Gd(III) ions. MRI contrast agent obtained could self-assemble in 
aqueous solution, forming nanosize micelles with PEG shells and ionic 
complex cores. Readily redox-induced degradable profiles were observed. 
Together with a low cytotoxicity and a high r1 value, poly(BAC-AMPD)-
g-PEG-g-Gd-DTPA is promising to provide better MRI imaging with 
lower side effects. 
 Redox-responsive nanoparticles with aggregation-induced emission (AIE) 
characteristic for fluorescence imaging were developed by encapsulation 
of fluorophore with  redox- “turn-on” AIE characteristic, TPE-MI, into the 
micelles of poly(ethylene glycol) (PEG)- and cholesterol (CE)-conjugated 
disulfide containing poly(amido amine)s. The redox-responsive 
fluorescence profiles of the nanoparticles were investigated after reaction 
with glutathione (GSH). The encapsulation of TPE-MI in micelles led to a 
higher efficiency and red shift in emission, and the fluorescence intensity 





microscopy imaging showed that the nanoparticles could provide obvious 
contrast between the intracellular compartments and the extracellular 
matrix in MCF-7 and HepG2 cells. Therefore, the nanoparticles with PEG 
shells and low cytotoxicity are promising to provide fluorescence 
bioimaging with a high contrast and for differentiation of cellular redox 
environment. 
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1.1. Cancer treatment and diagnosis 
Cancer is a disease in which cells do not undergo programmed cell death, 
apoptosis, and divide uncontrollably to form malignant tumors according to 
the definition from National Cancer Institute (NCI) and American Cancer 
Society (ACS). It is stated in “The History of Cancer” published by ACS that 
cancer was observed as early as 3000 B.C, but , the main causes of cancer are 
identified only until the 20
th
 century,  i.e., chemicals, radiation, viruses and 
genetics. The World Cancer Report 2014 by The International Agency for 
Research on Cancer (IARC), the specialized cancer agency of the World 
Health Organization (WHO), states that there were 14 and 8.2 million of new 
cancer cases and cancer death per year in 2012, respectively, this set of values 
are predicted to rise to 22 and 13 million in the next 20 years. It was also 
indicated that the total annual economic cost of cancer was estimated to be 
approximately US$1.16 trillion in 2010. Furthermore, cancer has overtaken 
heart disease as the number one cause of death globally. Therefore, it is 
motivated and encouraged to search for the elusive cure for cancer worldwide. 
To completely eliminate the cancerous cells, patients usually have to 
undergo a series of treatments including (1) surgical removal of the malignant 
tumor, (2) chemotherapy which uses drugs to kill the cancerous cells, and (3) 
radiation therapy which uses high energy electromagnetic waves to kill the 
cancerous cells. While bulk of the tumor can be successfully removed through 
surgery and radiation therapy, chemotherapy is still needed to completely 





 However, most of anti-cancer drugs used in chemotherapy, e.g., 
doxorubicin (DOX) and paclitaxel, are highly hydrophobic and insoluble in 
the circulatory system, thus these drugs tend to aggregate which render the 
drugs useless and cause serious complications like embolism [1-3]. It is also 
not effective to use organic solvents and surfactants to improve the drugs’ 
solubility [3]. The free anti-cancer drugs are also very susceptible to clearance 
from the reticuloendothelial system (RES) due to their hydrophobic nature [4]. 
Furthermore, free anti-cancer drugs have a very low specificity to cancerous 
cells [5] so that normal healthy cells are also damaged and killed. As a result, 
cancer patients have to take in a high dose of drugs in high frequency, which 
result in high risk of toxicity and side effects like poor body immune system. 
 The cancer survival rate can be significantly improved if the condition 
is detected as early as possible and diagnosed accurately. NCI has classified 
the various screening and diagnosis methods into four different types: (1) 
physical examination and history – a general health examination and history of 
past illness, (2) laboratory test – conduct tests on tissue, urine and blood 
samples, (3) imaging procedures – imaging mainly via computed tomography 
(CT), and (4) genetic tests – to identify genetic mutations. Of all the four 
screening and diagnosis methods, only imaging provides the exact location of 
the tumor which is vital information before surgery and radiation therapy can 
be conducted. CT scan may be a useful form of imaging technique, however, 
extensive CT scanning may cause undesirable complications due to the 
ionizing effects of X-rays. Fortunately, in recent years, magnetic resonance 
imaging (MRI) and fluorescence imaging have emerged as possible 





Since cancerous cells have water content similar to surrounding normal 
healthy cells, it is difficult to differentiate them using MRI scanning. 







) commonly contain 
heavy metals like gadolinium ions (Gd(III)) to create signal contrast between 
desired area and its surroundings. However, these contrast agents are 
unsuitable for cancer detection due to the short retention time, low relaxivity 
values, and lack intracellular accumulation which is related to the low 
molecular weight [5-8] and low specificity to cancerous cells [5-10]. 
Similarly, for fluorescence imaging, agents like organic fluorophores 
or quantum dots which provide imaging contrast are also needed to highlight 
the malignant tumor. However, organic fluorophores which are usually highly 
hydrophobic with low solubility in aqueous environment can create issues like 
short half-life and embolism alike hydrophobic anti-cancer drugs mentioned 
above. Furthermore, these fluorophores have low specificity to cancerous cells 
too [11]. On the other hand, quantum dots have cytotoxicity issues [12]. 
 
1.2. Delivery systems of active species for cancer treatment and diagnosis 
To address the challenges of cancer treatment and diagnosis, one way is to 
develop suitable systems to deliver anti-cancer drugs, MRI contrast agents and 
organic fluorophores to cancer sites with a high specificity. 
Generally the delivery systems can be divided into two categories: one 
is realized via non-covalent encapsulation, and the other is via covalent 
conjugation of the active species onto the carriers. One of the important 





nano-sized delivery systems, i.e., nanocarriers. Normally nanocarries are 
composed of hydrophobic cores and hydrophilic shells. The delivery systems 
can enhance the effectiveness and efficacy and reduce side effects of anti-
cancer drugs, MRI contrast agents and fluorophores due to the features below. 
 Nanocarriers with hydrophilic shell and hydrophobic core, can hold 
hydrophobic drugs or organic fluorophores within the cores for secure 
encapsulation, and also form good dispersion in the aqueous solution 
[3,13,14-20]. Therefore, the aggregation of the active species can be 
avoided. 
 Nanocarriers with suitable size and hydrophilic shells can effectively 
evade the RES and increase the circulation time or half-life after 
administration [4,17,20,21]; or the retention time of the contrast agents 
significantly [22]. 
 Nanocarriers can target the active species to the cancerous cells via passive 
(Enhanced Permeability and Retention (EPR) effect) or active (via 
conjugation of surface ligands) targeting, thus increasing the efficacy and 
reducing side effects of chemotherapy and cancer diagnosis [22-24]. 
Moreover, the contrast agents conjugated nanocarriers can also be 
modified with stimuli-sensitive moieties that only response to the unique 
intrinsic conditions of tumors to provide high contrast imaging [25]. 
 
However, the challenges as listed below in developing suitable delivery 
systems for anti-cancer drugs, MRI contrast agents and fluorophores for 
cancer treatment and diagnosis are still daunting, and these hinder their 





 For anti-cancer drug delivery: 
 The payload is released prematurely due to the inherent low stability of 
the systems and/or uncontrolled release of the payload. An example is 
Taxol
®
, formulation of paclitaxel using cremophor, which apply 
cremophor to enhance the solubility of paclitaxel. However, cremophor 
has a relatively high critical micelle concentration (CMC) leading to a 
low stability [26]. Abraxane
®
 may also face stability issue. The 130 nm 
albumin paclitaxel formulation was reported to break down into 10 nm 
particles after injected into circulation [27] and this may result in 







 which utilize liposomes as nanocarriers, show uncontrolled 
release behaviours, causing the payloads to be discharged during 
circulation before reaching the targeted sites [28,29]. On the other end 
of the spectrum, some delivery systems have such low fluidity that 
even after reaching the targeted sites, the payloads cannot be released. 
 Low specificity of delivery systems result in undesirable distribution 
and release of payloads, and this can cause detrimental side effects. 
Taxol
®
 shows higher toxicity than Abraxane
®
, causing more death in 
mice which might be contributed by its non-specific nature [30a]. 
DOXIL
®
 also shows non-specific behaviour leading to cardiotoxicity 
which is a prevalent concern with DOX delivery systems. 
 
 For MRI contrast agent 
 In cancer diagnosis, it is possible to produce suitable MRI contrast 





to form macromolecular MRI contrast agents. This can reduce vascular 
extravasation [177,179,472-475], improve the tumour targeting 
capability and T1 relaxivity [177,472-477]. However, macromolecular 
MRI contrast agents might lead to a slow and incomplete excretion of 
Gd(III) ions integrated in these macromolecules, which can result in 
side effects such as nephrogenic systemic fibrosis (NSF) especially in 
renal dysfunctional patients [32-34]. Therefore macromolecular MRI 
contrast agents with suitable degradation rate are needed for feasible 
excretion of Gd(III) chelates after imaging [478]. 
 
 Suitable fluorophores for better cancer diagnosis are needed to provide the 
features below: 
 To provide high imaging contrast between the cancer tissues and 
background.  
 To provide indication of the redox status of cancer tissues. Intracellular 
compartments of cells are much more reductive than the extracellular 
matrix, and the combined redox state of cellular redox couples, like 
glutathione/glutathione disulfide (GSH/GSSG) which is often regarded 
as the major redox buffer, forms the redox environment [43,507]. 
Oxidative stress is closely linked to the status of cancer [508-510], e.g. 









1.3. Scope of study 
A perfect stimuli-responsive polymer delivery system can carry the payloads 
securely in the absence of certain stimulus, but can release the payloads when 
the stimulus is present. So suitable stimuli-responsive polymers delivery 
systems can address the challenges discussed above. It is well recognized that 
intracellular compartments of cells are much more reductive than the 
extracellular matrix. The GSH/GSSG couple is regarded as the representative 
cellular redox couple which plays a critical role in redox homeostasis. The 
concentration of GSH in intracellular compartments is 100-1000 times higher 
than in the extracellular matrixes. Hence this thesis focus on developing 
redox-responsive poly(amido amine)s for anti-cancer drugs, MRI contrast 
agents and fluorophores to improve the efficacy and reduce side effects.  
 Redox-responsive polymers were prepared via Michael addition 
polymerization of trifunctional amines with disulfide-containing bisacrylamide. 
The polymers obtained were then finely tuned for delivery of anti-cancer drug, 
MRI contrast agent and fluorophores, respectively. 
 For anti-cancer drug delivery: In order to develop delivery systems for 
anti-cancer drug, DOX, two types of polymers micelles were developed 
and investigated. The first is from poly(ethylene glycol) (PEG) and 
cholesterol-conjugated poly(amido amine)s; and the second is from 
hyperbranched poly(amido amine)s. Beyond redox-response, pH-response 
also contributes to the improved performance of the delivery systems 
developed due to the acidic environment of cancer cells. The chemistry of 
poly(amido amine)s, the structures of delivery systems, release profiles 





 For MRI contrast agent: Macromolecular Gd(III) based MRI contrast 
agents containing polydisulfide units in the backbone was developed. The 
chemistry, structure and redox-induced degradation of the polydisulfide 
MRI contrast agents were characterized and investigated. 
 For fluorophore: Delivery system of fluorophores with aggregate-induced 
emission (AIE) characteristic was developed. The structure and the redox-
responsive “turn-on” photoluminescence profiles of system was 










2.1. Stimuli-responsive polymers for anti-cancer drug delivery 
Cancer is one of the top killers of human. So far, chemotherapy adopting 
chemical compounds to kill cancer cells is still one of the major therapies of 
cancer. Most of the chemical compounds investigated for the chemotherapy 
are water insoluble and cannot be used directly. Suitable formulations are 
necessary to render the chemical compounds with certain dispersion in 
aqueous solution, suitable in vivo clearance rate and capability to target the 
cancer site [1-3,5,41]. This requirement applies to new chemical compounds 
explored for chemotherapy. For anti-cancer drugs already in the market, it is 
also desirable to develop new formulations with better performances which 
benefit both the patients and the producers. One of the most important 
formulations of anti-cancer drugs is to develop suitable drug delivery systems. 
Organic materials including polymers, lipids, proteins, surfactants are 
important materials for developing drug delivery systems. Although 
tremendous efforts have been put to develop suitable drug delivery systems, 
however, only very few have been in clinic use such as ABRAXANE
®
, a 
formulation of paclitaxel using albumin; DOXIL
®
, a formulation  of DOX 
using PEGylated liposome; DaunoXome, a formulation of daunorubicin using 
liposome; and LiPlaCis
®
, a formulation of cisplatin using liposome also [1-
3,5,41]. 
Anti-cancer drugs’ high toxicity can lead to serious side effects. One 





without leaking into other organs. This requires the drug delivery systems to 
provide secure encapsulation of the drugs before reaching the tumor without 
drug leakage, but be able to release the drugs after entering the cancerous cells. 
Therefore, the drug delivery systems are required to provide secure 
encapsulation of the drugs loaded before reaching the cancer site but 
disassemble after entering the cancerous tissues. To achieve these 
requirements, stimuli-responsive materials are indispensable. The stimuli-
responsive materials can undergo significant changes in physical or chemical 
properties in response to the variations in the environment. The stimuli-
responsive materials are expected to provide secure encapsulation of drugs in 
the absence of the stimuli, but release the drugs when the stimuli are presented. 
The stimuli explored can be divided into two categories: endogenous and 
exogenous stimuli. Endogenous stimuli are the intrinsic conditions of the 
cancer tissues such as a tough redox environment, an acidic condition, and 
certain types of enzyme present. The exogenous stimuli can be change in 
temperature, photo and ultrasound. 
One important category of materials for formulation of drug delivery 
systems is polymers. Here the polymers responsive to the endogenous stimuli 
including redox, pH and enzyme, and to the exogenous stimuli including 
change in temperature, photo, and ultrasound are reviewed. 
 
2.1.1. Endogenous stimuli-responsive polymers 
2.1.1.1. Redox-responsive polymers 
Intracellular compartments of cells are much more reductive than the 





representative cellular redox couple which plays a critical role in redox 
homeostasis. The concentration of GSH in intracellular compartments is 100-
1000 times higher than in the extracellular matrixes. GSH has significant 
effects on many cellular functions such as gene expression, protein function, 
immune responses, cell-cycle regulation and activation of cell death [42-45]. 
Furthermore, it was also reported that in numerous human diseases like 
neurodegenerative diseases, liver diseases, stroke, seizure and diabetes, the 
GSH level is affected [42,46-49]. For example, abnormally high concentration 
of GSH found in cancerous cells protects the cells against the anti-cancer 
drugs and free radical generated during radiation therapy, which result in 
multi-drugs and radiation resistance [42,48,50]. Recently the significant 
different in the redox environment has been explored for developing redox-
responsive drugs delivery systems [43]. One important approach is to 
incorporate disulfide bonds within the systems via different methods. 
Redox-responsive cross-linking is introduced into drug delivery 
systems via disulfide containing crosslinkers, oxidization of thiol group, and 
disulfide-thiol exchange reaction.  The cross-linking can render good stability 
to the drug delivery systems such as polymeric micelles [51-53] which have 
compact structures [51-54], to provide secure encapsulation of drugs in the 
absence of thiol group. Many types of disulfide containing cross-linker are 
applied. 3,3’-dithiobis(sulfosuccinimidylpropionate) was used to form cross-
linking in poly(L-lysine) shell of micelles from triblock copolymer, PEG-b-
poly(L-lysine)-b-poly(L-phenylalanine). 30% more of docetaxel was released 
upon treatment with 10 mM GSH than with 2 µM GSH because the cleavage 





of docetaxel. in vivo study showed that docetaxel loaded cross-linked micelles 
is more effective in inhibiting tumor growth than free docetaxel and its non-
cross-linked counterpart [55]. Other redox-sensitive linkers like disulfide-
containing dimethyacrylate [56], 2-(2-pent-4-
ynoyloxyethyldisulfanyl)ethylpent4-ynoate (bis-alkyne cross-linker with a 
disulfide bridge) [57] bis(2-azidoethyl) disulfide [58], cystamine [59] were 
also used. 
 Oxidation of thiol groups in cysteamine [60] and cysteine [61] 
conjugated to polymer chains can be achieved by reaction with purged oxygen, 
which resulted in formation of disulfide bonds containing cross-linking. Also 
disulfide bonds such as of pyridyldisulfide [62-64] conjugated o polymer 
chains can form cross-linking by a deficient amount of dithiothreitol (DTT), 
which led to the formation of thiol and further thiol-disulfide exchange 
reaction [62,63]. Recently our work showed that thiol-disulfide exchange 
reaction could occur under a basic condition leading to cross-linked polymers 
from disulfide-containing hyperbranched poly(amido amine)s [64]. 
Redox-responsive self-assembly of amphiphilic polymers in the form 
of micelles or polymersomes were explored for drug delivery [65]. One way is 
to combine the hydrophobic and hydrophilic segment via disulfide bond. 
Hydrophobic poly(Ɛ-caprolactone) (PCL) was combined with PEG [66] or 
dextran [67] via the disulfide bonds. The intracellular release of DOX from 
redox-responsive micelles is faster than their non-reducible counterparts, 
which agrees with in vitro release profile. The additional advantage that is the 
detachment of shells upon reduction of the disulfide bonds leads to formation 





prevent the efflux of drugs, one of the causes of cancer drug resistance [68-
71]. Amphiphilic polymers can also be obtained by grafting different groups to 
polymer backbones via the disulfide bond [72-74]. The polymer backbone can 
be water soluble biopolymer like chitosan [75], hyaluronic acid [76] and 
chondroitin sulfate [73].  
Fully biodegradable polymers were also prepared from disulfide-
containing monomers. The polymer backbone can be either linear [77-79] or 
dendritic [80,81]. In our recent works, linear redox-responsive poly(amido 
amine)s  was obtained from Michael addition polymerization of disulfide 
containing N,N-cystaminebis(acrylamide) (BAC) and trifunctional amine, 4-
(aminomethyl)piperidine (AMPD), due to the different reactivity of the three 
types of amines [82,83]. Then PEG and cholesterol were conjugated to the 
polymer backbone. Upon reduction, the redox-responsive micelles released 
13% and 15% more DOX in 24 h and 72 h respectively. The redox-responsive 
DOX loaded micelles also exhibited a higher cytotoxicity than free DOX in 
both MCF-7 and HepG2 cell lines [77]. Another type of amphiphilic graft 
copolymer with disulfide bonds along the polymer backbone also form 
micelles which released DOX in the presence of DTT [78]. Dendritic 
amphiphilic hyperbranched multiarm copolyphosphate (HPHSEP-star-PEPx) 
with disulfide bonds in the backbone could be loaded with DOX and the in 
vitro cytotoxicity of the DOX loaded micelles is higher when a higher GSH 
level is present [80].  
Also redox-responsive polymer-drug conjugates or polymer prodrugs 
were prepared [84]. Linear redox-responsive polymer-drug conjugate was 





even after a long period of time [85-87]. Dendritic polymers were also 
explored [81,87,88]. N-Acetyl-L-cysteine (NAC), an antioxidant and anti-
inflammatory agent, was conjugated to either amine or carboxyl terminal 
PAMAM dendrimer. Around 18 of the 64 terminal groups of the dendrimers 
could be conjugated with NAC via disulfide linkages. When the NAC 
conjugated dendrimers were subjected to 2 µM of GSH to mimic the 
extracellular GSH concentration, only less than 1% of NAC was released 
within 1 h. However, more than 50 times greater of NAC was released in the 
same length of time when intracellular (10 mM) GSH concentration was used 
[88]. Sometimes, the conjugation of drugs to polymer can be challenging 
especially when the drugs have limited reactive functional groups like 
camptothecin with just one hydroxyl group [87,89,90]. On the other hand, 
drugs like DOX with more functional groups allow more variation in the 
conjugation process which might affect the drug functions [85,91]. 
Beyond applying disulfide linkage, recently trimethyl-locked 
benzoquinone (TMBQ), which can be reduced into lactone, was used to form 
redox-responsive drug delivery systems [92]. The polymers were synthesized 
by reacting TMBQ serinol monomer with adipoyl chloride which can self-
assemble and encapsulate paclitaxel within the nanoparticles. After reaction 
with reducing agent sodium dithionite, the conversion of TMBQ to lactone 
destabilized the nanoparticles leading to the release of drugs. However, 
TMBQ is commonly known to undergo intracellular enzymatic reduction and 
might not to react with thiols like GSH [93.94]. Therefore, more work has to 






2.1.1.2. pH-responsive polymers  
To meet the high demand for energy to maintain rapid cell divisions, 
cancerous cells adopt the metabolism of glycolysis instead of normal oxidative 
phosphorylation, an phenomenon known as the Warburg effect. As a result, 
lactic acid, the product of glycolysis, accumulates around the tumors in high 
concentration which lowers the pH of the extracellular environment [95]. 
Furthermore, the lower pH found in endosomes (5-6) and lysosomes (4-5) 
have also been explored for developing pH-responsive drug delivery systems, 
which are designed to only release their loaded drugs after endocytosis [96]. 
 One category of the responsive polymers which contains amino or 
carboxylic acid groups undergoes protonation-induced change in polymer 
hydrophobicity [77,97,98]. When pH was dropped from 10 to 4, the diameter 
of micelles of PEG-b-poly(L-lysine)-b-poly(L-phenylalanine) increased from 
15 nm to 60 nm facilitating the release of drug loaded. Reversibly, hydrogels 
with carboxylic acid groups swell when the pH of the aqueous medium is 
raised [99-101]. A higher degree of ionization of carboxylic acid increases 
electrostatic repulsion among the polymer chains leading to higher solubility 
in aqueous solution [102,103]. If the ratio of carboxylic group within the 
hydrogels is raised, a greater extend of swelling can be expected [99]. Due to 
the swelling, these systems release drugs faster at a high pH condition 
[104,105]. This effect is particularly useful for oral delivery route. As the drug 
delivery systems pass through the stomach usually with a pH of ca. 2, the 
condensed systems can protect the drugs. However the drugs are released for 
absorption into the body after reaching the intestine usually with a neutral pH 





transformation occurs when the charge balance is disrupted with pH 
[106,107]. PAMAM dendrimers were complexed with diblock copolymer of 
poly(methacryloyl sufladimethoxin)-PEG modified by lactose (LA-PEG-b-
PSD) [106]. The complexes have hydrodynamic size of ca. 50 nm at pH 7.4 
and the drugs loaded within the complexes were released much slower than 
PAMAM dendrimers due to the presence of LA-PEG-b-PSD. However, when 
the pH was reduced to 6.5, the complexes were disintegrated, leading to fast 
release of the drug similar to PAMAM dendrimers. 
 Poly(L-histidine) (polyHis) was also explored for preparation of pH-
responsive drug delivery systems. PolyHis was used to form the core of 
polymer micelles, the ionization of polyHis disrupts the hydrophobic 
interaction within the core to release the drugs [108-110]. It was shown that a 
higher content of polyHis in the diblock copolymer caused a faster release of 
DOX at both pH 7.4 and 5.5 [108]. Besides inducing structural deformation, 
polyHis was used in micelles to expose TAT peptides for membrane 
penetration [111,112]. At physiological pH, due to hydrophobic interaction of 
the TAT peptide and polyHis, the TAT peptides are shielded within the PEG 
shells. However, when the polyHis are ionized at low pH, the freed TAT 
peptides protrude out of the PEG shell making the micelles more susceptible 
for cellular uptake. To demonstrate this idea, MCF-7 cells were incubated with 
the micelles at different pH. The result showed that at pH 7.4, the uptake by 
MCF-7 is minimal, but at pH 7.0 and 6.8, the uptake is increased by 30 and 70 
times respectively. This indicates that cellular uptake of the micelles can be 






 pH-responsive polymer prodrugs were also developed. Hydrazone 
linkage which undergo acid catalyze hydrolysis, is extensively studied by 
Younsoo and coworkers. A variety of block copolymers were conjugated to 
different drugs like adriamycin (ADR) [113-115], DOX [116-118], 
dexamethasone [119] and others [120,121]. ADR was conjugated to PEG-b-
poly(aspartate) via the hydrazone bonds and the micelles formed showed pH 
dependent release of the drugs with the fastest release rate being observed at 
pH 3. Both in vitro and in vivo studies of these micelles showed that the 
micelles can inhibit growth of the cancer cells. Furthermore, the studies also 
revealed that the toxicity of the micelles loaded with ADR is lower, the 
circulation of the drugs in the blood is extended, and a higher concentration of 
ADR is found in the tumor. To improve the cellular uptake of these micelles, 
the PEG-b-poly(Asp-Hyd-ADR) was further functionalized with folate which 
has corresponding binding protein overexpressed on the cancer cell 
membrane. in vitro results showed that the folate enhanced the uptake leading 
to a higher toxicity. Another pH-responsive linkage is the acetal bond with its 
hydrolytic rate being tuneable by varying the alcohol derivatives [122]. pH-
responsive bonds are also frequently used in the pH induced degradation of 
drug delivery systems [123-126]. The degradation and dissociation of the drug 
delivery systems under acidic condition facilitate the release of drugs. 
 
2.1.1.3. Enzyme-responsive polymers 
Enzymes are a group of proteins which play vital roles in many biological 
functions, and one unique feature of enzymes is their specific activities based 





cleave alanine-valine (Ala-Val) and glycine-proline (Gly-Pro) peptide 
sequence. While thermolysin and proline endopeptidase can readily break 
down Ala-Val and Gly-Pro peptides respectively, thermolysin cannot cleave 
Gly-Pro and proline endopeptidase cannot break Ala-Val [127]. Furthermore, 
it has been observed that there are upregulated expression of certain enzymes 
in some pathological conditions like cancer and inflammation. Therefore, 
these features can be exploited for developing enzyme-responsive materials 
for drug delivery systems. There are six groups of enzymes, i.e., oxidases, 
transferases, hydrolases, lyases, isomerases and ligases. However, hydrolases, 
which catalyses the hydrolysis reaction, is widely investigated. 
 A well-documented class of hydrolase is the cancer-associated 
proteases (CAP) which include urokinase plasminogen activator (uPA), 
membrane-type matrix metalloproteinase (MMP), and these enzymes have 
been used to design protease sensitive biomaterials for controlled drug 
delivery. Self-assembled matrix with uPA sensitive motif connecting two 
peptide β-sheets was developed. In the presence of uPA, the matrix 
disassembled and released the drugs with the degradation being uPA 
concentration dependent. Moreover, when the sequence of uPA sensitive motif 
was scrambled, the degradation was impeded [128]. Other uPA responsive 
drug delivery systems including polymer caged liposomes with uPA sensitive 
crosslinker [129] and albumin conjugated DOX prodrug with uPA sensitive 
linker [130] were also reported. MMP- responsive cisplatin hydrogel delivery 
system was developed by forming hydrogel of PEG diacrylate matrix 
conjugated with cisplatin via MMP sensitive linker. It was observed that only 





due to the larger mesh size of the hydrogel allows free diffusion of MMPs to 
cleave the linker [131,132]. Cathepsin is primarily an intracellular enzyme 
related to upregulation in cancer [133]. N-(2-hydroxypropyl)methacrylamide 
copolymers were conjugated to DOX via cathepsin sensitive linker, and this 
prodrug showed cathepsin sensitivity [134]. Furthermore, the effectiveness of 
this prodrug can be enhanced by applying the polymer-directed enzyme 
prodrug therapy (PDEPT) which is a two-steps approach. The prodrug is 
administrated followed by the polymer-cathepsin B conjugate. The second 
dose of polymer-enzyme conjugate will cleave the cathepsin sensitive linker of 
the prodrugs that are already accumulated in the tumor to release the DOX. in 
vivo study demonstrated that the concentration of DOX detected in the tumor 
is much higher using PDEPT than the one-step approach with the DOX level 
in the liver and heart being comparable [135]. 
 
2.1.2. Exogenous stimuli-responsive polymers 
Unlike endogenous stimuli, exogenous stimuli are exposed via an external 
treatment. Although this additional step seems unappealing, exogenous 
stimuli-responsive drug delivery systems might be more encouraging and 
favourable because endogenous stimuli vary due to the heterogeneous 
physiological conditions of human population [136]. 
 
2.1.2.1. Thermoresponsive polymers 
Thermoresponsive polymers undergo phase transition when subjected to 
temperature change. The temperature change can be realized via heat 





containing systems or iron oxide-containing systems respectively. A prime 
thermoresponsive polymer is the poly(N-isopropyl acrylamide) (PNIPAAM) 
[137-140]. PNIPAAM has a lower critical solution temperature (LCST) of 
around 31-32 
o
C. PNIPAAM polymer chains become water soluble or 
insoluble when the temperature is below or above LCST, respectively [141]. 
The LCST of PNIPAAM can also be raised by copolymerization or 
conjugation with other hydrophilic polymers and vice versa [142]. 
Thermoresponsive polymer formed by grafting chitosan to PNIPAAM, can 
self-assemble to encapsulate curcumin forming nanoparticles (TRC-NP) [143]. 
Depending on the ratio of chitosan to PNIPAAM, the TRC-NP has a LCST 
ranging from 38 to 44 
o
C. Moreover, the in vitro drug release profiles showed 
that the TRC-NP released 5% and 100% of the drugs loaded when incubated 
at temperature below and above its LCST respectively. Thermoresponsive 
block copolymers composed of the poly(NIPAAM-co-N,N-
dimethylacrylamide) and poly(D,L-lactide), PCL or poly(D,L-lactide-co-ε-
caprolactone) were also reported [144]. A longer poly(D,L-lactide) or 
poly(D,L-lactide-co-ε-caprolactone) hydrophobic block results in a lower 
LCST, and the block copolymers also display temperature dependent drug 
release behaviour. PNIPAAM has a non-biodegradable polyacrylate backbone 
so the biocompatibility might be an issue, so biodegradable PNIPAAM with 
adjustable LCST was reported by conjugating NIPAAM to poly(amino ester)s. 
The resulting thermoresponsive and pH-responsive polymer is capable of self-
assembly [145].  
 Another thermoresponsive system consists of dipalmitoyl 





heat is applied, the increase in passive permeability of the lipid bilayer during 
the gel to liquid crystalline phase transition period, allows the entrapped drugs 
to diffuse out at a faster rate [146]. The ratio of DPPC and DSPC also 
determines the temperature of the phase transition and permeability of the 
liposomes. A higher content of DPPC results in a lower transition temperature 
and a more permeable liposomes [147,148]. These thermoresponsive 
liposomes have been explored for the formulations of drugs including cisplatin 
[149,150] and methotrexate [151,152]. Gold nanoparticles were also used as 
localized heat sources [147,153]. The gold nanoparticles were either 
embedded within the lipid bilayer, the inner and outer surface of the lipid layer 
or loaded within the core of the liposomes. The results showed the presence of 
gold nanoparticles in the liposomes affected the structural integrity of lipid 
bilayer and cause calcein to leak slightly even without light activation 
regardless of position. However, upon UV irradiation, only the gold 
nanoparticles embedded/loaded liposomes were able to release calcein readily, 
with the release more pronounced in liposomes that had gold nanoparticles 
embedded in the lipid bilayer. The gold nanoparticles were able to absorb 
energy from the UV irradiation and transfer the heat to the lipid molecules 
more efficiently when it is in contact with the molecules. Furthermore, it was 
proven that the gold nanoparticles were indeed acting as localized heat source 
heating the neighbouring environment. If the UV irradiation lasts 30 s or more, 
the DPPC undergo phase transition from lamellar gel phase to ripple phase 
then further to fluid lamellar phase. 
 Also magnetically induced thermoresponsive drug delivery systems 





applied to convert magnetic energy to heat under the influence of alternating 
magnetic field. An additional advantage of magnetically induced 
thermoresponsive drug delivery systems is target guiding by permanent 
magnetic field. Using Fe3O4 coated with PNIPAAM microgel under 
alternating magnetic field, the LCST of NIPAAM was determined [154]. 
Furthermore, under the alternating magnetic field, mitoxantrone loaded 
PNIPAAM-SA-Fe3O4 microgel could get heated up from 298 to 323 K in 4 
minutes and displayed temperature dependent drug release. Thermoresponsive 
liposomes loaded with DOX and magnetic nanoparticles were functionalized 
with folate targeting group (MagFolDox) [155]. Under the influence of 
permanent magnetic field, the cytotoxicity of MagFolDox was higher than 
liposomes without the magnetic nanoparticles. In other work where Fe3O4 was 
also used, similar drug release behaviour was observed. Only when alternating 
magnetic field was applied, drugs were released [156,157]. 
 
2.1.2.2. Photo and ultrasound- responsive polymers 
Irradiation energy can be used to directly trigger the drug release. A photo- 
responsive liposome, consisting of PEG2000-dioleoylPE, 
cholesterol,dioleoylPC, and 1,2-bis[10-(2',4'-hexadienoyloxy)decanoyl]-sn-
glycero-3-phosphocholine(bis-SorbPC) which disassemble upon UV 
irradiation was reported [158]. These sterically stabilized liposomes release 
220 times more water soluble fluorescence markers (ANTS) than non-
irradiated liposomes. Moreover, the irradiation led to the release of the bis-
SorbPC monomer from the lipid bilayer. It was suggested that the photo-





and increase its permeability. Also a photosensitizer, distearoyl 
indocarbocynaine (DiIC (18)3), was added into a similar photo-sensitive 
liposomes which still contain bis-SorbPC to enable visible light stimulation 
[159]. The photoactivation of DiIC (18)3 generates oxygen radicals which 
initiate the polymerization of bis-SorbPC to increase the lipid's permeability. 
Photopolymerizable lipid, (1,2-bis (tricosa-10,12-diynoyl)-sn-glycero-3-
phosphocholine) (DC8,9PC) was also applied. A higher ratio of DC8,9PC 
increases the sensitivity of the liposomes to irradiation, releasing calcein more 
rapidly. No change in the size distribution of the liposomes after UV 
irradiation indicates that the release of calcein is not due to rupture of the lipid 
bilayer but the formation of pores [160,161]. Besides photopolymerization, 
other reactions like photooxidation and photodeprotonation can also affect the 
permeability of the lipid bilayer [162]. 
 For liposomes which lipids are non-photo sensitive, it is still possible 
to achieve photo triggered release by introducing this photosensitizer, 
aluminium phthalocyanine disulfonic acid (AlPcS2) in the lipid bilayer [163]. 
This photo-release mechanism is based on the photodynamic action of AlPcS2. 
Upon irradiation by red light, oxygen radical generated by AlPcS2 reacts with 
the unsaturated fatty acids thus increasing lipid bilayer permeability and cause 
10 times faster release of 5-carboxyfluorescein. 
 Acoustic cavitation of surfactant stabilized microbubbles can 
temporarily change the permeability of cell membrane to enhance drug uptake 
which is known as the sonoporation [164,165]. It was shown that the cellular 
uptake of DOX was enhanced and more cell apoptosis was induced using the 





However, this method of co-injecting the free DOX and DOX loaded delivery 
systems can lead to accumulation in undesirable areas [167]. Therefore, a 
connecting system of microbubbles and drug loaded liposomes was developed. 
DOX loaded liposomes are conjugated to the surface perfluorobutane gas 
microbubbles stabilized by lipid. The in vitro cytotoxicity studies 
demonstrated that the cytotoxicity of these DOX-liposomes-microbubbles 
under the influence of ultrasound is much higher than that of DOX-liposomes 
with or without ultrasound, and DOX-liposomes-microbubbles without 
ultrasound [168,169].  
Although the sonoporation technique seems like a favourable method 
to increase the effectiveness of drugs, it does not achieve controlled release. 
Therefore, polymer coated microbubbles are exploited as ultrasound- 
responsive drug delivery. One of such systems is the nanodroplets of 
perfluoropentane (PFP) coated by PEG-co-PLA or PEG-co-PCL [170]. When 
ultrasound is applied to these block copolymer stabilized nanodroplets, the 
PFP vaporizes and microbubbles are formed. This ultrasound-induced droplet-
to-bubble transition is known as the acoustic droplet vaporization. If drugs are 
loaded into the polymer coating, during the ultrasound transition, a significant 
increase in the volume and surface area of the microbubbles may facilitate the 
release of the drugs. in vivo studies, paclitaxel loaded nanodroplets can 
effectively inhibit the growth of ovarian, breast and pancreatic tumor grafted 
onto mice. Another similar work, using PFP nanodroplet, showed that the 
cellular uptake of DOX is highest with fully vaporized droplets as compared to 
non-vaporized or partial vaporized nanodroplets [171]. Besides microbubbles, 





distearoylphosphatidylethanolamine (DSPE) based liposomes are ultrasound 
responsive and the sensitivity increases with the content of DSPE in the 
liposomes [172]. Upon ultrasound exposure, there is an increase in the mean 
size of the liposomes, and the DOX release is seven times faster than DSPC 
based liposomes. It was suggest that the enhanced in permeability may be due 
to the induction of local defect or polymorphic phase transition in the lipid 
bilayer during ultrasound exposure. The temperature effect like those observed 
in thermoresponsive liposomes as the cause of the leakage was ruled out. in 
vivo experiment on the DSPE-based liposomes showed that together with 
ultrasound, the DSPE-based liposomes can effectively inhibit the growth of 
tumor grafted on mice [173]. 
 
2.2. T1 MRI contrast agents 
In comparison with other diagnosis techniques such as X-ray CT, positron-
emission tomography (PET), single photon-emission computed tomography 
(SPECT) and ultrasound, MRI is non-invasive and can provide tomographic 
information of whole animals with a high spatial resolution and soft tissue 
contrast [174,175]. There are many types of MRI technique, including the 
longitudinal relaxation time (T1)-weighted imaging with a hyper-intense signal 
and the transverse relaxation time (T2)-weighted imaging with a hypo-intense 
signal. The key challenge in MRI technique is its low diagnosis sensitivity. 
Currently, 40-50% of MRI scans use contrast agents that contain magnetic 
metal ions to enhance the intensity of signal [174,176]. The contrast agents for 





transitional metal ion (Gd(III) or Mn(II)) that is chelated to reduce serious side 
effects [177-179]. 
Since nuclear magnetic resonance was explored for diagnosis of 
disease in 1971 [2], MRI has been well developed for diagnosis of various 
diseases.  For tumor diagnosis, MRI contrast agents are useful to obtain good 
contrasts for differentiating tumor from healthy tissues, and indicating tumor 
malignant status and the treatment efficacy. There are many seminal reviews 
on MRI contrast agents, most of which are generally about MRI contrast 
agents for diagnosis of various diseases [177-179]. In this review, we focus on 
contrast agents for tumor diagnosis based on T1-weighted MRI. The contrast 
agents used in clinical tumor diagnosis are described first, followed by an 
update of the progress in developing T1 MRI contrast agents through exploring 
new chelates and combining low molecular weight T1 MRI contrast agents 
with various types of carriers. The approaches to improving targeting 
capability of both T1 MRI contrast agents via either passive targeting or active 
targeting are covered. 
 
2.2.1. T1 MRI contrast agents for clinical tumor diagnosis 





) and Gd-DTPA-BMA (Omniscan
®
), have been 
employed for clinical tumor diagnosis. Petterssonet al. showed that Gd-DTPA 
enhanced only the richly vascularized parts and the surrounding of the soft 
tissue tumors in 10-15 minutes after injection [180]. For the detection of 
mediastinal lymph nodes, Gd-DTPA-enhanced MRI could provide a diagnosis 





compared to 62%, 74% and 100% for non-enhanced MRI, respectively [181]. 
However, Gd-DTPA might not be helpful in screening other types of cancer. 
Hawnaur et al. demonstrated that it is complicated to identify tumor in bladder 
using Gd-DTPA-enhanced MRI due to the excretion of Gd-DTPA in urine and 
changes in bladder volume, which could affect the interpretation of results; it 
was also not reliable in determining the effectiveness of the radiotherapy due 
to structural changes in the bladder after radiotherapy [182]. 
Gd-EOB-DTPA is suitable for liver tumor diagnosis due to its good 
liver-specificity [183]. Vander et al. reported that Gd-EOB-DTPA was taken 
preferably by an excised and perfused rat liver than Gd-DTPA [184]. Shimada 
et al. showed that Gd-EOB-DTPA-enhanced MRI was more accurate and 
sensitive in detecting small hepatic metastases of a diameter smaller than 2 cm 
than diffusion-weighted MRI [185]. Gd-EOB-DTPA induced a much better 
tumor enhancement of solid hepatocellular carcinoma lesion of rats than Gd-
DTPA and Mn-DPDP. The Gd-EOB-DTPA almost disappeared in 24 hours 
while a high concentration of Mn-DPDP still remained in the liver [186].  
Recently, USFDA approved clinical use of MS-325 in magnetic 
resonance angiography (MRA). MS-325 can form complex with endogenous 
serum albumin via hydrophobic interaction without covalent linkages [187-
189], and provide longitudinal relaxivity (r1) of a value 10 times higher and a 
longer vascular residence time than non-protein-binding contrast agents. The 
reversible bonding between albumin and MS-325 could facilitate the excretion 
of MS-325 and avoided poor clearance. MS-325 was also used in the 





Although several types of T1 MRI contrast agents have been employed 
for clinical tumor diagnosis, their sensitivities still need to be improved in 
terms of higher r1 value and/or capability to target tumor.    
 
2.2.2. New T1 MRI contrast agents for tumor diagnosis under 
investigation 
Two approaches are discussed below regarding development of T1 MRI 
contrast agents for tumor diagnosis with improved sensitivity, i.e., low 
molecular weight Gd(III) complex composed of suitable chelates and targeting 
ligands, and low molecular weight T1 MRI contrast agents combined with 
various carriers.  
 
2.2.2.1. Low molecular weight T1 MRI contrast agents  
One of the most promising chelates for preparing T1 MRI contrast agents for 
tumor diagnosis is porphyrin-based compounds with possible multi-
functionality. Porphyrin could function as a ligand and was potentially 
applicable for cancer photodynamic therapy [191]. As the ring of porphyrin is 
too small to accommodate Gd(III) ions securely in vivo [192], porphyrin-like 
synthetic macrocycle, texaphyrin, was explored as a chelate of Gd(III) instead, 
which could provide a longer MRI contrast enhancement of the V2 carcinoma 
than Gd-DTPA [193]. Another type of contrast agent obtained from 
texaphyrin, Motexafin-Gd, could provide MRI contrast enhancement of brain 
tumor and killed the cancer cells via redox cycling simultaneously [194, 195].  
Enhanced targeting of MRI contrast agents to tumor sites can improve 





improve the tumor specificity of low molecular weight T1 MRI contrast 
agents. Arginine-glycine-aspartic acid (RGD) peptide is well known for its 
high and specific affinity for αvβ3-integrins which are over-expressed in 
endothelial cells during angiogenesis of tumors. Parket al. reported a liver 
specific contrast agent, cyclic RGD conjugated gadolinium-1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid(Gd-DOTA) (Gd-DOTA-
RGD) [196]. Gd-DOTA-RGD could produce a high signal intensity of the 
tumor, but almost lost this enhancement when the αvβ3-integrins were blocked 
[196]. Deoxyglucosamine conjugated Gd-DTPA (Gd-DTPA-DG) was 
developed to target the hypermetabolic cancer cells because 
deoxyglucosamine was rapidly taken up by tumor due to the over-expressed 
glucose transporters [197]. Gd-DTPA-DG could provide a higher MRI 
enhancement of A549 tumor than Gd-DTPA and a higher retention rate 
because the metabolism pathway was blocked by the deoxyglucosamine 
analogy [197]. MRI contrast agents were also developed to target the 
overexpression of estrogen and estrogen related progesterone receptors in 
breast and ovarian cancers. Sukerkar et al. conjugated progesterone to Gd-
DO3A to improve the cellular uptake by around 3 times higher in two breast 
cancer cell lines and provided a higher contrast enhancement of the xenograft 
tumors in nude mice [198]. Pais et al. developed another type of breast cancer 
specific MRI contrast agent, EPTA-Gd, by conjugating 17b-estradiol to 
pyridinetetra-acetate-Gd (PTA-Gd) for differentiating estrogen receptors-






2.2.2.2. Low molecular weight T1 MRI contrast agents combined with 
carriers  
Combination of low molecular weight T1 MRI contrast agents with carriers 
including polymers and nanomaterials can produce contrast agents with a high 
payload of chelated Gd(III), normally a higher r1 value, and enhanced tumor 
targeting capability. One factor contributing to the enhanced targeting 
capability is the EPR effect owing to accumulation of complexes of carriers 
and low molecular weight T1 contrast agents, which are larger, in tumors with 
loosely vascular structures [23]. However, the possible release of free 
Gd(III)was observed from some liposome loaded with low molecular weight 
T1 MRI contrast agent, which showed a long retention time [200]. Therefore, 
the safety issues of the complex of carriers and low molecular weight T1 
contrast agent should be taken into account as well.  
 
2.2.2.2.1. Water-soluble polymer as carriers 
Many types of water soluble polymers, including linear polymers, dendrimers, 
and proteins, have been explored for carrying low molecular weight T1 MRI 
contrast agents.  Generally, such conjugation limits the rotation and motion of 
the chelated Gd(III) leading to a higher r1 value [201-204]. 
Gd-DTPA conjugated polylysine was able to accumulate in grafted 
tumor in rat models and therefore provided an enhanced imaging for several 
days [205]. Gd-DTPA conjugated polyaspartamide demonstrated a preferential 
uptake and therefore an enhanced MRI contrast in hepatoma in mouse models 
[206]. A high molecular weight polyglutamic acid based MRI contrast agent 





MRI contrast agents were also conjugated with polysaccharides including 
dextran, starch, inulin and oligoglucoamines. Conjugates of Gd-DTPA with 
dextran or oligopolyglucoamines were investigated for delineation of tumor in 
rabbits [208], while Gd-DO3A conjugated carboxymethyl hydroxyethyl starch 
showed the ability to image leaky vasculature of tumor [209]. Galatose units 
targeting the lectin asialoglycoprotein receptor (ASGPR) expressed on liver 
hepatocytes [210] were explore for imaging of hepatocyte carcinoma through 
combination with either DOTA [211] or DTPA [210,212]. 
In comparison with linear polymers, dendrimers have well-defined, 
rigid dendritic structures together with abundant terminal groups. The 
conjugation to the terminal groups produces dense peripheral layers of low 
molecular weight T1 MRI contrast agents which can induce high r1 values. For 
example, the r1 of G6-(C-DOTA-Gd)115, prepared using a preligation 









[201]. It was also found that G6 or G7 dendrimers provided the highest r1 
values, while protonation of amines [213,214] and formation of adducts 
[215,216] could further improve the values by forming more rigid and open 
structures with a lower internal motion. Therefore, a higher level of contrast 
enhancement of tumors could be obtained using a lower amount of PAMAM 
[217-220] and polylysine dendrimer [221] conjugated with low molecular 
weight T1 MRI contrast agents. PEGylated and non-PEGylated Gd labelled 




 together with a longer 
retention time [222-224]. Targeting ligands, e.g., OST7 [225], murine 
monoclonal IgG1, folic acid which targets folate receptor (hFR) [226-229], 





active targeting of the conjugates of PAMAM and low molecular weight T1 
MRI contrast agents. Also, dendrimer nanoclusters with folic acid as ligand 
were developed with a high payload of low molecular weight T1 MRI contrast 
agents [231]. In order to improve biocompatibility, biodegradable esteramide 
dendrimer was combined with low molecular weight T1 MRI contrast agents 
[202] which showed a low toxicity similar to Gd-DTPA [232,233].  
Low molecular weight T1 MRI contrast agents were also combined 
with proteins such as albumin [234,235], IgG and fibrinogen [236] and could 
increase r1 by 3 folds. Albumin-Gd-DTPA was employed to monitor the 
histological profile of tumor and abnormal capillary permeability in cancer 
models [36-40]. The changes in capillary permeability could estimate 
angiogenic activity and the effects of pharmacological stress [237], radiation 
and toxins. The combination with certain types of proteins could improve the 
tumor targeting capability. Through the interaction between biotin and avidin, 
Gd(III)-labelled avidin was used to image the dynamic response of tumors to 
etoposide treatment in mice [238] and breast cancer [239]. Antibody was also 
explored to deliver MRI contrast agents to tumor specifically. It was shown 
that antibody labelled Gd-DTPA could visualize melanoma [240,241], human 
rectal carcinoma [242] and human gastrointestinal cancer. However, many 
results have shown that conjugation could destroy the immune reactivity of 
antibodies; therefore, the targeting capability of these MRI contrast agents was 








2.2.2.2.2. Nanomaterials as carriers 
With the advancement in nanotechnology, many types of nanomaterials have 
been developed, such as polymer micelles and vesicles, liposomes and lipid 
particles, viral particles, carbon nanotubes and fullerenes, gold nanoparticles, 
and silica particles; most of them have been explored as carriers of Gd(III) as 
MRI contrast agents for tumor diagnosis. 
Ratzinger et al. reported Gd-DTPA and Gd-DOTA labelled PLGA 




 [245]. In another work, Gd-DOTA 
was conjugated to PEG-polylysine which could form micelles [246].  Micelles 
containing low molecular weight T1 contrast agents could also be obtained by 
mixing Gd-DTPA conjugated PEG-b-poly(aspartic acid) with 
polyallylamine/protamine or Gd-DOTA conjugated PEG-polylysine with 
poly(methacrylic acid) [10,247] via forming polyelectrolyte complex. The r1 









, respectively, once the 
micelles were dissociated [10,247]. All these micelles containing low 
molecular weight T1 contrast agents showed a preferential accumulation in 
tumors [216,246]. Gd-DTPA loaded into PEG-b-poly(glutamic 
acid)/bis(nitrato) (trans-l-1,2-diaminocyclohexane) platinum(II) micelle 
complex resulted in an increase in r1 value by 24 times[248]. Theranostic 
systems such as Gd-DOTA conjugated to unimolecular micelles which 
composed of fourth generation hyperbranched polyester (Boltorn H40) cores, 
hydrophobic PCL inner layers and hydrophilic poly(oligo(ethylene glycol) 
shells coated with folic acid. Paclitaxel, an anti-cancer drug, was encapsulated 









 and a long retention time of up to 
20 hours [249].  Other theranostic systems with higher r1 values have also 
been reported with FA as targeting moiety and DOX as drug [6,250,251]. 
Bui et al. incorporated Gd-DTPA into PEG-coated phospholipid 





Gd-DTPA loaded LNP was excreted from the body through the biliary system 
instead of the renal system due to its lipid nature [252]. Low molecular weight 
T1 MRI contrast agents were loaded into liposomes in several ways [179,253]. 
For example, ensomes with reduced r1 values and memsomes with higher r1 
values were formed when low molecular weight T1 MRI contrast agents were 
trapped in the inner parts and the membranes of liposomes, respectively. 
These systems demonstrated an enhanced passive targeting of tumor such as 
liver tumor [254]. For active targeting, RGD was employed to label 
PEGylated liposomes encapsulated with Gd-DTPA and provided a higher 
MRI contrast enhancement of human lung cancer in xenograft mice [255]. 
Transferrin, which is over-expressed in many cancerous cells, was used to 
label liposomes loaded with Gd-DTPA to image the detailed pathway of the 
liposomes in the human prostate cancer cells inoculated in nude mice [256]. 
These liposomes entered the peripheral region of the tumor reflected by higher 
signal intensity observed in 10 minutes after injection of the contrast agent, 
and then entered the cells via endocytosis where Gd-DTPA was released. 
Finally liposomes and the released Gd-DTPA were pumped out by the cancer 
cells and were then accumulated in the necrotic area due to the lack of 
washout mechanism indicated by the significant increase in signal intensity in 





saturation transfer (CEST) has a high potential to provide better imaging 
[179,253,257]. MRI contrast agents for this technology can be obtained by 
loading low molecular weight T1 MRI contrast agents into non-spherical 
liposomes to form LipoCEST agents. 
Nanosize silica has been explored for loading low molecular weight T1 
MRI contrast agents.  Gd-DTPA was conjugated to PEG functionalized 
mesoporous silica nanospheres (MSN) with anisamide as a targeting ligand  





[258]. Such nanospheres could be taken up by AsPC-1 pancreatic cancer cells, 
and the in vivo results indicated that Gd-DTPA was cut from MSN in 15 
minutes after injection, reflected by a strong imaging enhancement of the 
bladder, due to rapid reduction of the disulfide linkage by plasma thiols [258]. 
The biocompatibility of silica nanoparticles was investigated using Gd2O3 
doped mesoporous silica nanocomposite, which indicated that silica particles 
showed a low toxicity in cell lines and no potential immunotoxicity [259]. 
Silica nanoparticles coated with Gd2(CO3)3 were also prepared and exhibited a 





Low molecular weight T1 MRI contrast agents were also conjugated 
with other types of nanomateirals. Conjugation with viral capsids could 
significantly improve r1 values [261]. Anchoring low molecular weight T1 
MRI contrast agent onto Au nanoparticles could improve r1 value by several 
times [262,263]. Furthermore, these Gd conjugated Au nanoparticles help to 
achieve desirable and detectable contrast enhancement at only µM Gd(III) 
incubation concentration indicating favorable cellular uptake of the 





Gd conjugated Au nanoparticles can achieve multimodal cell imaging (CT, 
MRI and fluorescence) which is not possible with polymer based MRI contrast 
agents developed earlier on by the same group [264]. When Gd was loaded 
into fullerenes, gadofullerene formed with either PEG shells or succinic acid 
shells provided r1 50 to 60 times higher than Gd-DTPA, and the gadofullerene 
was tested for imaging of brain tumor in rat models [265,266]. 
 
2.3. Biodegradable polymers 
It is preferred to use biodegradable polymers for preparation of delivery 
systems, which are biocompatible and safe [267, 268]. Any materials which 
are not intended to be in contact with living system for long period of time like 
those used in permanent joint implants should be eliminated to avoid 
accumulate in the body [269]. These polymers being biodegradable not only 
facilitate glomerular clearance of non-toxic degradation products, their 
degradation behaviours can also modulate the release profile of payload (if 
any is loaded) [270]. The degradation of polymers is realized via the reactions 
of the species in the biological systems with certain units of polymers. The 
biological species can be water which can lead to hydrolysis of units including 
ester, thiol which cut disulfide unit, enzymes which can cut certain units 
specifically. Biodegradable polymers based on the water-induced hydrolysis 
are the most common polymers investigated for bio-related applications, 










Poly(lactide)s (PLAs) is one of the most prominent biodegradable synthetic 
polymers. Similar to all other poly(ester)s, the presence of ester groups in 
PLAs allows the polymers to readily undergo bulk hydrolysis in hydrated 
environment like in human tissues. There are mainly two different synthesis 
routes for PLAs. First, via the condensation polymerization, lactic acid 
monomers are polymerized under high temperature and vacuum, without or 
with catalyst to yield low to intermediate molecular weight PLAs [271]. On 
the other hand, using the ring opening polymerization of lactides which are 
cyclic intermediate dimer of lactic acids with catalysts, PLAs with controlled 
molecular weight can be yielded [271]. Besides being biodegradable, PLAs 
also has low cytotoxicity and immunogenicity which are favourable for 
biomaterials [272]. Typically, PEG which promotes membrane penetration 
[273-278], prevents nonspecific proteins adsorption, provides long-circulation 
time in blood stream [279-284] and facilitates endocytosis[ 285], is attached to 
the free carboxylic end group of PLAs to form diblock copolymer which can 
self-assemble to form nanocarriers. Therefore, due to these encouraging 
properties, PLA-b-PEG has been studied in the area of drug and protein 
delivery [286-288]. Among them, some studies have achieved controlled 
release through the degradation of PLAs [287,289,290]. 
 
2.3.1.2. Poly(glycolide)s  
Poly(glycolide)s (PGAs) is also another poly(ester) which is a well-known 





either by condensation polymerization or ring opening polymerization [291]. 
However, due to the formation of water during condensation polymerization 
which leads to lower molecular weight polymer, the ring opening 
polymerization is usually preferred. The ability of PGAs to biodegrade in vitro 
and in vivo and biocompatibility are well demonstrated in resorbable sulture, 
Dexon
®
, which is used since the 1970s [292-294]. In comparison to 
degradation rate of the homopolymers of PLAs and PGAs, the copolymer, 
poly(lactide-co-glycolide)s (PLGAs), degrades at a faster speed which is 
dependent on the composition ratio. 75% PLA : 25% PGA and 75% PGA : 
25% PLA have similar in vivo degradation half-life of 0.6 months while 50% 
PLA : 50% PGA has 1 week in vivo degradation half-life [295]. The increase 
in degradation rate of PLGA is due to the decrease in crystallinity, amorphous 
regions of the polymers are more susceptible to hydrolysis of the ester bonds 
[296]. Therefore with well-controlled and documented degradation rate and 
profile, PLGAs are used in a wide range of biomedical applications like 
controlled release and imaging [245,297-300]. 
 
2.3.1.3. Poly(Ɛ-caprolactone)s 
PCLs, another synthetic biodegradable poly(ester)s, is also extensively studied 
and investigated. Likewise, the synthesis of PCLs is generally via the ring-
opening polymerization and among the different reaction mechanisms (divided 
by initiator), coordination-insertion ring-opening polymerization is preferred 
since well-defined PCLs may be yielded by living polymerization [301,302]. 
Although PCLs degrade much slowly than PLAs, PGAs or PLGAs, like all 





polymer is larger than 10
-1
 m [303]. According to a model drawn to predict the 
mode of degradation; surface or bulk, if the degradation of the polymer is 
more rapid than the diffuse of water into the polymer bulk, the polymer is 
likely to undergo surface degradation. On the other hand, if the diffusion is 
faster than degradation, the polymer is expected to go through bulk 
degradation [303]. PCLs, PLAs, PGAs and PLGAs all also exhibit a 
characteristic autocatalytic degradation. The trapped carboxyl groups 
produced after the hydrolysis of ester bonds further catalyse the remaining 
ester bonds, resulting in the acceleration of internal degradation compared to 
the surface [304,305]. Likewise, when PCLs are PEGylated, the polymers 
demonstrated minimal in vitro and in vivo cytotoxicity [306,307] and are 
reported in vast range of biomedical applications [308-311]. Similarly, some 
of these studies have indicated the degradation of PCLs has affected the 
release behaviours [287,312,313]. 
 
2.3.2. Polyanhydrides 
If poly(ester)s are classical examples of bulk degradation polymer, then the 
representative polymer for surface degradation is polyanhydrides which can be 
synthesized by a whole range of techniques, melt condensation, ring-opening 
polymerization, interfacial condensation, dehydrochlorination and dehydrative 
coupling agents [314]. Due to its hydrophobicity which restricts the 
penetration of water into the bulk, hydrolysis of highly water labile anhydride 
bonds only happens on the surface. Moreover, by altering the type of 
monomer and their ratio, the rate of degradation can be controlled [270,315]. 





[316-318]. Unlike bulk degrading polymers, polyanhydrides are able to release 
their payload at a constant rate which is directly proportional to their 
degradation rate, as a result, polyanhydrides have gained lots of interest in the 
area of controlled delivery [319-322]. One of such polyanhydrides worth 
mentioning is the P(CPP-SA) which the FDA has approved for brain cancer 
treatment. The degradation studies done on this polyanhydrides clearly 
indicates the ability to alter degradation rate of the polymer by varying the 
hydrophobicity [323]. Furthermore, their results also shows that the 
degradation profile of P(CPP-SA) matched the drug release profile and 
controlled release was achieved [323]. 
 
2.4. Poly(amido amine)s 
For different bio-related applications, the requirements are different so various 
types of polymers are also explored. Poly(amido amine)s is a category of 
polymers promising for different applications including drug delivery, gene 
delivery, protein delivery, MRI imaging and fluorescent imaging. 
 
2.4.1. Poly(amido amine) dendrimers 
Poly(amido amine)s, a versatile class of synthetic polymers, are extensively 
studied for use as biomaterials and polymer therapeutics and a well-known 
form of these polymers is the poly(amido amine) (PAMAM) dendrimers 
which are also commercially known as the first family of the Starburst
®
 
dendrimers. These PAMAM dendrimers consist of concentric amidoamine 
shells around a central initiator core such as ammonia and ethylenediamine 





[326]. The resulting poly(amido amine)s with dendritic architecture have very 
well-defined three-dimensional structures, very low polydispersity and high 
functionality [326]. 
With numerous intramolecular voids within each PAMAM dendrimer 
to aid in the solubilization of small organic molecules and affect their release 
rates [327,328], PAMAM dendrimers are thus promising drug carriers. 
However, concerns on the cytotoxicity and haemolytic issues of PAMAM 
dendrimers are widespread [326,329,330]. The in vitro cytotoxicity of 
PAMAM dendrimers is dose and generation dependent and high generation 
PAMAM dendrimers are highly capable of damaging and creating leakage in 
cell membranes [331-333]. Furthermore, 4th generation PAMAM dendrimers 
have shown to exhibit significant haemolytic toxicity [334,335]. Fortunately, 
although PAMAM dendrimers can induce intracellular reactive oxygen 
species generation and cytokine production which may lead to cell death in 
macrophages [336], they are concluded to have weak immunogenicity 
[329,331]. There are limited reports on the in vivo toxicity of PAMAM 
dendrimers and for those which did observed that PAMAM dendrimers are 
rapidly cleared from circulation [337] and the results are unlikely to deter 
future development of PAMAM dendrimers in biomedical applications [331]. 
Since the cytotoxicity is strongly influenced by the cationic surface amino 
groups of PAMAM dendrimers [336,337], surface modification may be the 
key in abating the cytotoxicity. Many reports have demonstrated surface 
modification like PEGylation [335,338], acetylation [339,340], with anionic 
groups [337,338,341], etc. can considerably reduce the cytotoxicity of 





development of PAMAM dendrimers in the area of biomedical applications 
like gene delivery [340,342-344], drug delivery [345-348], MRI contrast 
agents [349-351], etc can flourish. 
 
2.4.2. Linear poly(amido amine)s 
Unlike the PAMAM dendrimer, the linear poly(amido amine)s (PAAs) 
especially the amphoteric ones have raised lesser concern on cytotoxic [352]. 
The synthesis of these linear PAAs via Michael addition specifically aza-
Michael addition is usually the stepwise polyaddition of primary or secondary 
aliphatic amines to an activated bisacrylamide [352-354]. Typically, a Michael 
addition reaction is performed in protic solvent to expedite proton transfer 
[352,355] and catalysed by a base. However in aza-Michael addition reaction, 
the amine monomer itself functions as the catalyst and its basicity affects the 
rate of reaction [353,82]. To facilitate further functionalization of the resulting 
linear PAAs, functional groups which do not participate in the polymerization 
like hydroxyl, ether, etc but not groups which can react with activated double 
bonds like SH and NH2, can be introduced by using properly functionalized 
monomers [352]. Linear PAAs which contain amide group can undergo 
hydrolytic degradation in aqueous buffer solution [356,357] and the 
degradation rate is affected by pH but not in the presence of lysosomal 
enzymes [358]. Furthermore, the introduction of disulfide bonds which can be 
reduced by intracellular thiols and enzymes along the PAAs background can 
hasten the rate of degradation [359]. Similarly, linear PAAs are also explored 






2.4.3. Poly(amido amine)s derived with trifunctional amines 
Linear PAAs are usually yielded using bifunctional amine monomers with the 
third functional amine (if present) protected from the reaction. However, a 
handful of publications on Michael addition polymerization with trifunctional 
amines have surfaced in the recent decade. In 2003, Liu.et al first reported the 
use of trifunctional amines, 1-(2-aminoethyl)piperazine, and equimolar 
diacrylate to synthesize linear poly(amino ester) via Michael addition 
polymerization. Their result clearly showed that the yielded polymers are 
linear and potential biodegradable DNA carriers [83]. Subsequently, the same 
group examined the polymerization mechanism in detail and confirmed the 
reactivity sequence of the three types of amines in the trifunctional amines as 
such: 2
o
 amine (original) > 1
o
 amine >> 2
o
 amine (formed) in poly(amino 
ester)s [82], PAAs [366] and poly(sulfone amine)s [367]. Furthermore, using 
similar monomers and polymerization techniques, several PAAs based 
polymers are studied in the area of controlled gene and drug delivery 
[77,368,369]. 
 Due to ease of synthesis, hyperbranched polymers which have 
comparable three-dimensional structure as dendrimer are gaining popularity. 
A comprehensive study on the polymerization mechanism with trifunctional 
amines to form hyperbranched polymer was first reported by Wu. et al [370]. 
They observed in situ that during the one-pot Michael addition polymerization 
of trifunctional amines and double molar diacrylates, hyperbranched 
poly(amino ester)s were formed from the B’’A2-type intermediates which 
were in turn from the B’B’’A-type intermediate. Although the resulting 





they contain negligible linear portion which is akin to the well-defined 
structure of dendrimers. Almost immediately, Wang et al. also reported similar 
results with hyperbranched PAMAM derived from trifunctional amines in a 
one-pot Michael addition polymerization [371]. Ever since, a few 
hyperbranched PAMAM based polymers were explored in controlled gene and 
drug delivery [372-376]. Interestingly, as amino-containing polymers 
fluoresce [377], several hyperbranched PAMAMs are also investigated for 









Characterization Instruments and Assay 
 
3.1. Nuclear magnetic resonance spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy is a technique which uses 
the NMR phenomenon to study physical, chemical and biological properties of 
materials. When atom with non-zero nuclear spin is placed in an external static 
magnetic field, spin polarization which is the alignment of the nuclear spin 
with the external magnetic field occurs. Then, subsequent irradiation with 
radio frequency signal of proper frequency on the atom can induce a transition 
or flip between spin states. Once the radio frequency signal is removed, the 
relaxation of the spin to lower state generates a detectable amount of radio 
frequency signal which is related to the spin flip [382]. 
Very often, to determine the chemical structure of organic molecules 





which is a plot of the absorption of radio frequency energy against the external 
field is necessary. The shift in frequency or chemical shift in the NMR 
spectrum is characteristic to atom or molecules in their given environment and 
the area under the signal in the NMR spectrum is proportional to the number 
of nucleus in the atom group. Using this information, the chemical structure of 
the organic molecules measured can be determined. 
In our work, 
1
H NMR and 
13
C NMR spectra were obtained using a 
Bruker DPX 400 MHz NMR spectrometer. The polymers were dissolved in 
suitable deuterated solvent in a concentration of ~5 % for 
1
H NMR or 20-25 % 
for 
13





3.2. Gel permeation chromatography 
Gel permeation chromatography (GPC) is a chromatographic technique which 
characterizes the molecular weight distribution of polymers. The separation of 
the polymers is based on the size of the polymers in solution and not 
molecular weight, therefore for accurate measurement, suitable solvent is 
essential. The general concept of GPC is macromolecular polymers have 
lower tendency to penetrate the well-controlled pores of cross-linked gel bead 
and thus are wash away with the elute more rapidly. On the other hand, 
smaller polymers can enter these pores more easily and be retained for a 
longer period of time before eluting. To determine the molecular weight 
distribution of the sample polymer, usually polystyrene or polyethylene oxide 
with narrow molecular weight distribution is used as standards [383]. 
The distribution coefficient (K) in GPC is defined as 
K = Vsi/Vs        (E3.1) 
where Vsi is the pore volume of the bead accessible to permeation by the ith 
polymer with a specific molecular size and Vs is the volume of the stationary 
phase. 
The GPC chromatograph is a plot of detector signal against retention 
volume. In this graph, the peak height of the signal is proportional to the value 
of NiMi, where Ni is the number of molecules of the ith kind with molecular 
weight Mi. With calibration, these values can be easily obtained to calculate 
Mn, Mw and the polydispersity, Mw/Mn. 
Mn=∑ NiMi / ∑ Ni       (E3.2) 
Mw=∑ NiMi
2





In this report, the Waters 2690 apparatus with two columns in series 
(Waters Ultrahydrogel 250 and 200) and a Waters 410 refractive index 
detector were used anda mixture of 0.5 M acetic acid/0.5 M sodium acetate 
was used as eluent. The polymer concentration is ~ 5 mg/mL. 
 
3.3. Dynamic and static light scattering 
Dynamic light scattering (DLS), also known as photon correlation 
spectroscopy, is a popular technique to determine the size of particles in the 
sub-micron range. By shining laser onto a solution of particles, the changes in 
the scattered light such as frequency, angular distribution, polarization and 
intensity fluctuation by the particles are related the diffusion coefficient and 
size of the particles. This technique is also based 2 assumptions which the 
particles are in Brownian motion and the particles are assumed to be spherical. 
Most of the commercial “particle sizing” systems can only operate at one 
angle (90
o
), use red light (675 nm) and are usually no dependent on the sample 
concentration [384]. 
On the other hand, static light scattering (SLS) is a technique to 
measure the intensity of scattered light to obtain molecular weight of 
macromolecules. By measuring the intensity of scattered light at various 
angles in different sample concentrations and plot the data in a Zimm plot, the 
radius of gyration, second virial coefficient and molecular weight can be 
obtained. 
In my study, the Brookhaven BIS200 laser light scattering system was 
used for both the DLS and SLS measurements. The sample solutions are 





scattering angle was fixed at 90
o
 for the measurement of hydrodynamic radius 
(Rh) and the Rh values were obtained using CONTIN and NNLS algorithm. 
As for SLS, the measurements were done at various scattering angles with 
different sample concentrations.  
 
3.4. Transmission electron microscopy 
Transmission electron microscopy (TEM) is an advanced microscopy 
technique which utilizes the same basic principle of optical microscopy. In 
TEM, instead of light, powerful electron beam is used to irradiate the sample 
to obtain images of resolution thousand times higher than normal optical 
microscope. Using electromagnetic lenses to focus the electrons into very fine 
beam, the TEM images are obtained from electrons which transmit through the 
sample unscattered and hit onto a fluorescent screen [385]. 
The TEM used in this report is the high resolution Philips CM300 
transmission electron microscope (FEGTEM) at 300 kV, and the samples were 
prepared by dropping micelles suspension onto a copper grid cover with 
carbon followed by drying in a desiccator. Then, the dried grid was left in 1% 
osmium oxide in heptane for 2 hours. 
 
3.5. Fluorescence spectroscopy 
Fluorescence spectroscopy is a technique which detects the fluorescence 
emitted by excited samples. At room temperature, most molecules are at the 
lowest vibrational level of the ground electronic states and upon absorption of 
light, the electrons are excited to higher vibrational sub-level which 





rapidly fall back to the original ground states and emit a lower energy 
radiation which is collected by the machine [386]. Very often, the use of 
fluorescence spectroscopy is accompanied by the application of the Beer-
Lambert Law which states that absorption is directly proportional to the 
concentration of the sample. 
In our work, the fluorescence emission spectra were recorded on a 
Perkin–Elmer LS55 Fluorescence Spectroscopy instrument fitted with a R928-
sensitive sample photomultiplier. 
 
3.6. MTT assay 
MTT (3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay is 
a colorimetric assay for assessing cell viability. First described in 1983 by T. 
Mosmann [387], the MTT cytotoxicity assay is based on the mitochondrial 
activity of viable cells to convert yellow MTT to dark blue formazan by 
mitochondrial dehydrogenases and therefore, the amount of formazan 
generated is directly proportional to viable cell number. Then, the formazan 
which is solubilized in organic solvent and released from the cells can be 
spectrophotometrically measured to determine its quantity. 
The detailed MTT assay protocol used in this report is presented as 
following. The cells were seeded in 96-well plates with a typical seeding 
density of 10,000 cells/well and were cultured in DMEM supplemented with 
10% FBS and 1% penicillin-streptomycin solution in an incubator at 37 
o
C, 
5% CO2, and 95% relative humidity. The cells were allowed to adhere to the 
well bottom upon overnight incubation. Then the medium was replaced with 





only cell culture medium were prepared as untreated controls. After 
predetermined time, the medium containing samples was aspirated and the 
wells were washed with 1 ×PBS solution for two times to removed non-
internalized sample. Then 100 μL of DMEM and 10 μL of MTT solution (5 
mg/mL in 1 ×PBS solution) were added to the wells. After incubation for 4 h 
at 37 
o
C, the solution was removed and the formazan precipitate was dissolved 
in 100 μL of DMSO. The absorbance intensity of the solution was then 
quantified spectrophotometrically using a microplate reader (TECAN 
SpectraFluor Plus) at 570 nm. Cell viability was expressed by the following 
equation: 
Cell viability (%) = Abssample / Abscontroll  100% 
where Abssample was the absorbance for cells treated with samples, while 
Abscontroll was the absorbance for untreated control cells. All the tests were 
performed in multiples. 
 
3.7. Confocal laser scanning microscopy 
Confocal laser scanning microscopy (CLSM) is form of optical microscopy 
which can obtain high resolution images with depth selectivity [388]. With 
shallow depth of field, the CLSM image obtained has high z-resolution and 
reduced out-of-focus blur, thus making the image clearer. However, as the 
image is acquired point-by-point and reconstructed by computer, the imaging 
process is more time-consuming. 
 In my study, confocal imaging of either living or fixed cells was done 






3.8. Flow cytometry 
Flow cytometry is a laser-based technique which can be used for cell counting, 
cell sorting and biomarker detection. Basically in this machine, the cell 
suspension is forced into a narrow column through the flow chamber by the 
sheath fluid, thus allowing the cells to pass through the laser focal point 
singly. In the case of biomarker detection, the emitted fluorescence is 
collected and amplified by the photodiode detector and then processed into 
useful readings like the fluorescence intensity of the biomarker in each 
individual cell [389]. 
 The flow cytometer used here is the BD LSR Fortessa Flow Cytometry 








pH- and Redox-Responsive Poly(ethylene glycol) and 
Cholesterol-Conjugated Poly(amido amine)s Based 
Micelles for Controlled Drug Delivery 
 
4.1. Introduction 
Nanomedicine technology can overcome some limitations of cancer 
chemotherapy such as a short half-life and a low specificity [5,41]. Several 
products including Taxol®, Doxil® and Abraxane® are already in clinical 
applications [390,391]. In order to further reduce the side effects and improve 
the efficacy of anti-cancer drugs, stimuli-responsive nanocarriers are being 
pursued which can ensure secure drug encapsulation before reaching cancer 
sites and be triggered to release the drugs after entering the cells [142,392-
394]. The release of drugs from these stimuli-responsive nanocarriers can be 
realized using external triggers such as thermal treatment; however, it is 
preferred to explore the intrinsic conditions in malignant tumor as internal 
triggers [144,395].  
 Among the internal triggers, pH- and redox-stimuli are generating 
more and more interest. As malignant tumor generates most of its energy 
through glycolysis instead of the normal oxidative phosphorylation, the 
Warburg effect results in a lower pH environment [396]. pH-responsive drug 
carriers can be realized either via the hydrolysis of pH sensitive bonds 
[113,114,397-399], or the swelling and dissociation of protonatable groups 





antioxidant in the body and plays many roles in cell metabolisms, is 
significantly higher in the intracellular compartments (2-10 mM) than in the 
extracellular matrix (2-20 µM) [403]. Moreover, it was also reported that 
malignant tumor contains an elevated level of GSH than normal healthy 
tissues, with a few studies reporting as much as a 10 times difference 
[42,47,48,404]. Therefore, redox-responsive drug delivery systems can 
encapsulate cancer drugs securely and release drugs once within the cells. 
Redox-responsive drug carriers have been developed by integrating disulfide 
groups in various ways such as into backbones of polymers [364,405], as 
linkages between polymer blocks or hydrophilic/hydrophobic segments 
[67,69,74,,364,406,407] or gates of silica based carriers [408], and forming 
cross-linker [53,55,59,61,409-413]. 
 Poly(amido amine)s, a versatile class of polymers, are promising 
biomaterials due to the low hemolytic activity and peptide-mimicking 
properties and have been explored for preparation of drug and gene delivery 
systems [64,359,364,405,414-417]. One type of poly(amido amine)s for pH- 
and redox-responsive drug delivery was prepared by Michael Addition 
polymerization of disulfide containing diacrylamide with two primary amines 
with different functional groups [364].  
 Our previous works have demonstrated that the Michael Addition 
polymerization of trifunctional amines with an equimolar diacrylic monomer 
can produce linear poly(amino ester)s and poly(amido amine)s containing 
secondary amines in the backbone [83,370,418], and the secondary amines in 
the polymer backbone can be further conjugated with functional species 





amphiphilic poly(amido amine)s based drug delivery systems as shown in 
Scheme 4.1. First linear disulfide- and secondary amine-containing 
poly(amido amine)s, poly(BAC-AMPD), was obtained via Michael Addition 
polymerization of trifunctional amine, AMPD, with an equimolar 
diacrylamide, BAC, under an optimized condition. Then the secondary amines 
in the backbone of poly(BAC-AMPD) were further conjugated with PEG and 
cholesterol (CE), respectively, to form poly(BAC-AMPD)-g-PEG-g-CE. 
Micelles were formed via self-assembly of poly(BAC-AMPD)-g-PEG-g-CE in 
aqueous solution. Anti-cancer drug, DOX, could be loaded into the micelles. 
The DOX loaded micelles showed pH- and redox-responsive release of DOX 
and redox-induced formation of aggregates. The DOX loaded micelles could 
deliver drugs into the cancer cells and showed a higher efficacy in killing 
cancer cells than free drug.  
 

















4.2. Experimental section 
4.2.1. Materials 
N,N-cystaminebis(acrylamide) (BAC) from Polysciences, 4-
(aminomethyl)piperidine (AMPD) from Alfa Aesar, cholesteryl chloroformate 
and doxorubicin hydrochloride (DOX-HCl) from Fluka Analytical, and L-
dithiothreitol (DTT) from Sigma Aldrich were used as received. Monomethyl 
poly(ethylene glycol) (PEG) (~2000 g/mol) 4-nitrophenyl carbonate was 
prepared as in our previous report [419]. Methanol, dimethylsulfoxide 
(DMSO), and other solvents used in this study were purchased from Tedia and 
used as received.  
  MCF-7 (human breast adenocarcinoma) cells and HepG2 (human 
hepatoma) cells were obtained from American Type Culture Collection 
(ATCC, Rockville, MD). They were maintained in Dulbecco's modified eagle 
medium (DMEM, invitrogen) with 10% fetal bovine serum (FBS), 2 mM 
glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin at 37 C in an 
incubator with 5% CO2 atmosphere. 
 
4.2.2. Synthesis of poly(BAC-AMPD) 
In a typical experiment, 6.96 g (26.7 mmol) of BAC was added into 3.10 g 
(26.8 mmol) of AMPD in a mixture of 16 ml of anhydrous methanol and 24 
ml of anhydrous DMSO under stirring at 50 
o
C with argon.  After 25 days, 1% 
of AMPD was added to the solution. 24 h later, some of the solution was taken 
for GPC measurements and the rest was dialyzed using dialysis membrane 
with a molecular weight cutting-off of 3500 in methanol. Also the 





polymerization in NMR tube using methanol-d4 and DMSO-d6 instead. The 
total monomer concentrations were kept around 20% (w/v), and 
13
C NMR 
spectra were measured using a power-gated decoupling program (PD) with 
200 times scan taking ca.10 minutes. 
  In order to investigate the effects of solvent, a mixture of anhydrous 
methanol and DMSO with various contents of methanol, i.e., 90% (v/v), 70% 
(v/v), 40% (v/v), 20% (v/v), were adopted. 
 
4.2.3. Synthesis of poly(BAC-AMPD)-g-PEG-g-CE 
In a typical experiment, 5.31 g (2.35 mmol) of monomethyl PEG(~2000 
g/mol) 4-nitrophenyl carbonate was added to 3.98 g (10.6 mmol) of 
poly(BAC-AMPD) in 50 mL of anhydrous DMSO. The solution was stirred 
for 5 days at room temperature under argon, and then was dialyzed using 
membrane with a molecular weight cutting-off of 3500 in methanol. In a 
typical experiment for conjugation of CE, 2.28 g (5.1 mmol) of cholesteryl 
chloroformate and 1.84 mL (13.2 mmol) of TEA were added into 2.86 g (0.27 
mmol) of poly(BAC-AMPD)-g-PEG in 25 mL of anhydrous DMSO under 
stirring at room temperature with argon. After 5 days, the solution was 





4.2.4. Formation and characterization of micelles of poly(BAC-AMPD)-g-
PEG-g-CE 
40.5 mL of deionized water was added at a rate of 0.25 mL/h using a syringe 





under a rapid stirring. Then the solution was dialyzed using membrane with a 
molecular weight cutting-off of 1000 in deionized water to remove DMSO. 
 
4.2.5. Degradation of micelles 
10 mL of micelles solution was incubated with 2 mM of DTT at 37 
o
C under 
stirring. 5 days later, precipitate in the solution was lyophilized. 
1
H NMR 
spectrum of the dried solid sample in chloroform-d was obtained. 
 
4.2.6. Preparation of DOX loaded micelles 
22.5 mL of deionized water was added at a rate of 0.25 mL/h using a syringe 
pump to 2.5 mL of DMSO containing 25 mg of poly(BAC-AMPD)-g-PEG-g-
CE (25 mg),  5 mg of DOX-HCl and 2.5 µL of triethylamine (TEA) under 
rapid stirring. Then the solution was dialyzed using membrane with a 
molecular weight cutting-offof 1000 in deionized water to remove the DMSO 
and DOX. After dialysis, aggregates of unloaded DOX were removed by 
filtration through a filter with a pore diameter of 0.45 µm. 
 
4.2.7. in vitro DOX release of DOX loaded micelles 
2 mL of the DOX loaded micelle solution in dialysis membrane with a 
molecular weight cutting-off of 10 000 was submerged in 40 mL of phosphate 
buffered saline(PBS) at 37 
o
C with various conditions, i.e., pH 7, pH 5, pH 7 
with 2 mM of DTT, pH 5 with 2 mM of DTT, respectively. At fixed intervals, 
4 mL of dialysis solution (PBS) was collected and 4 mL of fresh PBS was 





with an excitation of 440 nm, and the concentration of DOX was determined 
based on a calibration curve. 
 
4.2.8. DOX loading capacity 
The DOX loaded micelles solution was lyophilized, and a certain amount of 
dried DOX loaded micelles was dissolved in DMSO. The solution was 
dialyzed using membrane with a molecular weight cutting-off of 2000 in 
DMSO. The concentration of DOX in the dialysis solution was measured as 
above. The loading capacity and the loading efficiency were calculated:  
Loading capacity = Mass of DOX loaded / Mass of DOX loaded micelles × 
100% 
Loading efficiency = Mass of DOX loaded / Mass of DOX added × 100 % 
 
4.2.9. Cellular imaging 
MCF-7 and HepG2 cell lines were seeded in 8 chamber borosilicate 
coverglass with a cell density of 5,000 cells/chamber and were cultured in 
DMEM supplemented with 10% FBS and 1% penicillin-streptomycin solution 
in an incubator at 37
o
C, 5% CO2, and 95% relative humidity. The cells were 
allowed to adhere to the chamber bottom upon overnight incubation. Then the 
medium was replaced with DOX loaded micelles solution in DMEM. At a 
designed time interval, the medium was removed and the wells washed with 
500 µL of PBS once followed by adding 250 µL of 90 % (v/v) cold ethanol to 
fix the cells in dark for 10 minutes. After the ethanol was aspired, the wells 
were washed with 500 µL of PBS, and 200 µL of 4',6-diamidino-2-





minutes later, DAPI was removed, and the wells were washed with 500 µL of 
PBS twice followed by adding 150 µL of PBS to prevent the cells from drying 
up. The cells were imaged under a confocal laser scanning microscope 
(CLSM) (FV1000, Olympus, Japan). 
 
4.2.10. in vitro cytotoxicity evaluation of samples 
Cytotoxicity of micelles of poly(BAC-AMPD)-g-PEG-g-CE, DOX-HCl, and 
DOX loaded  micelles of poly(BAC-AMPD)-g-PEG-g-CE were evaluated in 
MCF-7 and HepG2 cell lines. Viability of the cells was assessed by the 
standard thiazolyl blue [3-(4,5-dimethyliazolyl-2)-2,5-diphenyl tetrazolium 
bromide] (MTT) assay. This colorimetric assay allows determination of the 
number of viable cells through the metabolic activity of the cells.  
The cancer cells were seeded in 96-well plates with a seeding density 
of 10,000 cells/well and were cultured in DMEM supplemented with 10% 
FBS and 1% penicillin-streptomycin solution in an incubator at 37 
o
C, 5% 
CO2, and 95% relative humidity. The cells were allowed to adhere to the well 
bottom upon overnight incubation. Then the medium was replaced with the 
sample solutions of different concentrations. Meanwhile, wells containing 
only cell culture medium were prepared as untreated controls. At the 
predetermined time, the medium containing samples was aspirated and the 
wells were washed with 1 ×PBS solution for two times to removed non-
internalized sample. Then 100 μL of DMEM and 10 μL of MTT solution (5 
mg/mL in 1 ×PBS solution) were added to the wells. After incubation for 4 h 
at 37 
o
C, the solution was removed and the formazan precipitate was dissolved 





solution was then quantified spectrophotometrically using a microplate reader 
(TECAN SpectraFluor Plus) at 570 nm. Cell viability was expressed by the 
following equation:  
Cell viability (%) = Abssample / Abscontroll  100% 
where Abssample was the absorbance for cells treated with samples, while 
Abscontroll was the absorbance for untreated control cells. All the tests were 
performed in multiples. 
 
4.2.11. Measurements 
Gel permeation chromatography (GPC) was performed on a Waters 2690 
apparatus with two columns in series (Waters Ultrahydrogel 250 and 200) and 
a Waters 410 refractive index detector. A mixture of 0.5 M acetic acid/0.5 M 
sodium acetate was used as eluent, and poly(ethylene oxide) standards were 
used. Nuclear magnetic resonance (NMR) spectra were obtained on a Bruker 
DPX 400 MHz NMR spectrometer. A Brookhaven BIS200 laser light 
scattering system was used for dynamic light scattering (DLS) measurements. 
The light source is a power adjustable vertically polarized 35 mW argon ion 
laser with a wavelength of 633 nm. The scattering angle was fixed at 90
 o
 for 
measuring the hydrodynamic radius (Rh) and the average scattering intensity. 
Rh values were obtained using a CONTIN analysis. TEM images were 
obtained using a high resolution Philips CM300 transmission electron 
microscope (FEGTEM) at 300 kV, and the samples were prepared by 
dropping micelles solution onto a copper grid cover with carbon followed by 
drying in a desiccator. Then, the dried grid was left in 1% osmium oxide in 





recorded on a Perkin–Elmer LS55 Fluorescence Spectroscopy instrument 
fitted with a R928-sensitive sample photomultiplier. Confocal imaging was 
done with Olympus Fluoview FV1000 with excitation wavelength of 405 nm. 
 
4.3. Results and discussion  
4.3.1. Synthesis of linear poly(BAC-AMPD) 
Disulfide- and 2
o
 amine- containing linear poly(BAC-AMPD) was prepared 
via Michael Addition polymerization of AMPD with an equimolar BAC in 
methanol. According to the previous reports [83,368,369,418], linear 
poly(BAC-AMPD)  should be produced due to the reactivity sequence of the 
three type of amines in AMPD, i.e., 2
o
 amine (original) > 1
o
 amine >> 2
o
 
amine (formed), with the 2
o
 amine (formed) being kept intact when 
trifunctional amine was polymerized with an equimolar diacryl monomer. 
However, poly(BAC-AMPD) synthesized in methanol was found containing 
branching units as indicated by the appearance of peak at ca. 50.2 ppm in the 
13
C NMR spectrum as shown in Figure 4.1a, and the degree of branching was 
determined to be ca. ~20% via equation E4.1. 
Degree of branching = I50.2 / I46.5 × 100%    (E4.1) 
















C NMR spectra of poly(BAC-AMPD) synthesized and measured 
in a) methanol-d4; b) mixture of methanol-d4/DMSO-d6 (70/30); c) mixture of 
methanol-d4/DMSO-d6 (40/60); d)DMSO-d6. The peaks attribution is listed in 
Scheme 4.1.  
 
Considering that the branched structure might affect the self-assembly 
behaviour of poly(BAC-AMPD)-g-PEG-g-CE and lead to loss and instable 
aggregates with a poor and insecure drug encapsulation, linear poly(BAC-
AMPD) was pursued [420,421]. The formation of branching unit was due to 
the narrow reactivity difference among the three types of amines in AMPD, 
i.e., 2
o
 amine (original), 1
o
 amine and 2
o
 amine (formed), in methanol which 
led to the participation of 2
o
 amine (formed) in the reaction. So the reactivity 
of 2
o
 amine (formed) in AMPD should be reduced in order to produce linear 
poly(BAC-AMPD). Here the Michael Addition reaction is a base-catalyzed 
nucleophilic addition of amine to α,β-unsaturated carbonyl [353]. The amine 
also functions as the base catalyst, and its basicity determines the 
polymerization rate and the reactivity of its functional amine moieties 



































[353,418]. Many of poly(amido amine)s were prepared in methanol or 
methanol/water mixture [368,422,423], as protic methanol can facilitate 
hydrogen transfer and thus increase the reactivity of the amines. In order to 
reduce the reactivity of the 2
o
 amine (formed) in AMPD, aprotic DMSO was 
explored as the polymerization solvent [355]. No peak attributed to the 
branching unit can be observed in 
13
C NMR spectrum of poly(BAC-AMPD) 
produced in polymerization performed in DMSO as shown in Figure 4.1d. 
However, the polymerization rate was so slow that the peaks attributing to the 
carbon double bonds in BAC in
 1
H NMR spectrum disappeared only after 68 
days. Therefore, a mixture of methanol and DMSO was used as 
polymerization solvent. 
13
C NMR spectra of the polymers produced in a 
mixture of solvent of methanol and DMSO with different compositions are 
shown in Figure 4.1. Table 4.1 summarizes the effects of the solvent 
composition on the degree of branching in the polymer produced.  The results 
reflect that the methanol content should be kept below 40% (v/v) to produce 
linear poly(BCA-AMPD). Thus a mixture of 40 % (v/v) methanol and 60% 
(v/v) DMSO was chosen to produce linear poly(BAC-AMPD). Figure 4.1c 
shows 
13
C NMR spectrum of poly(BAC-AMPD) obtained from 
polymerization of AMPD with an equimolar BAC in 40% methanol (v/v) and 
60% DMSO (v/v) at 50 
o
C for 25 days, and it is obvious that no peak 
attributed to the branching units can be observed. The polymerization in the 
mixture of methanol/DMSO (40/60 in v/v) was also monitored using 
13
C 
NMR, and the results shown in Figure 4.2 indicates that the polymerization 
mechanism is the same as the Michael Addition polymerization forming 
linear poly(amino ester)s [83]. First the 2
o





to form the intermediate as shown in Scheme 4.1, and then the 1
o
 amine joins 
in the reaction to form linear poly(BAC-AMPD). The weight average 
molecular weight (Mw) and the molecular weight polydispersity index (PDI) 
of linear poly(BAC-AMPD) produced were determined to be 7175 g/mol and 
2.20, respectively, using GPC. Linear poly(BAC-AMPD) obtained is 










Figure 4.2. Comparison of 
13
C NMR spectra recorded for the polymerization 
of AMPD with an equimolar BAC in 40% methanol-d4 / 60% DMSO-d6 (v/v) 
with a monomer concentration of 20% (w/v) at 50 
o
C for a) 0.75 h; b) 4.5 h; c) 
24.5 h; d) 25 days. The attribution of the peaks is listed in Scheme 4.1.  
 
Table 4.1. Structures of poly(BAC-AMPD) synthesized in a mixture of 
methanol and DMSO of different compositions. 








Branching (%) Methanol DMSO 
100 0 4 12521 2.73 20 
90 10 7 12516 2.77 11 
70 30 12 11631 2.60 9 
40 60 25 7175 2.20 Negligible 
20 80 38 4217 1.69 Negligible 
0 100 68 3397 1.56 Negligible 
 
 


























































4.3.2. Synthesis of poly(BAC-AMPD)-g-PEG-g-CE 
PEG was grafted onto poly(BAC-AMPD) to improve water solubility and 
introduce other performances such as minimizing non-specific adsorption of 
proteins and increasing circulation time in bloodstream [279,424]. As shown 
in Scheme 4.1, PEG was grafted via urethane groups formed by the reaction of 
2
o
 amines in the backbone of poly(BAC-AMPD) with monomethyl PEG 4-
nitrophenyl carbonate. In order to control the grafting degree, the feeding 
molar ratio of PEG to 2
o
 amine in poly(BAC-AMPD) was kept at 1 : 4.5. 
Figure 4.3b shows 
1
H NMR spectrum of poly(BAC-AMPD)-g-PEG, and the 
peaks attributed to the protons of the carbon in PEG adjacent to the urethane 
groups can be observed at ca. 4.17 ppm. The molar ratio of the grafted PEG to 
the BAC-AMPD unit was determined to be ca. 1: 4.3 on the basis of equation 
E4.2: 
Molar ratio of PEG/BAC-AMPD  =  I4.20 / I1.29   (E4.2)                                  
Where I4.20 and I1.29 are the integral intensity of the peaks at 4.20 ppm and 1.29 
ppm, respectively. 
Poly(BAC-AMPD)-g-PEG obtained is soluble in water, methanol and 
DMSO. Then CE was also conjugated onto poly(BAC-AMPD)-g-PEG 
through urethane bonds formed via the reaction of  the remaining 2
o
 amines in 
the backbone of poly(BAC-AMPD) with cholesteryl chloroformate. Figure 
4.3c is 
1
H NMR spectrum of poly(BAC-AMPD)-g-PEG-g-CE, and the 
grafting of CE is confirmed by the appearance of peaks attributed to CE such 
as the peak at ca. 4.43 ppm which is attributed to protons of the double bond in 
CE. The molar ratio of the grafted CE and PEG unit was determined to be 1.8 : 





Molar ratio of CE /PEG = 2 × I4.43 / I4.20    (E4.3) 
Where I4.43  and I4.20  are the integral intensity of the peaks at 4.43 ppm and 
4.20 ppm, respectively. 
Although a great excess of cholesteryl chloroformate was added in the 
reaction, only 1.8 of 3.3 free 2
o
 amines were conjugated. This is probably due 














H NMR spectra of a) poly(BAC-AMPD) in methanol-d4; 
b)poly(BAC-AMPD)-g-PEG in methanol-d4; c) poly(BAC-AMPD)-g-PEG-g-
CE in chloroform-d; d) poly(BAC-AMPD)-g-PEG-g-CE in D2O; e) precipitate 
of aqueous micelles solution of poly(BAC-AMPD)-g-PEG-g-CE after treated 
with 2 mM DTT for 5 days in chloroform-d. 
 
4.3.3. Self-assembly of poly(BAC-AMPD)-g-PEG-g-CE 
Micelles were formed from self-assembly of poly(BAC-AMPD)-g-PEG-g-CE 
in aqueous solution. Figure 4.4a presents the TEM images of the micelles of 
poly(BAC-AMPD)-g-PEG-g-CE, and the average diameter of the micelles is 
determined to be ca. 100 nm. DLS measurement illustrated that the micelles 



































































have an average hydrodynamic diameter of 135.7 ± 13.6 nm, which is larger 
than the micelles in a dry state observed in TEM due to the micelles’ tendency 
to swell in aqeuous solution.Since only the protons of polymer segments with 
a high solution mobility can be observed in solution 
1
H NMR spectrum [425-
427], solution 
1
H NMR spectra were used to get more information of the 
micelles formed. Figure 4.3d shows the 
1
H NMR spectrum of poly(BAC-
AMPD)-g-PEG-g-CE in D2O. Comparing with the 
1
H NMR spectrum of 
poly(BAC-AMPD)-g-PEG-g-CE in chloroform-d as shown in Figure 4.3c, it is 
obvious that the peaks attributed to CE and poly(BAC-AMPD) almost 
disappear, meanwhile the peaks attributed to PEG still can be observed as 
shown in Figure 4.3d. These reflect that the micelles formed contain 
hydrophobic cores composed of CE and poly(BAC-AMPD),which are 
inaccessbile to water, and PEG shells soluble in water.  The CMC of the 
micelles of poly(BAC-AMPD)-g-PEG-g-CE were determined via the 
relationship between the average light scattering intensity and the 
concentration of polymers shown in Figure 4.5 [428], and CMC of the 




















Figure 4.4. TEM images of a) micelles of poly(BAC-AMPD)-g-PEG-g-CE 












Figure 4.5. Relationship between the average scattering intensity from DLS 
measurements and the concentration of poly(BAC-AMPD)-g-PEG-g-CE 
(µg/mL) in deionized water. 
 
Redox-induced degradation of the micelles of poly(BAC-AMPD)-g-
PEG-g-CE were investigated using a model compound, DTT. After incubation 
with 2 mM DTT for 5 days,  some precipitation was formed in the micelles 
solution of poly(BAC-AMPD)-g-PEG-g-CE. The precipitate was collected 
and lyophilized, and 
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obtained as shown in Figure 4.3e. From Figure 4.3e, the molar ratio of CE to 
PEG in the precipitate could be measured using equation E4.3. It was found 
that the molar ratio of CE to PEG in the precipitate is 8 times higher than that 
of poly(BAC-AMPD)-g-PEG-g-CE. So it could be concluded that the 
segments containing hydrophobic CE precipitated and those containing PEG 
remained soluble in the solution after DTT-induced degradation. Furthermore, 
the formation of precipitate upon DTT-induced degradation also illustrates 
non-uniform degradation of the amphiphilic polymers. The polymer sections 
grafted to PEG which is more hydrophilic tends to degrade more rapidly than 
parts conjugated to CE which is more hydrophobic. As a result, after shedding 
the PEG shells, the hydrophobic cores aggregate to form the precipitate. 
The cytotoxicity of micelles of poly(BAC-AMPD)-g-PEG-g-CE was evaluted 
in MCF-7 and HepG2 cell lines using the MTT assay, and the results are 
shown in Figure 4.6. In both MCF-7 and HepG2 cell lines, the micelles of 
poly(BAC-AMPD)-g-PEG-g-CE show limited cytotoxicity. Around 80% and 
90% of MCF-7 cells and HepG2 cells are still viable, respectively, when 























Figure 4.6. in vitro cytotoxicity of polymer in MCF-7 cells and HepG2 cells. 
All data represent mean  SD (n = 6). 
 
4.3.4. DOX loaded micelles 
DOX loading was performed by dropwise addition of water into DMSO 
solution of poly(BAC-AMPD)-g-PEG-g-CE and DOX followed by dialysis. 
The loading capacity and efficiency of DOX loaded micelles were measured 
to be 5.4 ± 1.7 % and ~ 27.1 ± 8.9 %, respectively. Figure 4.4b shows TEM 
images of DOX loaded micelles, and the diameter was determined to be ca. 
100 nm. DLS measurement showed that the diameter of the micelles in 
aqueous solution was ca. 131 nm. Thus the loading of DOX did not increase 
the micelle size significantly.  
The drug release profiles of DOX loaded micelles were investigated in 
PBS buffer under pH 7 and pH 5 with and without DTT (2 mM) at 37 
o
C, 
respectively, and the results are presented in Figure 4.7. Figure 4.7 shows that 
the release profiles of DOX are similar at pH 7 and pH 5 without DTT in the 






However, ca. 29% and 50% of DOX are released at pH 7 and pH 5 in 72 h, 
respectively. These might reflect that ca. 24% - 27% of DOX was loaded near 
the surface of the hydrophobic cores and possibly in the PEG shells of the 
micelles which were released in the early period regardless of pH 
environment. So similar release profiles are observed at pH 7 and pH 5 in first 
10 h. Then the remaining DOX, which were probably encapsulated deep in the 
hydrophobic core, exhibited a release profile at pH 7 different from that at pH 
5.At pH 7, the integrity of the hydrophobic cores were maintained well, so 
only 5% more of the encapsulated DOX was released from 10 h to 72 h. In 
comparison, at pH 5, the protonated amines in the backbone of poly(BAC-
AMPD)-g-PEG-g-CE formed at pH 5 caused swelling of the cores resulting in 
the release of more DOX in 72 h [97]; also the protonated DOX formed at pH 
5 with a high solubility in aqueous solution could also lead to release of more 
DOX. Figure 4.7 shows that DOX is released faster in the presence of DTT at 
both pH 7 and pH 5. At pH 7 and pH 5, ca. 37% and 38% of DOX are released 
in 10 h, and ca. 44% and 54% of DOX are released in 72 h, respectively. So 
DTT-induced degradation of hydrophobic cores resulted in a fast release of 
more DOX although the degradation resulted in obvious precipitation in 





















Figure 4.7. DOX release profiles of DOX loaded micelles of poly(BAC-
AMPD)-g-PEG-g-CE at (a) pH 7; (b) pH 7 with 2 mM DTT; (c) pH 5; (d) pH 








Figure 4.8. Photograph of DOX loaded micelles aqueous solution at pH 7 and 
pH 5 with and without DTT. 
 
4.3.5. Cellular uptake of DOX loaded micelles and intracellular 
distribution of DOX 
Confocal laser scanning microscopy (CLSM) was applied to investigate the 
cellular uptake of DOX loaded micelles and the intracellular distribution of 
DOX. The micelles were incubated with MCF-7 and HepG2 cell lines which 
contain a high level of GSH intracellularly [373]. The concentration of DOX 
 



































used was kept at 0.8 µg/mL to minimize cytotoxicity but allow sufficient 
uptake for visualization using confocal microscopy. Due to the low 
concentration of DOX applied, very weak DOX fluorescence in the cells could 
be observed after an incubation of 24 h. However, obvious DOX fluorescence 
could be observed in both MCF-7 cells and HepG2 cells after an incubation of 
48 h as shown in Figure 4.9. After an incubation of 48 h, the majority of DOX 
is found in the cytoplasm together with some located around the nuclei of 
MCF-7 cells and HepG2 cells as shown in Figure 4.9.  However, more DOX 
can be observed in the cytoplasm and around the nuclei after an incubation of 
72 h. These results reflect that the DOX loaded micelles of poly(BAC-
AMPD)-g-PEG-g-CE can deliver DOX into cancer cells and also probably to 

































Figure 4.9. Confocal microscopy images of cells after incubation with DOX 
loaded micelles of poly(BAC-AMPD)-g-PEG-g-CE: 1st row and 2nd row: 
MCF-7 cells after an incubation of 48 h and 72 h respectively; 3rd row and 4th 
row: HepG2 cells after an incubation of 48 h and 72 h, respectively. For each 
panel, images from left to right show a,e,i,m) cells with nuclear staining with 
DAPI; b,f,j,n) cells with DOX fluorescence; c.g,k,o) overlays of cells with 
nuclear staining with DAPI and DOX fluorescence; d.h,l,p) under bright field. 
 
4.3.6. Efficacy of DOX loaded micelles in killing cancer cells 
The cytotoxicity of DOX loaded micelles of poly(BAC-AMPD)-g-PEG-g-CE 
was evaluated in MCF-7 and HepG2 cell lines using the MTT assay. As 
shown in Figure 4.10, the DOX loaded micelles display a higher efficacy in 
killing both MCF-7 cells and HepG2 cells than free drug after an incubation of 






several times lower than those of free DOX in MCF-7 cells and HepG2 cells, 
respectively. There are several factors which might have contributed to the 
higher efficacy of DOX loaded micelles of poly(BAC-AMPD)-g-PEG-g-CE. 
The DOX loaded micelles can enter the cells via endocytosis as other drug 
loaded delivery systems [429], which can avoid the efflux of drug out of 
cancerous cells by P-glycoprotein [430].Furthermore, the high intracellular 
GSH concentration can result in the formation of aggregates of the DOX 
loaded micelle cores, which remain in the cells favourably and at the same 
time continue to release more DOX into the cytoplasm [431]. Hence more 
DOX can get into the nuclei of cancer cells to stop DNA replication, inhibit 








Figure 4.10. in vitro cytotoxicity of DOX loaded micelles and free DOX in a) 
MCF-7 cells; b) HepG2 cells. All data represent mean  SD (n = 12). 
 
Table 4.2. IC50 of DOX loaded micelles in MCF-7 cells and HepG2 cells. 
IC50 (µg/mL) MCF-7 HepG2 
DOX loaded micelles 1.44 1.57 









Linear poly(BAC-AMPD) was produced by applying a mixture of 40% 
methanol and 60% DMSO (v/v) as a solvent for Michael Addition 
polymerization of trifunctional amine, AMPD,  with an equimolar 
diacrylamide, BAC. Amphiphilic poly(BAC-AMPD)-g-PEG-g-CE  was 
obtained by conjugating PEG and cholesterol onto the linear poly(BAC-
AMPD) through reactions with the 2
o
 amine groups. Self-assembly of 
poly(BAC-AMPD)-g-PEG-g-CE in aqueous solution formed micelles with 
PEG shells and cores composed of poly(BAC-AMPD) and CE. DOX could be 
loaded into the micelles, and DOX loaded micelles showed pH- and redox-
responsive drug release of DOX and could form redox-induced aggregates. 
These factors contribute to the higher efficacy of the DOX loaded micelles of 
poly(BAC-AMPD)-g-PEG-g-CE in killing cancer cells than free drug. The 
biodegradability and high efficacy of DOX loaded micelles in killing cancer 
cells render poly(BAC-AMPD)-g-PEG-g-CE promising for preparation of 






pH- and redox-responsive micelles of hyperbranched 
poly(amido amine)s for controlled drug delivery 
 
5.1. Introduction 
Dendritic polymers mainly include dendrimers and hyperbranched polymers 
and a classical example is poly(amido amine)s dendimer, Starburst
®
. Although 
hyperbranched polymers may not have structure and polydispersity as well-
defined and uniform as dendrimers respectively, they also possess numerous 
surface functionality and similar three dimensional structures. However, one 
main feature which makes hyperbranched polymers distinctly superior than 
dendrimers, is their ease of synthesis. While hyperbranched polymers can 
usually be fabricated in an one-pot synthesis [370-373,433], dendrimers 
regardless of synthesis method (divergent or convergent) require multiple 
steps and extensive purifications to yield perfect dendrimer structure [326]. So 
hyperbranched polymers are attracting more interest for various applications. 
  With high surface functionality, hyperbranched polymers are 
exceptionally favorable for preparation of prodrugs or drug conjugates with 
drugs being conjugated to the polymers. With this mode of delivery, the drugs 
can remain inactive during delivery and only become potent upon cleavage at 
target sites. As a result of these advantageous features, many drugs like DOX 
[434-436], chlorambucil [437], ibuprofen [438], methyl prednisolone [439], 





hyperbranched polymers and demonstrated their feasibility as drug delivery 
systems.  
  However, compared to drug conjugation, physical encapsulation of 
drugs is a more preferred mode of drug delivery. This is because many 
polymers and drugs do not possess reactive functional groups and without 
chemical modification, pharmacological effectiveness of the drug is 
maintained [442]. When dendritic polymers are applied for encapsulation and 
delivery of drugs, the drugs can be encapsulated within either the 
hyperbranched polymers or the core of the micelles formed. It has been 
reported that ibuprofen, DOX, chlorambucil have been successfully 
encapsulated within hyperbranched polyesters [443,444], hyperbranched 
poly(amine ester)s [445,446] and poly(amido amine)s [447], respectively. In 
some cases, the hyperbranched polymers are modified to yield either 
amphiphilic or double hydrophilic hyperbranched polymers which can serve 
as unimolecular micelles. Typically, the hyperbranched polymers are 
functionalized with PEG to facilitate unimicellar formation. Besides 
commonly employing PEG, numerous works have been carried out with 
hyperbranched aliphatic polyester Boltorn
®
 H40 due to its biodegradability, 
three dimensional structure and chain end functionalities [448-450]. The most 
basic form of such amphiphilic hyperbranched polymer is the PEGylated 
Boltorn
®
 H40 which has been shown to enhance the solubility of paclitaxel by 
more than 35 times [451]. Then, another two groups independently fabricated 
a similar amphiphilic hyperbranched copolymer with H40 core, PLA inner 
shell and PEG outer shells. Disulfide linkages were also introduced as redox-





[452]. On the other hand, the unimicelles are functionalized with folate to 
afford targeted drug delivery [453]. Alternatively, drugs can also be 
encapsulated within the core of the micelles formed by the hyperbranched 
polymers [454-458], with stimuli-responsive micelle systems being 
particularly interesting [436,459]. 
  Low drug loading capacity and efficiency is a major hurdle in the 
development of polymeric micelles for drug delivery [460]. There are several 
factors which can affect the loading capacity of the polymeric micelles. One is 
the affinity of the loaded drugs to the core polymer. For example, due to 
increase in electrostatic interaction, in the form of hydrogen bonds, a higher 
PCL / poly(ethylene oxide) ratio results in a higher loading capacities of 
cucurbitacin B and cucurbitacin I in diblock copolymer micelles [461]. 
Another factor which influences drug loading capacity is the volume of 
hydrophobic core. A higher core volume can hold more drugs. Other factors 
such as solubility and molecular volume of drugs can also have an effect on 
the loading capacity and efficiency [460,462,463].  
 In this chapter, we report a novel pH- and redox-responsive 
hyperbranched poly(amido amine)s for controlled drug delivery as shown in 
Scheme 5.1.Michael addition polymerization AMPD with double molar of 
BAC was performed to produce vinyl-terminated hyperbranched poly(BAC-
AMPD).Then terminal vinyl groups of hyperbranched poly(BAC-AMPD) is 
changed to amine group via reaction with excess AMPD. PEG was conjugated 
to form amphiphilic hyperbranched poly(BAC-AMPD)-PEG to impair 
hydrophilicity. Via self-assembly in aqueous solution, pH- and redox-





encapsulated within the core. The self-assembly and drug loading capacity of 
the micelles were investigated, and pH- and redox-responsive DOX releases 
profiles of the micelles was indicated. Using fluorescence technique, the 
endocytosis of micelles and DOX loaded micelles of hyperbranched 
poly(BAC-AMPD)-PEG by HepG2 and MCF-7 cell lines was imaged and 
quantified with CLSM and flow cytometry analysis, respectively, with GSH 
level being changed. in vitro cytotoxicity study of the micelles in HepG2 and 
MCF-7 cell lines were carried out. 






















5.2. Experimental section 
5.2.1. Materials 
N,N-cystaminebis(acrylamide) (BAC) from Polysciences, 4-
(aminomethyl)piperidine (AMPD) from Alfa Aesar, doxorubicin 
hydrochloride (DOX-HCl) from Fluka Analytical, and L-glutathione reduced 
(GSH), fluorescein isothiocyanate (FITC) and buthionine sulphoximine (BSO) 
from Sigma Aldrich were used as received. Monomethyl poly(ethylene glycol) 
(PEG) (~2000 g/mol) 4-nitrophenyl carbonate was prepared as in our previous 
report [419]. Methanol, ethanol, dimethylsulfoxide (DMSO), and other 
solvents used in this study were purchased from Tedia and used as received.  
  MCF-7 (human breast adenocarcinoma) cells and HepG2 (human 
hepatoma) cells were obtained from American Type Culture Collection 
(ATCC, Rockville, MD). They were maintained in Dulbecco's modified eagle 
medium (DMEM, invitrogen) with 10% fetal bovine serum (FBS), 2 mM 
glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin at 37 C in an 
incubator with 5% CO2 atmosphere. 
 
5.2.2. Synthesis of hyperbranched poly(BAC2-AMPD1) 
In a typical procedure, 2.36 g (20.4mmol) of AMPD in 10 mL of ethanol was 
added dropwise to 10.58g (40.6mmol) of BAC in 50 ml of ethanol at 65 
o
C 
under argon.  After 14 days, the reaction solution was added dropwise into 
11.79 g (101.9 mmol) of AMPD in 60 mL of anhydrous DMSO at room 
temperature under argon. 24 h later, the solution was dialyzed using dialysis 
membrane with a molecular weight cut-off of 3500 in methanol. To monitor 





dissolved in methanol-d4 for 
13
C NMR experiments with the total monomer 
concentrations being kept at ca. 25% (w/v). 
13
C NMR spectra were obtained 
using a power-gated decoupling program (PD) with 200 times scan taking 
ca.10 minutes. 
 
5.2.3. Synthesis of amphiphilic hyperbranched poly(BAC2-AMPD1)-PEG 
In a typical experiment, 3.93 g (1.7mmol) of monomethyl PEG(~2000 g/mol) 
4-nitrophenyl carbonate was added to 6.86 g (18.3mmol) of hyperbranched 
poly(BAC2-AMPD1) in 55 mL of anhydrous DMSO. The solution was stirred 
for 5 days at room temperature under argon followed by dialysis using 
membrane with a molecular weight cut-off of 10 000 in methanol.  
 
5.2.4. Formation and characterization of micelles of hyperbranched 
poly(BAC2-AMPD1)-PEG 
9 mL of deionized water was added at a rate of 0.5 mL/h using a syringe pump 
to 20 mg of hyperbranched poly(BAC2-AMPD1)-PEG in 1 mL of  DMSO 
under a rapid stirring. Then the solution was dialyzed using membrane with a 
molecular weight cut-off of 1000 in deionized water to remove DMSO. In 
order to investigate pH- and redox-responsive properties, 2 mL of micelle 
solution was treated using 10 mM hydrochloride or sodium hydroxide solution 
to designed pH or incubated with 10 mM of GSH at 37 
o
C under stirring, and 








5.2.5. Preparation of DOX loaded micelles 
22.5 mL of deionized water was added at a rate of 0.5 mL/h using a syringe 
pump to 2.5 mL of DMSO containing 50 mg of hyperbranched poly(BAC2-
AMPD1)-PEG, 10 mg of DOX-HCl and 5 µL of triethylamine (TEA) under 
rapid stirring. Then the solution was dialyzed using membrane with a 
molecular weight cut-off of 1000 in deionized water to remove DMSO and 
DOX. After dialysis, aggregates of unloaded DOX were removed by filtration 
through a filter with a pore diameter of 0.45 µm. To measure the DOX loading 
capacity, DOX loaded micelle solution was lyophilized, and a certain amount 
of dried DOX loaded micelles was dissolved in DMSO. The solution was 
dialyzed using membrane with a molecular weight cut-off of 2000 in DMSO. 
The concentration of DOX in the dialysis solution was measured with the 
concentration of DOX being determined based on a calibration curve. The 
loading capacity and the loading efficiency were calculated:  
Loading capacity = Mass of DOX loaded / Mass of DOX loaded micelles × 
100% 
Loading efficiency = Mass of DOX loaded / Mass of DOX added × 100 %. 
 
5.2.6. in vitro DOX release of DOX loaded micelles 
2 mL of the DOX loaded micelle solution in dialysis membrane with a 
molecular weight cut-off of 10 000 was submerged in 40 mL of PBS at 37 
o
C 
with various conditions, i.e., pH 7, pH 5, pH 7 with 10 mM of GSH 
respectively. At a predetermined interval, 4 mL of dialysis solution (PBS) was 





solutions at 590 nm was measured with an excitation of 440 nm, and the 
concentration of DOX was determined based on a calibration curve. 
 
5.2.7. Preparation of FITC tagged micelles of hyperbranched poly(BAC2-
AMPD1)-PEG 
The micelle solution was reacted with excess of FITC in the presence of TEA 
under stirring at room temperature. After 1 day, FITC tagged micelle solution 
was dialyzed extensively using a membrane a molecular weight cut-off of 
1000 in ample of deionized water. 
 
5.2.8. Cellular imaging 
MCF-7 and HepG2 cell lines were seeded in 8 chamber borosilicate 
coverglass with a cell density of 5,000 cells/chamber and were cultured in 
DMEM supplemented with 10% FBS and 1% penicillin-streptomycin solution 
in an incubator at 37
o
C, 5% CO2, and 95% relative humidity. The cells were 
allowed to adhere to the chamber bottom upon overnight incubation. Then, the 
medium was replaced with fresh medium which contained either with or 
without 0.2 mM of BSO. The cells were incubated for another 3 days before 
the medium was again replaced with DOX loaded micelles solution or FITC 
tagged micelle solution in DMEM. At a designed time interval, the medium 
was removed and the chamber washed with 500 µL of PBS once followed by 
adding 250 µL of 90 % (v/v) cold ethanol to fix the cells in dark for 10 
minutes. After the ethanol was aspired, the wells were washed with 500 µL of 
PBS, and 200 µL of 4',6-diamidino-2-phenylindole (DAPI) (10µg/mL) was 





the wells were washed with 500 µL of PBS twice followed by adding 150 µL 
of PBS to prevent the cells from drying up. The cells were imaged under a 
confocal laser scanning microscope (CLSM) (FV1000, Olympus, Japan). 
 
5.2.9. Flow cytometry analysis 
MCF-7 and HepG2 cell lines were seeded in 12 well-plates with a cell density 
of 6 x 10
4
 and 3 x 10
4
cells/chamber respectively and were cultured in DMEM 
supplemented with 10% FBS and 1% penicillin-streptomycin solution in an 
incubator at 37
o
C, 5% CO2, and 95% relative humidity. The cells were 
allowed to adhere to the well bottom upon overnight incubation. Then, the 
medium was replaced with fresh medium which contained either with or 
without 0.2 mM of BSO. The cells were incubated for another 3 days before 
the medium was again replaced with DOX loaded micelles solution or FITC 
tagged micelle solution in DMEM. At a designed time interval, the medium 
was removed and the chamber washed with 500 µL of PBS twice and the cells 
were unseeded. After centrifugation, the cell pellets were dispersed in 70 % 
(v/v) ethanol and stored in -20 
o
C freezer. Lastly, the fixed cell suspensions 
were analysed using the BD LSR Fortessa Flow Cytometry Analyser. 
 
5.2.10. in vitro cytotoxicity evaluation of samples 
The in vitro cytotoxicity of hyperbranched poly(BAC2-AMPD1)-PEG, DOX-
HCl, and DOX loaded micelles of hyperbranched poly(BAC2-AMPD1)-PEG 
were evaluated in MCF-7 and HepG2 cell lines. Viability of the cells was 
assessed by the standard thiazolyl blue [3-(4,5-dimethyliazolyl-2)-2,5-





determination of the number of viable cells through the metabolic activity of 
the cells.  
The cancer cells were seeded in 96-well plates with a cell density of 
2,500 cells/well and were cultured in DMEM supplemented with 10% FBS 
and 1% penicillin-streptomycin solution in an incubator at 37 
o
C, 5% CO2, and 
95% relative humidity. The cells were allowed to adhere to the well bottom 
upon overnight incubation. Then, the medium was replaced with fresh medium 
which contained either with or without 0.2 mM of BSO. The cells were 
incubated for another 3 days before the medium was exchanged with the 
sample solutions of different concentrations in DMEM containing with or 
without 0.2 mM BSO. Meanwhile, wells containing only cell culture medium 
were prepared as untreated controls. At the predetermined time, the medium 
containing samples was aspirated and the wells were washed with 1 ×PBS 
solution for two times to removed non-internalized sample. Then 100 μL of 
DMEM and 10 μL of MTT solution (5 mg/mL in 1 ×PBS solution) were 
added to the wells. After incubation for 4 h at 37 
o
C, the solution was removed 
and the formazan precipitate was dissolved in 100 μL of dimethyl sulfoxide 
(DMSO). The absorbance intensity of the solution was then quantified 
spectrophotometrically using a microplate reader (TECAN SpectraFluor Plus) 
at 570 nm. Cell viability was expressed by the following equation:  
Cell viability (%) = Abssample / Abscontroll  100% 
where Abssample was the absorbance for cells treated with samples, while 
Abscontroll was the absorbance for untreated control cells. All the tests were 







Gel permeation chromatography (GPC) was performed on a Waters 2690 
apparatus with two columns in series (Waters Ultrahydrogel 250 and 200) and 
a Waters 410 refractive index detector. A mixture of 0.5 M acetic acid/0.5 M 
sodium acetate was used as eluent, and poly(ethylene oxide) standards were 
used. Nuclear magnetic resonance (NMR) spectra were obtained on a Bruker 
DPX 400 MHz NMR spectrometer. A Brookhaven BIS200 laser light 
scattering system was used for dynamic light scattering (DLS) measurements. 
The light source is a power adjustable vertically polarized 35 mW argon ion 
laser with a wavelength of 633 nm. The scattering angle was fixed at 90
 o
 for 
measuring the hydrodynamic radius (Rh) and the average scattering intensity. 
Rh values were obtained using a NNLS analysis. TEM images were obtained 
using a high resolution Philips CM300 transmission electron microscope 
(FEGTEM) at 300 kV, and the samples were prepared by dropping micelles 
solution onto a copper grid cover with carbon followed by drying in a 
desiccator. Then, the dried grid was left in 1% osmium oxide in heptane for 2 
h.Fluorescence excitation and emission spectra were recorded on a Perkin–
Elmer LS55 Fluorescence Spectroscopy instrument fitted with a R928-
sensitive sample photomultiplier. Confocal imaging was done with Olympus 
Fluoview FV1000 with excitation wavelength of 405 nm while the flow 









5.3. Results and Discussion 
5.3.1. Synthesis of vinyl-terminated hyperbranched poly(BAC2-AMPD1) 
Michael Addition polymerization of AMPD with a double molar BAC was 
conducted in ethanol at 65 
o
C. Similar to the Michael addition polymerization 
of AEPZ with a double molar of diacrylate [370], the reaction of AMPD with 
a double molar BAC forms B’B”A intermediate first via the reaction of the 2o 
amine (original) with BAC as shown in Scheme 5.1. As shown in Figure 5.1a, 
the peaks attributed to B’B”A intermediate appear, e.g., the peak d2 at ca. 52.9 
ppm, after the reaction is performed in ethanol at 65 
o
C for 0.25 h. At this 
stage, Figure 5.1a also shows that unreacted AMPD monomer still exists as 
reflected by the corresponding peaks, e.g., the peak c1 at ca. 30.0 ppm. After 
the reaction was performed for 4 h, Figure 5.1b shows that B’’A2 intermediate 
is formed as reflected by the appearance of the corresponding peaks, e.g., the 
peak a3 at 55.0 ppm. Vinyl-terminated hyperbranched poly(BAC2-AMPD1) is 
formed via the polymerization of B’’A2 intermediate. Figure 5.1c indicates 
that the dendritic unit is formed as reflected by the appearance of the 
corresponding peaks, e.g., the peak a4 at ca. 59.7 ppm, after the reaction is 
performed for 48 h, with the 2
o
 amine (formed) still existing. Figure 5.1d 
indicates that almost all the 2
o
 amine (formed) is consumed as reflected by the 
disappearance of the corresponding peaks, e.g., the peak a3, after the reaction 
is performed for 240 h. Originally, the polymerization was performed in 
methanol at 50 
o
C following our previous works [64], however, the reaction 
was slow with the dendritic unit being formed 3 days later, and the 2
o
 amine 
(formed) being consumed after 28 days. When the polymerization was 
performed in a mixture of DMSO/water (80/20) (v/v) at 80 
o





reaction rate, no dendritic unit was formed even after 11 days. Therefore, 
ethanol was adopted for the polymerization.  
 The vinyl terminal group of hyperbranched poly(BAC2-AMPD1) was 
converted into amine via the reaction with excess AMPD in DMSO [370]. The 
complete conversion of the vinyl group to amine is indicated by the 
disappearance of the vinyl peaks at 125.5 ppm and 130.5 ppm as shown in 
Figure 5.1e. Three possible reactions may occur between the vinyl group and 
AMPD as shown in Scheme 5.1, i.e., the reaction between the vinyl group and 
2
o
 amine (original), 1
o
 amine and the crosslinking reaction with 2 vinyl 
terminals, respectively. Since the reactivity sequence of the three amines of 
AMPD is 2
o
 amine (original) > 1
o
 amine >> 2
o
 amine (formed) [77,82], the 
vinyl group reacts with the 2
o
 amine (original) instead of 1
o
 amine when 
excess AMPD is presented. This is supported by the appearance of the 
characteristic peaks of the unit such as the peak c2 at 29.4 ppm in Figure 5.1e. 
Meanwhile, the peaks attributed to the unit from the reaction with 1
o
 amine 
such as the peaks a3 and h3 cannot be observed. Therefore, most of the vinyl 
groups react with the 2
o
 amine (original) of AMPD forming hyperbranched 
poly(BAC2-AMPD1) terminated with –NH2, hyperbranched poly(BAC2-
AMPD1)-NH2. The molecular weight of hyperbranched poly(BAC2-
AMPD1)-NH2 is determined to be 75.4 ± 1.1 k Dalton from Zimm plot 
obtained in methanol shown in Figure 5.2a. Hyperbranched poly(BAC2-

























































































































Figure 5.1. Comparison of 
13
C NMR spectra of the product of Michael 
Addition polymerization of AMPD with a double molar BAC in ethanol with a 
monomer concentration of 25% (w/v) at 65 
o
C obtained a) for 0.25 h; b) for 4 
h; c) for 48 h; d) for 240 h; e) after reaction with AMPD, and f) after 
PEGylation. The spectra were obtained in methanol-d4.The attribution of the 














Figure 5.2. Zimm plot of a) amino-terminated hyperbranched poly(BAC2-






5.3.2. Synthesis of hyperbranched poly(BAC2-AMPD1)-PEG 
PEG has been demonstrated to have various functions including membrane 
penetration [273-278], prevent nonspecific protein adsorption, provide long-
circulation time in blood vessel [279-284] and facilitate endocytosis [285]. So 
PEG was conjugated to the –NH2 terminals of hyperbranched poly(BAC2-
AMPD1)-NH2  via the formation of urethane bond as shown in Scheme 5.1. To 
control the degree of PEG conjugation, the feeding molar ratio of PEG to the 
terminal –NH2 was kept at 1 : 3.5. From the 
13
C NMR spectrum shown in 
Figure 5.1f, the molar ratio of PEG attached is determined to be ca. 1 : 4.1 
using equation E5.1. 
Molar ratio of PEG / terminals = 2 ×  I157.48 / I29.29   (E5.1) 
Where I157.48 and I29.4 are the integral intensities of the peaks of k and c2 at 
157.5 ppm and 29.4 ppm, respectively. 
Hyperbranched poly(BAC2-AMPD1)-PEG is soluble in methanol, 
ethanol, and DMSO. The molecular weight of hyperbranched poly(BAC2-
AMPD1)-PEG is 125.6 ± 2.6 k Dalton obtained from Zimm plot in methanol 
shown in Figure 5.2b. So each hyperbranched poly(BAC2-AMPD1) 
macromolecule is conjugated with ~25 PEG chains determined using equation 
E5.2: 
Number of PEG chains conjugated to each hyperbranched poly(BAC2-
AMPD1) macromolecule = (MwB – MwA) / 2000   (E5.2) 
Where MwB and MwA are the molecular weights of hyperbranched 







5.3.3. Self-assembly of hyperbranched poly(BAC2-AMPD1)-PEG 
Polymer self-assembly occurred when deionized water was added at a rate of 
0.5 ml/h into DMSO solution of hyperbranched poly(BAC2-AMPD1)-PEG. 
Figure 5.3a presents TEM images of the self-assembly obtained stained with 
OsO4. It can be observed that the self-assembly is in the form of micelles with 
an average diameter of ca. 87 nm at dry state. DLS measurements show that 
the diameter of the swollen micelles obtained in aqueous solution is ca. 233.2 
± 13.4 nm. The CMC of the micelles was determined to be ca. 21.1 µg/mL 
using DLS by plotting the average scattering intensities of different polymer 
concentrations as shown in Figure 5.4b [77,428]. Since only the protons of 
polymer segments with a high mobility in solution can be observed in solution 
1
H NMR spectrum [425-427],
 1
H NMR spectra were used to get more 
information of the micelles formed. Figures 5.5a and 5.5b show 
1
H NMR 
spectra of hyperbranched poly(BAC2-AMPD1)-PEG in methanol-d4 and in 
D2O obtained by dissolving directly, respectively. Although the peaks become 
broadened, most of the peaks in Figure 5.5a can still be observed in Figure 
5.5b. Figure 5.5c shows 
1
H NMR spectrum of micelles obtained by adding 
D2O slowly into DMSO solution of hyperbranched poly(BAC2-AMPD1)-PEG 
followed by dialysis. In comparison with Figure 5.5b, it is obvious that only 
the peaks attributed to PEG can be observed which indicates that the micelles 
are formed with PEG shells and poly(BAC2-AMPD1) cores inaccessible to 
water [77,425-427]. So the micelles can only be obtained via slow addition of 
water into DMSO solution of hyperbranched poly(BAC2-AMPD1)-PEG 
rather than dissolving in water directly. So the self-assembly of hyperbranched 





solvent for both the hydrophilic and hydrophobic components to a selective 
solvent only for the hydrophilic component.  
 
Figure 5.3. TEM images of a) micelles of hyperbranched poly(BAC2-
AMPD1)-PEG stained with osmium oxide; b) DOX loaded micelles of 











Figure 5.4. Relationship between the average scattering intensity from DLS 
measurements and the concentration of hyperbranched poly(BAC2-AMPD1)-
PEG (µg/mL) in deionized water, a) hyperbranched poly(BAC2-AMPD1)-
PEG dissolved in deionized directly; b) micelles of hyperbranched 















































H NMR spectra of a) hyperbranched poly(BAC2-AMPD1)-PEG 
in methanol-d4; b) hyperbranched poly(BAC2-AMPD1)-PEG dissolved in 
D2O directly; c) micelles of hyperbranched poly(BAC2-AMPD1)-PEG in D2O 
formed by adding D2O into DMSO followed by dialysis.  
 
pH dependent hydrodynamic diameter of the micelles of 
hyperbranched poly(BAC2-AMPD1)-PEG was investigated using DLS, the 
results shown in Figure 5.6. As pH was decreased, the diameter of the micelles 
increased due to swelling induced by the protonation of the amines. Also it 
was shown that the average scattering intensity of the micelles declined by 
more than 95% in 15 minutes after incubation with 10 mM of GSH, present in 



























Figure 5.6. pH dependent a) hydrodynamic size; b) average scattering 
intensity from DLS measurement, of micelles of hyperbranched poly(BAC2-









Figure 5.7. Hydrodynamic size distribution of micelles of hyperbranched 
poly(BAC2-AMPD1)-PEG in the presence of 10 mM GSH, a) before 
incubation; b) 15 min post incubation at 37 
o
C. (Normalized intensity) 
 
5.3.4. DOX loaded micelles of hyperbranched poly(BAC2-AMPD1)-PEG 
Anti-cancer drug, doxorubicin (DOX) which intercalate with DNA to induce 
cell death [432,467], was loaded into the micelles of hyperbranched 
poly(BAC2-AMPD1)-PEG during the self-assembly process. DOX content 
and loading efficiency of the micelles of hyperbranched poly(BAC2-
































































AMPD1)-PEG are ca. 10.5 % and ca. 52.3 %, respectively. DOX loaded 
micelles have a hydrodynamic diameter of ca. 193.1 ± 17.65 nm determined 
using DLS, and a diameter of ca. 108 nm in dry state obtained from TEM 
image as shown Figure 5.3b. CMC of DOX loaded micelles is 4.5 µg/ml, 
which is lower than the micelles without DOX as illustrated in Figure 5.4c. 
The release profiles of DOX from micelles of hyperbranched 
poly(BAC2-AMPD1)-PEG were investigated in PBS under pH 7, pH 5, and 
pH 7 with 10 mM GSH, respectively, and the results are shown in Figure 5.8. 
The release rate of DOX is considerably faster at pH 5 than at pH 7. After 10 
h, 17 % of DOX is released at pH 7 as compared to 35% at pH 5. A lower pH 
leads to a higher protonation degree of the amines of poly(BAC2-AMPD1) 
associated with a greater swelling of the micelles and therefore a faster release 
of DOX. When the DOX loaded micelle solution is incubated with 10 mM of 
GSH, a much faster release is observed with 50 % and 100% of DOX being 
released in 10 h and 72 h, respectively. This is caused by thiol-induced 
degradation leading to dissociation of the micelles.  
Comparing these results to the systems described in chapter 4, we can 
infer that micelles self-assembled from less hydrophobic polymers which is 
poly(BAC2-AMPD1)-PEG tend to release the drugs more quickly. Weaker 
hydrophobic interactions between drugs and polymers, and less stable micelles 
can contribute to this rapid release significantly. Nevertheless, it is also 
important to note that the structures of the polymers in both cases are highly 


































Figure 5.8. DOX release profiles of DOX loaded micelles of hyperbranched 
poly(BAC2-AMPD1)-PEG at (a) pH 7; (b) pH 5; (c) pH 7 with 10 mM GSH. 
All data represent mean  SD (n = 3). 
 
5.3.5. Cellular uptake of FITC tagged micelles and DOX loaded micelles 
The cellular uptake of the micelles of hyperbranched poly(BAC2-AMPD1)-
PEG was investigated using confocal microscopy. Although fluorescence can 
be observed from poly(amido amine)s similar to those amine-containing 
polymers [377], the micelles were tagged with FITC for accurate analysis. 
FITC tagged micelles were incubated with HepG2 and MCF-7 cells for 72 h. 
Both HepG2 and MCF-7 cells, with a high intracellular GSH level, were also 
incubated with 0.2 mM of BSO for 72 h to reduce the intracellular GSH 
concentration by ca. 4 times in order to investigate the effects of reductive 
potential [373]. Figure 5.9 shows the confocal microscopy images of HepG2 
cells after incubation with FITC tagged micelles of hyperbranched 
poly(BAC2-AMPD1)-PEG for different time intervals. In HepG2 without or 
with BSO treatment, FITC fluorescence is detected in the cytoplasm after 





readily probably via endocytosis. The effect of BSO treatment on the HepG2 
is indicated by the results of flow cytometry shown in Figure 5.10. BSO 
treatment results in a higher fluorescence intensity from HepG2, and the 
fluorescence intensity increases with the incubation time from 5 h to 72 h. In 
contrast, the fluorescence intensity from the cells without BSO treatment 
increases by ca. 40% as the incubation time increases from 5 h to 24 h, and 
then drops ca. 12% after 72h incubation. This might be due to that a lower 
reduction potential in the intracellular apartments induced by BSO treatment 
retards the degradation of the micelles, and therefore leads to accumulation of 






































Figure 5.9. CLSM images of HepG2 incubated with FITC tagged micelles of 
hyperbranched poly(BAC2-AMPD1)-PEG and DOX loaded micelles of 
hyperbranched poly(BAC2-AMPD1)-PEG. a,e) cells with nucleus staining 
with DAPI; b,f) cells with FITC or DOX fluorescence; c,g) overlays of cells 
with nucleus staining with DAPI and FITC or DOX fluorescence; d,h) under 








Figure 5.10. Mean FITC and DOX fluorescence intensity detected by flow 
cytometry when HepG2 cells were incubated with FITC tagged micelles of 
hyperbranched poly(BAC2-AMPD1) and DOX loaded micelles of 
hyperbranched poly(BAC2-AMPD1) respectively. All data represent mean ± 
SD. (n = 3). 
 
Figure 5.11 shows the confocal microscopy images of MCF-7 cells 
after incubation with FITC tagged micelles of hyperbranched poly(BAC2-
AMPD1)-PEG. Similarly the micelles can enter the cells readily without or 
with BSO treatment.  The flow cytometry results shown in Figure 5.12 
indicates that the fluorescence intensity reaches the maximum at 24 h and then 
decreases with time, and the effect of BSO treatment on MCF-7 cells is a 





































































Figure 5.11. CLSM images of MCF-7 incubated with FITC tagged micelles of 
hyperbranched poly(BAC2-AMPD1)-PEG and DOX loaded micelles of 
hyperbranched poly(BAC2-AMPD1)-PEG. a,e) cells with nucleus staining 
with DAPI; b,f) cells with FITC or DOX fluorescence; c,g) overlays of cells 
with nucleus staining with DAPI and FITC or DOX fluorescence; d,h) under 























Figure 5.12. Mean FITC and DOX fluorescence intensity detected by flow 
cytometry when MCF-7 cells were incubated with FITC tagged micelles of 
hyperbranched poly(BAC2-AMPD1) and DOX loaded micelles of 
hyperbranched poly(BAC2-AMPD1) respectively. All data represent mean ± 
SD. (n = 3). 
 
DOX loaded micelles of hyperbranched poly(BAC2-AMPD1)-PEG 
were incubated with HepG2 and MCF-7 cells without or with BSO treatment, 
respectively. As shown in Figure 5.9 and 5.11, DOX can be observed in the 
cytoplasm and nucleus of HepG2 and MCF-7 cells after incubation of 5 h. The 
results from flow cytometry shown in Figure 5.10 and 5.12 shows that DOX 
fluorescence intensity increase insignificantly with incubation time from 5 h to 
72 h in HepG2 cells; and increase from 5 h to 24 h but level off till 72 h in 
MCF-7 cells. The effect of BSO treatment is negligible on the DOX 
fluorescence intensity in both HepG2 and MCF-7 cells.  
 
5.3.6. in vitro cytotoxicity of DOX loaded micelles 
in vitro cytotoxicity of hyperbranched poly(BAC2-AMPD1)-PEG and DOX 






































treatment, respectively. More than 70 % of the HepG2 cells and MCF-7 cells 
are viable after incubation with 200 µg/ml of hyperbranched poly(BAC2-
AMPD1)-PEG for 72 h regardless of without or with BSO treatment, which 
shows a low cytotoxicity of the polymer as shown in Figure 5.13. Figure 5.14 
and 5.15 illustrate the cytotoxicity of DOX loaded micelles of hyperbranched 
poly(BAC2-AMPD1)-PEG in HepG2 cells and MCF-7 cells, respectively. 
Figure 5.14 indicates that free DOX-HCl displays a higher cytotoxicity than 
DOX loaded micelles in HepG2 cells without or with BSO treatment. 
Furthermore, it is also reflected that BSO treatment shows insignificant effects 
on the cytotoxicity of free DOX-HCl and DOX loaded micelles of 
hyperbranched poly(BAC2-AMPD1)-PEG. Figure 5.15 shows that DOX 
loaded micelles of hyperbranched poly(BAC2-AMPD1)-PEG shows 
cytotoxicity comparable to free DOX-HCl in MCF-7 cells without or with 
BSO treatment, and the effects of BSO treatment is also insignificant. Since 
the DOX loaded micelles can release all the DOX loaded in 72 h at pH 7 with 
10 mM GSH as shown in Figure 5.8, the difference in cytotoxicity of DOX 
loaded micelles and free DOX-HCl in HepG2 and MCF-7 cells should not be 
due to the incomplete release of DOX, and should be attributed to the different 
cell endocytosis process instead. So far, the cell endocytosis is still not well 
understood. Many features of nanoparticles including shape, size, and surface 
properties affect the cellular uptake [468,469], and endocytosis process is also 
cell type dependent and has many internalization routes such as clathrin-















Figure 5.13. in vitro cytotoxicity of hyperbranched poly(BAC2-AMPD1)-
PEG in HepG2 and MCF-7 with or without BSO treatment. All data represent 











Figure 5.14. in vitro cytotoxicity of DOX loaded micelles of hyperbranched 
poly(BAC2-AMPD1)-PEG and free DOX-HCl in HepG2 with or without 































 HepG2 without BSO treatment
 HepG2 with BSO treatment
 MCF-7 without BSO treatment
 MCF-7 with BSO treatment
 



























 DOX loaded micelles without BSO treatment
 DOX loaded micelles with BSO treatment
 Free DOX-HCl without BSO treatment















Figure 5.15. in vitro cytotoxicity of DOX loaded micelles of hyperbranched 
poly(BAC2-AMPD1)-PEG and free DOX-HCl in MCF-7 with or without 
BSO treatment. All data represent mean ± SD. (n = 3). 
 
5.4. Conclusions 
Vinyl terminated hyperbranched poly(amido amine)s is synthesized via 
Michael Addition polymerization of AMDP with a  double molar BAC in 
ethanol. After the terminal vinyl groups is converted to primary amines via 
reaction with excess AMPD, PEG is conjugated to form hyperbranched 
poly(BAC2-AMPD1)-PEG. pH- and redox-responsive micelles with PEG 
shells and hydrophobic cores of poly(BAC2-AMPD1) can be formed via self-
assembly of hyperbranched poly(BAC2-AMPD1)-PEG in aqueous solution, 
and DOX can be loaded within the micelles with loading capacity and 
efficiency of ca. 10.5 % and ca. 52.3 % respectively. DOX can be released 
faster at pH 5 and in the presence of 10 mM of GSH. The micelles of 
hyperbranched poly(BAC2-AMPD1)-PEG without or with DOX can enter 
HepG2 and MCF-7 cells readily, and DOX can be observed in the nucleus of 
the cells. DOX loaded micelles of hyperbranched poly(BAC2-AMPD1)-PEG 
can kill HepG2 and MCF-7 cells with the cytotoxicity lower or close to free 
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DOX. A lower reductive potential induced by BSO treatment shows 
insignificant effects on these performances, excluding leading to more 










MRI is a powerful, non-invasive and non-radioactive diagnostic imaging 
technique which can provide imaging with a high spatial resolution and a 
multiple physical contrast, and MRI contrast agents are always needed to 
improve the quality of imaging to allow more accurate diagnosis of diseases 
[31,177]. Currently, MRI contrast agents used in clinic are small molecular 







. However, these MRI contrast agents have their limitations 
including short retention time and fast vascular extravasation due to their low 
molecular weight [471]. One of the approaches to overcome these limitations 
is to integrate small molecular Gd(III) chelates with polymers to form 
macromolecular MRI contrast agents which have shown to reduce vascular 
extravasation [177,179,472-475], are able to target tumor and have higher T1 
relaxivity [177,472-477]. However, the slow and incomplete excretion of 
Gd(III) ions integrated in these macromolecules can result in side effects such 
as nephrogenic systemic fibrosis (NSF) especially in renal dysfunctional 
patients [32-34], Therefore macromolecular MRI contrast agents with suitable 
degradation rate are needed for feasible excretion of Gd(III) chelates after 





Besides the conventional biodegradable synthetic polymers like 
poly(ester)s which hydrolyse in the presence of water, several types of 
biodegradable polydisulfide Gd(III) based MRI contrast agents were reported 
with Gd(III) chelates either being linked together or being conjugated to 
polymer via disulfide bonds respectively. Linear macromolecular Gd(III) 
based MRI contrast agents with disulfide in the backbone could be prepared 
by copolymerization of DTPA dianhydride and disulfide containing diamine 
followed by forming Gd-DTPA diamide which has low chelating stability 
[478]. These linear macromolecular Gd(III) based MRI contrast agents showed 
prolonged retention time and improved in vivo contrast enhancement, and are 
degradable and readily excreted via renal filtration [479-481]. Recently a new 
type of polydisulfide Gd(III) based contrast agent with improved chelating 
stability was reported. The agent was obtained by preparing chelate containing 
diamine monomer with chelate units, performing condensation polymerization 
with disulfide containing activated dianhydride to form Gd(III) chelates [482]. 
Here we report a facile approach to synthesize linear biodegradable 
Gd(III) based macromolecular MRI contrast agent with disulfide bonds in the 
backbones. As shown in Scheme 6.1, the disulfide-containing poly(amido 
amine)s, poly(BAC-AMPD), was synthesized via Michael Addition 
polymerization of trifunctional amine, AMPD, and an equimolar diacrylamide, 
BAC. Then PEG and DTPA were conjugated via the reactions with the 
secondary amine remained, respectively, to form poly(BAC-AMPD)-g-PEG-
g-DTPA. Poly(BAC-AMPD)-g-PEG-g-DTPA was complexed with Gd(III) 
ions to produce macromolecular MRI contrast agent, poly(BAC-AMPD)-g-





vitro cytotoxicity and the relaxivity of poly(BAC-AMPD)-g-PEG-g-Gd-DTPA 
were investigated. 











6.2. Experimental section 
6.2.1. Materials 
N,N-cystaminebis(acrylamide) (BAC) was purchased from Polysciences, Inc, 
4-(aminomethyl)piperidine(AMPD) (99%) was purchased from Alfa Aesar, 
and DTPA dianhydride (98%), gadolinium (III) chloride hexahydrate, L-
dithiothreitol (DTT), L-glutathione reduced (GSH) and xylenol orange sodium 
salt indicator for metal titration were purchased from Sigma Aldrich. 
Monomethyl PEG (~2000 g/mol) 4-nitrophenyl carbonate was prepared as in 
our previous report [419]. The other chemicals were of reagent grade and were 
used as purchased. 
MCF-7 (human breast adenocarcinoma) cells and HepG2 (human 






(ATCC, Rockville, MD). They were maintained in Dulbecco's modified eagle 
medium (DMEM, invitrogen) with 10% fetal bovine serum (FBS), 2 mM 
glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin at 37 C in an 
incubator with 5% CO2 atmosphere. 
 
6.2.2. Synthesis of poly(BAC-AMPD) 
3.08 g (26.7 mmol) of AMPD were added into 40 mL of anhydrous methanol 
containing 6.96 g (26.7 mmol) of BAC under stirring at room temperature and 
argon purging. After 1 month, 0.03 g (0.27 mmol) of AMPD was added, and 
the reaction was continued for 1 more day. Then the solution was dialysed in 
methanol using membrane with a molecular weight cutting of 2000. 
 
6.2.3. Preparation of poly(BAC-AMPD)-g-PEG-g-DTPA 
10.17 g (4.5 mmol) of monomethyl PEG 4-nitrophenyl carbonate was added 
into 6.78 g (18 mmol) of dried poly(BAC-AMPD) dissolved in 85 mL of 
anhydrous dimethyl sulfoxide (DMSO) under stirring and argon purging at 
room temperature. 5 days later, the solution was dialyzed in methanol using 
membrane with a molecular weight cutting of 3500.  
0.50 g (0.63 mmol) of dried poly(BAC-AMPD)-g-PEG in 6 mL of 
anhydrous DMSO was added dropwise into 9 mL of anhydrous DMSO 
containing 0.89 g (2.5 mmol) of DTPA dianhydride and 0.385 mL (2.7 mmol) 
of TEA at 50 
o
C under stirring and argon purging. 24 h later, the solution was 
dialyzed in deionized (DI) water using membrane with a molecular weight 






6.2.4. Complexation of poly(BAC-AMPD)-g-PEG-g-DTPA with Gd(III) 
0.04 g (0.11 mmol) of gadolinium (III) chloride hexahydrate was added into 5 
mL of deionized water containing 0.12 g of poly(BAC-AMPD)-g-PEG-g-
DTPA at pH 5.5 under stirring at room temperature for overnight. Then excess 
gadolinium (III) chloride hexahydrate was removed by dialysis in deionized 
water using membrane with a molecular weight cutting of 1000. Xylenol 
orange sodium salt indicator was used to ensure a complete removal of Gd(III) 
ions. After all the Gd(III) ions were removed, the solution was lyophilized. 
Poly(BAC-AMPD)-g-PEG-g-Gd-DTPA was dissolved in deionized water for 
characterization. 
 
6.2.5. in vitro cytotoxicity of poly(BAC-AMPD)-g-PEG-g-Gd-DTPA 
Cytotoxicity of poly(BAC-AMPD)-g-PEG-g-Gd-DTPA was evaluated in 
MCF-7 and HepG2 cell lines. Viability of the cells was assessed by the 
standard thiazolyl blue [3-(4,5-dimethyliazolyl-2)-2,5-diphenyl tetrazolium 
bromide] (MTT) assay. This colorimetric assay allows determination of the 
number of viable cells through the metabolic activity of the cells.  
The cancer cells were seeded in 96-well plates with a seeding density 
of 10,000 cells/well and were cultured in DMEM supplemented with 10% 
FBS and 1% penicillin-streptomycin solution in an incubator at 37
o
C, 5% 
CO2, and 95% relative humidity. The cells were allowed to adhere to the well 
bottom upon overnight incubation. Then the medium was replaced with the 
sample solutions of different concentrations. Meanwhile, wells containing 
only cell culture medium were prepared as untreated controls. At the 





wells were washed with 1 ×PBS solution for two times to removed non-
internalized sample. Then 100 μL of DMEM and 10 μL of MTT solution (5 
mg/mL in 1 ×PBS solution) were added to the wells. After incubation for 4 h 
at 37 
o
C, the solution was removed and the formazan precipitate was dissolved 
in 100 μL of dimethyl sulfoxide (DMSO). The absorbance intensity of the 
solution was then quantified spectrophotometrically using a microplate reader 
(TECAN SpectraFluor Plus) at 570 nm. Cell viability was expressed by the 
following equation:  
Cell viability (%) = Abssample / Abscontrol 100% 
Where Abssample was the absorbance for cells treated with samples, while 
Abscontrol was the absorbance for untreated control cells. All the tests were 
performed in multiples. 
 
6.2.6. Degradation studies of poly(BAC-AMPD) and micelles of 
poly(BAC-AMPD)-g-PEG-g-Gd-DTPA  
5.0 mg/mL of poly(BAC-AMPD) in pH 4.5 acetate buffer solution was treated 
with 10 mM of DTT at 37 
o
C under stirring for 2 h. GPC was applied to 
monitor the change in the molecular weight profile. 0.5 mg/mL of poly(BAC-
AMPD)-g-PEG-g-Gd-DTPA in DI water was treated with 20 µM of GSH at 
37 
o
C under stirring for certain time. Small amount of the samples were taken 
for dynamic light scattering measurement. 
 
6.2.7. MRI T1 relaxivity measurement  
A multi-slice localization scan was used to acquire images in the transverse 





of the syringes containing the sample. The multi-slice images acquired were 
assessed to select slices with minimal heterogeneity and absence of bubbles. 
T1 mapping was carried out with a spin-echo sequence with multiple TIs: 31 
ms, 50 ms, 100 ms, 200 ms, 400 ms, 600 ms, 800 ms, 1000 ms, 1500 ms, 2000 
ms, 3500 ms and 9980 ms with  FOV = 56 × 75 mm, TE = 6.9 ms, TR = 
10000 ms, slice thickness of 2 mm and number of slices = 1. The data was 
analysed using Matlab and the T1 relaxivity calculated from homogenous 
regions within each sample using AMIDE as shown in Figure 6.7. Relaxivity, 
the gradient of the slope of relaxation rates as a function of the concentrations 
of the contrast agent, was then calculated. 
 
6.2.8. Measurements  
The molecular weight and distribution of poly(BAC-AMPD) was measured by 
gel permeation chromatography (GPC) with column and refractive index 
detector from Waters. The eluent was pH 4.5 acetate buffer solution with flow 




H nuclear magnetic resonance (NMR) characterization of the polymers were 
done by Bruker 400 MHz NMR spectrometer with methanol-d4 and deuterium 
oxide (D2O) as solvent. The number of Gd(III) complexed was measured 
using the Dual-view Optima 5300 DV inductively coupled plasma optical 
emission spectrometry (ICP-OES). The hydrodynamic size and CMC of 
micelles prepared were determined by Brookhaven dynamic lightering 
scattering (DLS) instrument at 90
o
 (632.8 nm) using NNLS analysis. The 
micelles were also viewed under the high resolution Philips CM300 





by dropping micelles solution onto a copper grid cover with carbon followed 
by drying in a desiccator. Then, the dried grid was left in 1% osmium oxide in 
heptane for 2 h. The MRI experiments were carried out on a 7T MRI 
(ClinScan, BrukerBiospin GmbH, Germany) with a 20 cm bore size and a high 
performance gradient and shim coil (gradient strength of 63 G/cm, slew rate of 
6300 T/m/s) interfaced to a Siemens console. A volume coil (diameter: 72 
mm) was used for RF transmit and receive. The samples were placed at the 
isocentre of the magnet/coil. 
 
6.3. Results and discussion 
6.3.1. Synthesis of poly(BAC-AMPD)-g-PEG-g-Gd-DTPA 
As shown in Scheme 6.1, poly(BAC-AMPD) was synthesized via Michael 
Addition polymerization of AMDP and an equimolar BAC in methanol. 





 amine >> 2
o
 amine (formed) [82,366], the 2
o
 amine (formed) 
participated in the polymerization process, which resulted in formation of 
poly(BAC-AMPD) with ~20% branching units determined via the 
13
C NMR 
spectrum seen in Figure 6.1 [77]. The poly(BAC-AMPD) obtained is soluble 
in methanol and DMSO, but insoluble in water. Figure 6.2a and 6.3a show the 
GPC profile of poly(BAC-AMPD) in pH 4.5 acetate buffer solution and 
1
H 
NMR spectrum of poly(BAC-AMPD) obtained in methanol-d4 respectively. 
The molecular weight distribution of poly(BAC-AMPD) is wide with PDI of 
2.6 which is reasonable for polymers obtained from multistage polymerization 














































C NMR of poly(BAC-AMPD) in methanol-d4. (See 









Figure 6.2. GPC spectra of poly(BAC-AMPD) incubated with 10 mM of DTT 
at 37 
o






























H NMR spectrum of a) poly(BAC-AMPD) in methanol-d4; 
b)poly(BAC-AMPD)-g-PEG in methanol-d4; c) poly(BAC-AMPD)-g-PEG in 
D2O; d) poly(BAC-AMPD)-g-PEG-g-DTPA in D2O with pH 5.5; e) 
poly(BAC-AMPD)-g-PEG-g-DTPA in D2O with pH 7. 
 
PEG was grafted to poly(BAC-AMPD) via forming urethane groups 
through the reaction between the secondary amines in the backbone of 
poly(BAC-AMPD). The feed molar ratio of PEG to the 2
o
 amine in 
poly(BAC-AMPD) was kept at 1.25 : 5 to control the amount of PEG grafted 
for keeping some of the secondary amines for further functionalization. The 
molar ratio of the grafted PEG and BAC-AMPD unit in poly(BAC-AMPD) 
was determined to be 1: 5 using equation E6.1: 
Molar ratio of PEG/BAC-AMPD = I4.20 / I1.29   (E6.1)                                  
Where I4.20 and I1.29are the integral intensities of the peaks at 4.20 ppm and 
1.29 ppm in Figure 6.2a, respectively. 























































































Figures 6.3b and 6.3c shows the 
1
H NMR spectrum of poly(BAC-
AMPD)-g-PEG in methanol-d4 and D2O, respectively. Compared to Figure 
6.3b, the peaks attributed to poly(BAC-AMPD) can still be observed but are 
noticeably broader. The relative peak intensity of the peaks in 
1
H NMR 
spectrum is related to the mobility of the protons, and a broad and less 
intensive peak of a proton is caused by lower mobility in the solution [77,425-
427]. Therefore the solubility of poly(BAC-AMPD) in aqueous solution is still 
not as good as in methanol, however, no species with a diameter higher than 
10 nm could be observed in aqueous solution of poly(BAC-AMPD)-g-PEG 
using DLS. 
DTPA was conjugated to poly(BAC-AMPD)-g-PEG via the reaction 
with the remaining secondary amines in poly(BAC-AMPD) to form amide 
bonds as illustrated in Scheme 6.1. Figure 6.3d shows the 
1
H NMR spectrum 
of poly(BAC-AMPD)-g-PEG-g-DTPA in D2O at pH 5.5. The grafting of 
DTPA is confirmed by the appearance of the characteristic peaks such as the 
peaks at 3.7 ppm attributed to DTPA [415,477]. However, the content of 
conjugated DTPA cannot be determined using 
1
H NMR due to the self-
assembly existed as discussed below.  
Poly(BAC-AMPD)-g-PEG-g-Gd-DTPA was obtained through 
chelating with Gd(III) ions. The content of Gd(III) ions was determined using 
ICP-OES, and the result indicates that 1.9 out of 5 units of BAC-AMPD were 
complexed with Gd(III) ions. The composition of  poly(BAC-AMPD)-g-PEG-






Table 6.1. Feed and actual molar ratio of                                                       
poly(BAC-AMPD)-g-PEG-g-Gd-DTPA 
 Poly(BAC-
AMPD) / PEG 
Poly(BAC-AMPD) / 
PEG / DTPA 
Poly(BAC-AMPD) /  
PEG / Gd(III) 
Feed ratio 5 / 1.25 5 / 1 / 20 5 / 1 / 4.2 
Actual ratio 5 / 1 - 5 / 1 / 1.9 
 
 
6.3.2. Self-assembly of poly(BAC-AMPD)-g-PEG-g-Gd-DTPA in aqueous 
solution  
Self-assembly of poly(BAC-AMPD)-g-PEG-g-Gd-DTPA occurred in aqueous 
solution. Figure 6.4 shows TEM images of the micelles formed from the self-
assembly of poly(BAC-AMPD)-g-PEG-g-Gd-DTPA with or without osmium 
oxide staining. Dark irregular regions can be observed in micelles without 
osmium oxide staining as shown in Figure 6.4a. These dark regions were 
confirmed to be rich in Gd(III) ions through energy dispersive X-ray 
spectroscopy. After stained with osmium oxide as shown in Figure 6.4b, the 
diameter of micelles was ca. 113 nm in dry state. The hydrodynamic size of 
the micelles in aqueous solution was determined to be ca. 188.1 ± 17.2 nm 
using DLS. The CMC of poly(BAC-AMPD)-g-PEG-g-Gd-DTPA in aqueous 
solution was determined to be ca. 60.2 µg/mL by plotting the average 
scattering intensity against the polymer concentrationas as illustrated in Figure 
6.5 [77,428]. 
The structure of the self-assembly of poly(BAC-AMPD)-g-PEG-g-Gd-
DTPA could not be investigated using 
1
H NMR due to the existence of 
Gd(III). However, the self-assembly profile of the precursor of poly(BAC-
AMPD)-g-PEG-g-DTPA could be investigated using 
1





Figure 6.3d, the integral intensities of the peaks attributed to protons of AMPD 
unit are reduced significantly in comparison with the peaks attributed to BAC 
unit, e.g., ratio of the integrals of peak t and n is 3.8 times greater in Figure 2d 
than 2c. Meanwhile, the peaks of PEG are still obvious. This reflects that the 
self-assembly leads to a restricted mobility of these segments containing 
AMPD. Therefore, the self-assembly should be due to the formation of the 
ionic complex between the cationic amines of AMPD and DTPA and the 
anionic carbonate groups of DTPA. The ionization degree of the amine and 
carboxylic acid depends on pH; and a perfect polyelectrolyte complex is 
formed between cationic polymer and anionic polymer with an equimolar ratio 
between cationic group and anionic group together with the same polymer 
length [484]. Here there are different types of amines and carboxylic acid 
which have different pKa values [485,486], therefore different ionization 
profiles of the amine and carboxylic acid exist and result in a complicated pH 
dependence of the ionic complex.  In comparison to Figure 6.3d, 
1
H NMR 
spectrum of the assembly at pH 7, shown in Figure 6.3e, reflects that the 
integral intensities of the attributed to DTPA are reduced in comparison with 
those BAC. After Gd(III) was introduced, the formation of ionic complex still 
can be formed with Gd(III) being involved, and the self-assembly of 
poly(BAC-AMPD)-g-PEG-g-Gd-DTPA should be composed of the ionic 
complex with PEG shells. 
The cytotoxicity of poly(BAC-AMPD)-g-PEG-g-Gd-DTPA was 
evaluated in MCF-7 and HepG2 cell lines. Low cytotoxicity was observed. Ca. 
80% and 90% of MCF-7 and HepG2 cells are still viable after incubation with 





















































Figure 6.5. Relationship between the average scattering intensity from DLS 
measurements and the concentration of poly(BAC-AMPD)-g-PEG-g-Gd-









Figure 6.6. in vitro cytotoxicity of micelles of poly(BAC-AMPD)-g-PEG-g-








6.3.3. Degradation of poly(BAC-AMPD)-g-PEG-g-Gd-DTPA  
The thiol-induced degradation of the backbone of poly(BAC-AMPD)-g-PEG-
g-Gd-DTPA occurs readily. As shown in Figure 6.2b, almost complete 
degradation of poly(BAC-AMPD) can be observed in pH 4.5 acetate buffer 
solution in the presence of 10 mM of DTT after 2 h at 37 
o
C. Due to the 
formation of micelles via self-assembly, thiol-induced degradation of 
poly(BAC-AMPD)-g-PEG-g-Gd-DTPA could not be monitored using GPC. 
Instead the degradation of the micelles of poly(BAC-AMPD)-g-PEG-g-Gd-
DTPA was monitored using DLS. 
  Figure 6.7 shows the change in the DLS profile of the micelles 
from 0.5 mg/mL of poly(BAC-AMPD)-g-PEG-g-Gd-DTPA in DI water at 37 
o
C in the presence of 20 µM of GSH which is close to the concentration of 
GSH in biological extracellular matrix. The scattering intensity decreases by 
15% in 15 minutes of incubation, and another 10% and 40% in 60 minutes and 
24 h respectively. From 0 h to 2h, no obvious change in the diameter of the 
micelles is observed. However, the increase in the diameter of the micelles 
becomes obvious, from ca. 206 nm at 2 h to ca. 512 nm at 24 h.  
 The micelles are composed of the ionic complex and PEG shells, and 
GSH can diffuse into the PEG shells more easily than into the ionic complex; 
hence the PEG segments are removed easily. When a part of the PEG shells is 
removed without leading to formation of aggregate, the light scattering 
intensity, which is dependent on the mass of the assembly formed, decreases. 
When more PEG shells is removed leading to the formation of aggregate of 
the ionic complex, the size of the assembly increases. The formation of ionic 





the inherent degradability of poly(BAC-AMPD) as shown in Figure 6.2 will 
ensure the degradability of the assembly of poly(BAC-AMPD)-g-PEG-g-Gd-
DTPA. 
Due to low concentration of GSH used, no significant change in 
scattering intensity and size can be observed after 24 h of incubation. Similar 
behaviour was observed in the degradation profile of the nanosize complex of 
disulfide-containing poly(amido amine)s and DNA in the presence of 10 µM 
of DTT [373]. Here the molar ratio of GSH / disulfide bond is only 1 / 25 and 
a plasma GSH concentration of 20 µM were adopted, an obvious degradation 
of the assembly of poly(BAC-AMPD)-g-PEG-g-Gd-DTPA could be observed. 
A fast degradation can be expected when ample thiol compound is presented 









Figure 6.7. Hydrodynamic size distribution of micelles of poly(BAC-AMPD)-
g-PEG-g-Gd-DTPA (0.2 mM of Gd(III)) with 20 µM of GSH. (Normalized 
intensity) 
 
6.3.4. Relaxivity of poly(BAC-AMPD)-g-PEG-g-Gd-DTPA 
To determine the r1 of the micelles of poly(BAC-AMPD)-g-PEG-g-Gd-
DTPA, the T1 of different Gd(III) concentrations were measured and plotted 






















) as seen in Figure 
6.8. The micelles have greater r1 than most small molecular Gd(III) based 







Figure 6.8. T1 relaxation time measured at each Gd(III) concentration of the 
micelles of poly(BAC-AMPD)-g-PEG-g-Gd-DTPA. 
 
6.3.5. Redox-responsive relaxivity of poly(BAC-AMPD)-g-PEG-g-Gd-
DTPA 
Although macromolecular Gd(III) based MRI contrast agents like the one 
describe above with high relaxivity can improve the sensitivity of disease 
diagnosis, they are unable to reflect the metabolic statues of the diseased 
tissues. Therefore, an interesting class of contrast agent known as activatable 
MRI contrast agent which exhibits a change in relaxivity value usually higher 
upon stimulation, is highly desired. For some of these contrast agents, they are 




 [489] and Fe
2+
 [490,491] which 
reveal the conditions of many cellular processes and metabolic mechanisms. 
Hypoxia conditions in many diseases like cancer and ischemic diseases can 
lead to variation in the pH of cellular environment [491]. There are MRI 






coordinated (q) [493-495], rate of proton exchange [496,497] or rotational 
correlation time (τr) [498], to achieve activatable relaxivity in tissues with 
abormal pH level. Activatable MRI contrast agent can also be tuned to react to 
enzymatic response [499,500]. Last but not least is the redox-responsive 
contrast agents, these agents are exceptionally useful in the diagnosis of 
diseases. Louie A.Y. and coworkers developed a series of Gd(III) based 
activatable agents which rely on the change in q. In their early effort, 
spirobenzopyran- and (dinitro)spirobenzopyran-Gd-DO3A displayed decrease 
in relaxivities upon stimulation by UV or UV/NADH respectively [501,502]. 
Instead of raising q in the stable closed ring (SP) isomeric form, the indoline 
part interrupted water coordination and sterically hindered the access of water 
molecules. However, further modification on the molecule facilitated the 
increase in q, resulting in the contrast agent to exhibit a reversible positive 
change in relaxivity upon activation [503]. On the other hand, work on Gd-
DO3A with thiol moiety demonstrated that through the reversible binding of 
thiol on cysteine-34 of human serum albumin, the contrast agent can exhibit 
an increase in relaxivity which was attributed to the reduced in τr [504,505]. 
As presented in the earlier paragraph, the micelles of poly(BAC-





to demonstrate the redox responsive relaxivity of the contrast agents, 5 mM of 
DTT was added to induce the change in r1 value. As expected, after DTT 





 which is a ca. 10% increase in the relaxivity. Since micelles incubated 
at 37 
o
C without DTT treatment, show r1 statistically similar to the value 





DTT reduction. As the redox interaction had no direct effect on the amines or 
carbonyls that coordinate the Gd(III) ions, the number of coordinated water 
molecules, value q, should stay the same before and after degradation, thus is 
not responsible for the change in relaxivity [494,495,499,506]. Therefore, it is 
likely that due to the degradation of the micelles of poly(BAC-AMPD)-g-
PEG-g-Gd-DTPA in the presence of DTT, the change in micellar structure and 
integrity facilitates proton exchange and increase the relaxivity. This 
preliminary result is highly promising and exciting, showing that the micelles 
of poly(BAC-AMPD)-g-PEG-g-Gd-DTPA is redox activatable. The increase 
in relaxivity upon redox stimulation allows the pinpoint and highlight of redox 











Figure 6.9. The change in relaxivity of micelles of poly(BAC-AMPD)-g-




























Table 6.2: Relaxivities of micelles of poly(BAC-AMPD)-g-PEG-g-Gd-DTPA 





Before incubation 5.90 ± 0.09 
After incubation without DTT 5.82 ± 0.05 
After incubation with 5mM DTT 6.48 ± 0.06 
 
6.4. Conclusions 
DTPA were conjugated to poly(BAC-AMPD)-g-PEG via the reaction with 2
o
 
amines of poly(BAC-AMPD) remained. A high payload of Gd(III) chelates 
was achieved by conjugation to 40% of BAC-AMPD unit of poly(BAC-
AMPD). Poly(BAC-AMPD)-g-PEG-g-Gd-DTPA could self-assemble to form 
micelles in aqueous solution due to electrostatic interactions between the 
cationic amines and anionic carbonate groups.  The micelles consist of the 
cores of ionic complex of DTPA/Gd-DTPA and poly(BAC-AMPD) and the 
PEG shell. With a low cytotoxicity, a readily realized thiol-induced 
degradability and a higher r1 poly(BAC-AMPD)-g-PEG-g-Gd-DTPA is a 







Redox-Responsive “Turn-on” Fluorescent Imaging 




Intracellular compartments of cells are much more reductive than the 
extracellular matrix, and the combined redox state of cellular redox couples, 
like GSH/GSSG which is often regarded as the major redox buffer, forms the 
redox environment [43,507]. Redox homeostasis is vital in many physiological 
functions like oxygen homeostasis, cell adhesion, immune response, apoptosis 
and the defence against free radical-induced oxidative stress [44-46]. 
Furthermore, in particularly, oxidative stress is closely linked to many diseases 
such as cancer, cardiovascular diseases, diabetes, neurological disorder, ageing 
[508-510] e.g., a high level of GSH in tumor is related to the resistance to 
therapies [50]. 
The cellular redox environment has been explored to develop better 
therapeutic and diagnostic approaches. Many types of redox-responsive 
systems have been fabricated for safe and efficient drug and gene delivery 
[43,64,77,373,507,511-513]. On the other hand, suitable methods to determine 
the cellular redox state are also being pursued. There are very few non-





-glutathione tracer in SPECT and isotope labelled GSH 





sensitivity [516,517]. Several procedures, such as spectromic assays and gas 
chromatography-mass spectroscopy (GC-MS), developed to quantify ex vivo 
GSH level [44], however, these methods are invasive and sensitive to 
artifactual oxidation and sample manipulation [518]. 
Fluorescence imaging technique, usually using fluorophores, can 
provide cost-effective and real time diagnosis of physiological processes at a 
molecular level [519-522]. Through using  “turn-on” fluorescent imaging 
probes activated by pH [523,524], enzyme [525-527], Zn
2+
 [528,529] and 
redox [530-534], the image contrast can be improved for the diagnosis of 
certain biological status due to an augmented signal to background ratio 
[11,535-538]. Fluorophores applied can be divided into two categories, i.e., 
with concentration quenching or aggregate caused quenching (ACQ) 
characteristic [519-535,536-539] or aggregate-induced emission (AIE) 
characteristic [540-542]. Fluorophores with ACQ characteristic can only be 
applied at a low concentration which will limit its applications. However, this 
disadvantage can be overcome by using fluorophores with AIE characteristic 
[540-542].
 
Redox-responsive fluorophores with ACQ characteristic have been 
investigated for imaging [532,543]. Redox “turn-on” fluorophore with AIE 
characteristic was also developed for the detection of thiol species [544], 
which is more promising in providing intense imaging, but it is not suitable for 
in vivo applications due to its poor biocompatibility including the poor water 
solubility and short circulation time in blood stream. One solution is to 
encapsulate fluorophore in suitable carriers such as polymers to form 





nanoparticles for biological fluorescence imaging, the polymer carrier adopted 
should be redox-responsive itself and preferably enhance the aggregation 
behaviours of the fluorophore with AIE characteristic. In this work, redox-
responsive amphiphilic poly(ethylene glycol) (PEG)- and cholesterol (CE)- 
conjugated poly(amido amine)s, poly(BAC-AMPD)-g-PEG-g-CE [62], is 
applied for the preparation of redox ‘turn-on” fluorescent nanoparticles with 
AIE characteristic. As shown in Scheme 7.1, the nanoparticles are produced 
by loading the fluorophore with redox “turn-on” AIE characteristic, TPE-MI, 
in the cores of the micelles of poly(BAC-AMPD)-g-PEG-g-CE. The PEG 
shells of the nanoparticles can promote penetration across the mucus 
membranes of many organs [273-278], prevent nonspecific proteins 
adsorption, provide long-circulation time in blood stream [279-284], and 
facilitate endocytosis [285]; and the cores  displays redox “turn-on” AIE 
characteristic with emission intensity increasing with GSH concentration. The 
redox ‘turn-on” fluorescence profile of the nanoparticles with AIE 
characteristic is demonstrated in MCF-7 and HepG2 cells. These features 
make the fluorescent nanoparticles developed here promising for more 





















7.2. Experimental section 
7.2.1. Materials 
TPE-MI and poly(BAC-AMPD)-g-PEG-g-CE were  prepared following the 
previous reports [77,544], respectively. L-glutathione (GSH) and chloroform-d 
from Sigma Aldrich were used as received. Dimethylsulfoxide (DMSO) and 
deuterium oxide (D2O) used in this study were purchased from Tedia and 
Cambridge Isotope Laboratories, Inc. respectively. MCF-7 (human breast 
adenocarcinoma cell line) and HepG2 (human hepatoma cell line) were 
obtained from American Type Culture Collection (ATCC, Rockville, MD). 
They were maintained in Dulbecco's modified eagle medium (DMEM, 
invitrogen) with 10% fetal bovine serum (FBS), 2 mM of glutamine, 100 
units/ml of penicillin and 100 µg/ml streptomycin at 37 C in an incubator 









7.2.2. Preparation of fluorescent nanoparticles 
9 mL of PBS was added at a rate of 0.25 mL/h to 1 mL of DMSO containing 
10 mg of poly(BAC-AMPD)-g-PEG-g-CE and 1 mg of TPE-MI using a 
syringe pump. The suspension formed was dialyzed using membrane with a 
molecular weight cutting-off of 1000 in PBS or deionized water to remove 
DMSO. After dialysis, any large TPE-MI aggregates were removed by 
filtration through a filter with a pore diameter of 0.45 µm. Sterile solvents and 
apparatus were used when the nanoparticles were prepared for cell works. 
To measure the content of TPE-MI, the fluorescent nanoparticles in 
aqueous solution was lyophilized, and a certain amount of the dried 
fluorescent nanoparticles was dissolved in chloroform-d for 
1
H NMR 
measurement. Using equation E7.1 and E7.2, the TPE-MI loading capacity 
was determined. 
Molar ratio of TPE-MI/CE = I7.02-7.09 / (I4.47 x 14)   (E7.1) 
Where I7.02-7.09 and I4.47 are the integral intensity of the peaks at 7.02-7.09 ppm 
and 4.47 ppm, respectively. 
Loading capacity (%) =  
MwTPE-MI loaded x VEq(E4.1) x 1.79 / (Mw(BAC-AMPD) x 4.3 + MwPEG x 1 + MwCE x 
1.79 + MwTPE-MI loaded x VEq(E4.1) x 1.79) x 100%   (E7.2) 
Where Veq(E7.1) is the molar ratio of TPE-MI / CE calculated in equation 
E7.1. 
 
7.2.3. Fluorescence measurement of GSH reacted nanoparticles 
A designed amount of GSH was added into 3 mL of buffer nanoparticles 
solution with certain concentration at 37
o





predetermined time interval, the fluorescence emission was measured under 
280 nm irradiation. 
 
7.2.4. in vitro cytotoxicity evaluation of samples 
Cytotoxicity of micelles of poly(BAC-AMPD)-g-PEG-g-CE and the 
nanoparticles were evaluated in MCF-7 and HepG2 cells. Viability of the cells 
was assessed by the standard thiazolyl blue [3-(4,5-dimethyliazolyl-2)-2,5-
diphenyl tetrazolium bromide] (MTT) assay. The cells were seeded in 96-well 
plates with a seeding density of 10,000 cells/well and were cultured in DMEM 
supplemented with 10% FBS and 1% penicillin-streptomycin solution in an 
incubator at 37 
o
C, 5% CO2, and 95% relative humidity. The cells were 
allowed to adhere to the well bottom upon overnight incubation. Then the 
medium was replaced with the sample solutions of different concentrations. 
Meanwhile, wells containing only cell culture medium were prepared as 
untreated controls. After 24 h, the medium containing samples was aspirated 
and the wells were washed with 1 ×PBS solution for two times to removed 
non-internalized sample. Then 100 μL of DMEM and 10 μL of MTT solution 
(5 mg/mL in 1 ×PBS solution) were added to the wells. After incubation for 4 
h at 37 
o
C, the solution was removed and the formazan precipitate was 
dissolved in 100 μL of DMSO. The absorbance intensity of the solution was 
then quantified spectrophotometrically using a microplate reader (TECAN 
SpectraFluor Plus) at 570 nm. Cell viability was expressed by the following 
equation: 





where Abssample was the absorbance for cells treated with samples, while 
Abscontroll was the absorbance for untreated control cells. All the tests were 
performed in multiples. 
 
7.2.5. Cellular imaging 
MCF-7 and HepG2 cells were seeded in 8 chamber borosilicate coverglass 
with a cell density of 5,000 cells/chamber and were cultured in DMEM 
supplemented with 10% FBS and 1% penicillin-streptomycin solution in an 
incubator at 37
o
C, 5% CO2, and 95% relative humidity. The cells were 
allowed to adhere to the chamber bottom upon overnight incubation. Then, the 
medium was replaced with the mixture (50% (v/v)) of DMEM and the buffer 
nanoparticles solution in 1 X PBS with final concentration of 0.2 mg/mL. At a 
predetermined time, the cells were imaged without removing the medium 
containing nanoparticles and fixation. As a control experiment, after 16 h of 
incubation with the nanoparticles, 5 mM of GSH was added to chambers 
followed by additional 6 h incubation. 
 
7.2.6. Measurements 
Nuclear magnetic resonance (NMR) spectra were obtained on a Bruker DPX 
400 MHz NMR spectrometer. A Brookhaven BIS200 laser light scattering 
system was used for dynamic light scattering measurements. The light source 
is a power adjustable vertically polarized 35 mW argon ion laser with a 
wavelength of 633 nm. The scattering angle was fixed at 90
 o
 for measuring 
the hydrodynamic radius (Rh) and the average scattering intensity. Rh values 





high resolution Philips CM300 transmission electron microscope (FEGTEM) 
at 300 kV, and the samples were prepared by dropping micelles suspension 
onto a copper grid cover with carbon followed by drying in a desiccator. Then, 
the dried grid was left in 1% osmium oxide in heptane for 2 h. Fluorescence 
emission spectra were recorded on a Perkin–Elmer LS55 Fluorescence 
Spectroscopy instrument fitted with a R928-sensitive sample photomultiplier. 
Confocal imaging was done with Olympus Fluoview FV1000 with excitation 
wavelength of 405 nm. 
 
7.3. Results and Discussion  
7.3.1. Characterization of fluorescent nanoparticles 
Suitable formulations such as encapsulation within PEG-conjugated lipid [15-
17] and bovine serum albumin (BSA) [18,19 ]or conjugation to chitosan [10] 
can improve the biocompatibility and functionality of AIE fluorophores. Here 
pH- and redox-responsive poly(BAC-AMPD)-g-PEG-g-CE [77] was applied 
for the encapsulation of the compound, TPE-MI [544],to prepare the redox 
‘turn-on” nanoparticles with AIE characteristic. The encapsulation was 
realized through self-assembly of amphiphilic poly(BAC-AMPD)-g-PEG-g-
CE in phosphate buffered solution in the presence of TPE-MI, with the 
hydrophobic TPE-MI being loaded in the cores of the formed micelles. Figure 
7.1A shows TEM images of the fluorescent nanoparticles obtained. The 
diameter of the nanoparticles was determined to be ca. 89 nm in dry state 
using TEM, and ca. 186.4 ± 14.7 nm in PBS buffer solution when measured 
using DLS. The content of TPE-MI in the nanoparticles is ca. 8% which was 
determined from 
1





chloroform-d as shown in Figure 7.1B(a). Figure 7.1B(b) shows the 
1
H NMR 
spectrum of the fluorescent nanoparticles in D2O. In comparison with Figure 
7.1B(a), the peaks attributed to TPE-MI is absent in Figure 7.1B(b). 
Meanwhile, only the peaks attributed to PEG at ca. 3.5 ppm can be observed, 
and the peaks attributed to CE and poly(BAC-AMPD) disappear. This 
indicates that the nanoparticles consist of hydrophilic PEG shells, and 
hydrophobic cores of poly(BAC-AMPD), CE and TPE-MI which are 
inaccessible to D2O [77,425-427]. The successful encapsulation of TPE-MI in 
the micelles of poly(BAC-AMPD)-g-PEG-g-CE is also confirmed by the 
changes in the fluorescence profile of TPE-MI after being encapsulated as 
described below. The cytotoxicity of the nanoparticles developed was 
evaluated in MCF-7 and HepG2 cells using MTT assay. As shown in Figure 
7.2, the nanoparticles show low cytotoxicity, with 80% of the cells still viable 







Figure 7.1. A) TEM image of the fluorescent nanoparticles stained with 
osmium oxide; B) 1H NMR spectra of a) the fluorescent nanoparticles in 
chloroform-d; b)the fluorescent nanoparticles in D2O; c) precipitate from PBS 
buffer solution of 0.3 mg/mL of the  fluorescent nanoparticles after reaction 

















Figure 7.2. in vitro cytotoxicity of micelles of poly(BAC-AMPD)-g-PEG-g-
CE and the fluorescent nanoparticles in MCF-7 and HepG2 cells. 
 
7.3.2. Redox “turn on” fluorescent behaviours of nanoparticles 
The nanoparticles can form a stable dispersion in PBS buffer solution as 
shown in Figure 7.3a because of the PEG shells and nanosize. The redox 
“turn-on” fluorescence profile of the nanoparticles in buffer solution was 
investigated in the presence of GSH. The interaction process of the 
nanoparticles with GSH should consist of the diffusion of GSH into the cores 
of the micelles, the degradation of poly(BAC-AMPD)-g-CE before reaching 
TPE-MI, and the reaction with TPE-MI to form TPE-MI-GSH. The redox-
induced degradation of the micelles of poly(BAC-AMPD)-g-PEG-g-CE 
resulted in formation of aggregates which precipitated in the PBS buffer 
solution [77]. Similarly redox-induced degradation of the fluorescent 
nanoparticles led to obvious precipitation as shown in Figure 7.3c after 
reaction with 2 mM of GSH. In comparison, a stable suspension of free TPE-
MI-GSH, from the reaction between free TPE-MI and GSH, in PBS buffer 
solution was formed as shown in Figure 7.3b. 
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precipitate formed consists of segments with a higher content of hydrophobic 
CE as shown in Figure 7.1B(c), and the peaks at ca. 7 ppm which correspond 










Figure 7.3. Photograph of PBS buffer solution of a) 0.3 mg/mL of fluorescent 
nanoparticles; b) free TPE-MI-GSH from 0.1 mg/mL of TPE-MI after reaction 
with 2 mM of GSH, and c) fluorescent nanoparticles (as shown in Figure 7.3a) 
after reaction with2 mM of  GSH for 2 h. 
 
Figure 7.4 shows the time dependent photoluminescence spectra of the 
PBS buffer solution of nanoparticles in the presence of 10 mM of GSH. The 
emission peaks are located at ca. 475 nm; and the emission intensity initially 
increases rapidly with time, but levels off after 60 minutes. This reflects that it 
takes time for GSH to diffuse into the cores of the micelles and degrade 
poly(BAC-AMPD)-g-CE before reacting with TPE-MI. TPE-MI is non-
fluorescent regardless of its aggregation state, however, the product of the 
reaction between TPE-MI and thiol group is fluorescent due to the restricted 
intramolecular rotation and  blockage of the non-radiative decay channels in 






of the reaction between GSH and TPE-MI, TPE-MI-GSH, might be in 
aggregates or dispersed in the precipitates composed of segments containing 











Figure 7.4. Time dependent emission spectra of PBS buffer solution of 0.1 
mg/mL of fluorescent nanoparticles after reaction with 10 mM of GSH at pH 
7. The time interval is 5 minutes. 
 
Considering the physiological condition where the amount of reduced 
thiols in the intracellular compartments is in excess, the nanoparticles should 
be the limiting agents in the reaction. As a result, the tissues redox 
environment cannot be differentiated if the concentrations of nanoparticles 
endocytosized by the cells are similar. However, before all the nanoparticles 
can react with reduced thiols, the amount of TPE-MI-thiol formed should be 
related to the diffusion rate of reduced thiols. A higher concentration of 
reduced thiols should lead to faster diffusion, which in turn results in 
formation of a higher amount of the fluorescent TPE-MI-thiol with a higher 
fluorescent intensity. Therefore, it is meaningful to investigate the 





































fluorescence profile of the nanoparticles before complete reaction with 
reduced thiols.  According to Figure 7.4, 15 minutes after treatment with 10 
mM of GSH is a suitable time point when a significant fluorescence intensity 
augment can already be observed. 
 
7.3.3. pH effect on fluorescent behaviours of nanoparticles 
The micelles of poly(BAC-AMPD)-g-PEG-g-CE is pH responsive due to the 
amino groups along the polymer backbone [77], so it can be expected that pH 
of the buffer solution of the nanoparticles will affect the fluorescence profile. 
Figure 7.5 shows the pH dependent emission spectra of aqueous solution of 
0.15 mg/mL of fluorescent nanoparticles after reaction with 10 mM of GSH 
for 15 minutes. When pH is changed from pH 3 to pH 8, the peaks remain at 
ca. 475 nm, but the fluorescence intensity varies. The highest emission 
intensity is observed at pH 7. The weaker intensity at pH 8 should be due to 
the slower diffusion of GSH into the less protonated and more hydrophobic 
cores of the nanoparticles. The emission intensity also decreases as the pH is 
lowered from 7 to 3. The increase in protonation degree of the amino groups is 
likely to cause a decline in aggregation density of the precipitate from the 
degradation of poly(BAC-AMPD)-g-CE, which should lower the restriction 























































Figure 7.5. pH dependent emission spectra of aqueous solution of 0.15 
mg/mL of fluorescent nanoparticles after reaction with 10 mM of GSH for 15 
minutes; and emission spectrum of aqueous solution mixture of 0.067 mg/mL 
of free TPE-MI and 0.23 mg/mL of the micelles of poly(BAC-AMPD)-g-
PEG-g-CE after reaction with 10 mM of GSH at pH 7 for 2 h. 
 
7.3.4. Evaluation of redox environment 
In a control experiment, an buffer solution of a mixture of 0.067 mg/mL of 
free TPE-MI and 0.23 mg/mL of the micelles of poly(BAC-AMPD)-g-PEG-g-
CE at pH 7 was treated with 10 mM of GSH for 2 h, and the fluorescence 
emission spectrum is also shown in Figure 7.5. The peak position of the 
emission is ca. 400 nm, which can be taken as a summation of the emissions 
of free TPE-MI-GSH and poly(BAC-AMPD)-g-PEG-g-CE (amino-containing 
polymers were reported to be fluorescent [377,546,547].) with the peaks at 
420 nm and 370 nm, respectivly as seen in Figure 7.6.In comparison, the 
emission peak of the fluorescent nanoparticles with TPE-MI encapsulated 
within the cores of the micelles shifts from 420 nm to 475 nm, and the 
fluorescence intensity of the nanoparticles containing 0.012 mg/mL of TPE-
MI is ca. 750 a. u. much higher than ca. 300 a. u. from 0.067 mg/mL of free 
TPE-MI. So the nanoparticles show more than 10 times higher emission 





might be due to a higher restriction on the intramolecular rotation of TPE-MI-
GSH trapped in the precipitate composed of segments containing extremely 
hydrophobic CE. This observation also confirms the encapsulation of TPE-MI 
in the cores of the micelles as other hydrophobic species [77]. 
While the redox- “turn-on” fluorescence property of the nanoparticles 
is advantageous in improving imaging contrast, it is equally attractive to be 
applicable for differentiation of cellular redox environment. Thus, the 
relationship between the fluorescence intensity of the nanoparticles with 
various GSH concentrations was investigated. Figure 7.7 shows the change in 
the emission intensity of the PBS buffer solution of nanoparticles at pH 7 after 
reaction with 10 µM to 10 mM of GSH, which is the in vivo GSH 
concentration range [43,507], for 15 minutes. It can be observed that the 
fluorescence intensity increases with GSH concentration, and the intensity 
obtained after reaction with 10 mM of GSH is ca. 3 times higher than that with 
10 µM of GSH. Under this condition, the amount of TPE-MI-GSH formed is 
dependent on the rate of GSH diffusion into the cores. A steeper concentration 
gradient should cause GSH to diffuse into the nanoparticles faster, resulting in 
the formation of a higher amount of TPE-MI-GSH. In this way, it is possible 


















Figure 7.6. Emission spectra of a) 10 mM GSH treated free TPE-MI dispersed 
in pH 7 PBS; b) PBS buffer micelle solution of poly(BAC-AMPD)-g-PEG-g-










Figure 7.7. [GSH] dependent emission spectra of PBS buffer solution of 0.2 
mg/mL of fluorescent nanoparticles at pH 7 after reaction with GSH for 15 
minutes. 
 
7.3.5. Enhanced cellular imaging 
Redox ‘turn-on” fluorescent behaviour of the fluorescent nanoparticles was 
evaluated in MCF-7 and HepG2 cells, which have a high intracellular GSH 
level [373]. Typical results are presented in Figures7.8 and 7.9. Figures 7.8a, 
7.8e, 7.8c and 7.8g illustrate the confocal microscopy images of MCF-7 and 












































































HepG2 cells incubated with the fluorescent nanoparticles for 22 h 
respectively. Note that the cells were imaged without removing the medium 
containing the nanoparticles and fixation. Figure 7.8a and 7.8c shows that only 
the fluorescence signal within the cytoplasm of live MCF-7 and HepG2 cells 
can be seen, and an obvious contrast between the intracellular compartments 
and the culture medium can observed. After the nanoparticles were 
endocytosized by the cells, the free reduced thiol-containing species diffused 
into the nanoparticles, degraded the cores and reacted with the encapsulated 
TPE-MI to form fluorescent species. In contrast, the concentration of free 
reduced thiol-containing species in the medium was so low that no redox- 
“turn-on” fluorescence could be observed from those nanoparticles that 
remained outside of the cells. However, when 5 mM of GSH was added into 
the medium after 16 h of incubation as positive control, the nanoparticles in 
the medium, either well dispersed or aggregated, became fluorescent as shown 
in Figures 7.8b and 7.8d. Since the MCF-7 and HepG2 cells incubated with 
5mM of GSH are still healthy and have the integrity of their cell membrane 
retained, the brightening of the background is should not be due to to the 



















Figure 7.8. Confocal microscopy imaging of live MCF-7(a,b,e,f) and HepG2 
(c,d,g,h) cells after incubation with the fluorescent nanoparticles for a,c,e,g) 22 
h; b,d,f,h) 16 h followed by additional 6 h incubation with 5 mM of GSH 









Figure 7.9. Confocal microscopy imaging of live MCF-7 (a,b,e,f) and HepG2 
(c,d,g,h) cells after incubation with the fluorescent nanoparticles for a,c,e,g) 6 




Redox-responsive nanoparicles with AIE characteristic are developed for 
achieving redox-responsive fluorescence imaging. The fluorescent 
nanoparticles are obtained by encapsulating redox-responsive fluorophores 







nanoparticles obtained are nanosize with PEG shells and have low cytotoxicity, 
and show redox “turn-on” fluorescence with AIE characteristic. The 
encapsulated TPE-MI displayed a higher efficiency and red shift in emission 
in comparison to free TPI-MI upon reaction with GSH. It took ca. 60 min for 
the fluorescent nanoparticles to reach the maximum intensity after reaction 
with 10 mM of GSH. Before reaching the maximum intensity, the 
fluorescence intensity is pH dependent with the highest intensity obtained at 
pH 7 within a range of pH 3 – 8; and it is important that the fluorescence 
intensity increases with GSH concentration, which make it possible to image 
the level of thiol species. The redox- “turn-on” fluorescence behaviour of the 
fluorescent nanoparticles with AIE characteristic was verified in MCF-7 and 
HepG2 cells. The fluorescent nanoparticles provided obvious imaging contrast 
between the intracellular compartments and extracellular matrix. These 
features make the fluorescent probes promising for bioimaging with a high 
contrast and differentiation of cellular redox environment. The in vivo 








Conclusions and Future Recommendations 
 
8.1. Conclusions 
In general, linear, branched, and hyperbranched redox-responsive poly(amido 
amine)s are obtained, and thereon delivery systems developed have been 
demonstrated to be promising for safe and efficient delivery of anti-cancer 
drug, DOX, preparation of safe macromolecular MRI contrast agents, and 
fluorescence imaging agents to provide imaging with improved contrast and 
indication of redox level. Further, the following key points can be concluded: 
 Linear poly(BAC-AMPD) was produced by applying a mixture of 40% 
methanol and 60% DMSO (v/v) as a solvent for Michael Addition 
polymerization of trifunctional amine, AMPD,  with an equimolar 
diacrylamide, BAC. Amphiphilic poly(BAC-AMPD)-g-PEG-g-CE was 
obtained by conjugating PEG and cholesterol onto the linear poly(BAC-
AMPD) through reactions with the 2
o
 amine groups. Self-assembly of 
poly(BAC-AMPD)-g-PEG-g-CE in aqueous solution formed micelles with 
PEG shells and cores composed of poly(BAC-AMPD) and CE. DOX 
could be successfully loaded into the micelles, and DOX loaded micelles 
showed pH- and redox-responsive drug release and could also form redox-
induced aggregates. These factors contribute to the higher efficacy of the 
DOX loaded micelles of poly(BAC-AMPD)-g-PEG-g-CE in killing cancer 
cells than free drug. The biodegradability and high efficacy of DOX 





CE promising for preparation of drug delivery system for safe and efficient 
cancer chemotherapy. 
 Vinyl terminated hyperbranched poly(amido amimes) was synthesized via 
Michael addition polymerization of AMDP with double molar of BAC in 
ethanol. After converting the terminal vinyl groups to primary amines via 
reaction with excess AMPD, PEG was conjugated to form hyperbranched 
poly(BAC2-AMPD1)-PEG. pH- and redox-responsive micelles with PEG 
shells and hydrophobic cores of poly(BAC2-AMPD1) can be formed via 
self-assembly of hyperbranched poly(BAC2-AMPD1)-PEG in aqueous 
solution. In comparison with linear and 20% branched poly(BAC-AMPD)-
g-PEG, hyperbranched poly(BAC2-AMPD1)-PEG formed the largest 
micelles with the highest DOX loading capacity and loading efficiency. In 
terms of DOX release profile, more DOX were released at pH 5 and with 
10 mM GSH. Endocytosis of micelles and DOX loaded micelles of 
hyperbranched poly(BAC2-AMPD1)-PEG was readily realized by HepG2 
and MCF-7 regardless of GSH level, but a lower GSH level in HepG2 
might result in a slower degradation of the micelles. However, differing 
GSH level shows unnoticeable effects on the degradation profiles of the 
micelles in MCF-7 cells. Imaging and quantifying the DOX levels and 
distribution in HepG2 and MCF-7 cells indicate that significant amount of 
DOX can be located within the nucleus. In comparison with free DOX-
HCl, DOX-loaded micelles of hyperbranched poly(BAC2-AMPD1)-PEG 
displays a lower and comparable cytotoxicity in HepG2 and MCF-7 cells, 





 DTPA were conjugated to poly(BAC-AMPD)-g-PEG via the reaction with 
2
o
 amines of poly(BAC-AMPD) remained. A high payload of Gd(III) 
chelates was achieved by conjugation to 40% of BAC-AMPD unit of 
poly(BAC-AMPD). Poly(BAC-AMPD)-g-PEG-g-Gd-DTPA could self-
assemble to form micelles in aqueous solution due to electrostatic 
interactions between the cationic amines and anionic carbonate groups.  
The micelles consist of the cores of ionic complex of DTPA/Gd-DTPA 
and poly(BAC-AMPD) and the PEG shell. With a low cytotoxicity, a 
readily realized thiol-induced degradability and a higher r1 poly(BAC-
AMPD)-g-PEG-g-Gd-DTPA is a promising T1 contrast agent for 
producing better MRI imaging with lower side effects. 
 Redox-responsive nanoparicles with AIE characteristic are developed for 
achieving redox-responsive fluorescence imaging. The fluorescent 
nanoparticles are obtained by encapsulating redox-responsive fluorophores 
with AIE characteristic in redox responsive polymers via self-assembly. 
The nanoparticles obtained are nanosize with PEG shells and have low 
cytotoxicity, and show redox “turn-on” fluorescence with AIE 
characteristic. The encapsulated TPE-MI displayed a higher efficiency and 
red shift in emission in comparison to free TPI-MI upon reaction with 
GSH. It took ca. 60 min for the fluorescent nanoparticles to reach the 
maximum intensity after reaction with 10 mM of GSH. Before reaching 
the maximum intensity, the fluorescence intensity is pH dependent with 
the highest intensity obtained at pH 7 within a range of pH 3 – 8; and it is 
important that the fluorescence intensity increases with GSH concentration, 





on” fluorescence behaviour of the fluorescent nanoparticles with AIE 
characteristic was verified in MCF-7 and HepG2 cells. The fluorescent 
nanoparticles provided obvious imaging contrast between the intracellular 
compartments and extracellular matrix. These features make the 
fluorescent probes promising for bioimaging with a high contrast and 
differentiation of cellular redox environment. The in vivo applications will 
be investigated. 
 
8.2. Future recommendations 
Although the PEG- and cholesterol- grafted linear poly(BAC-AMPD) based 
DOX delivery system discussed in chapter 4 is highly stable and more 
effective in killing cancer cells than free DOX-HCl, it has relatively low drug 
loading capacity and has a very slow DOX release rate after the initial burst 
release which may not be suitable for some treatment. Therefore, these are 
some suggestions which may be able to overcome these issues. 
 As mentioned in chapter 5, the loading capacity of a delivery system is 
affected by a few factors and one of them is the compatibility of the 
hydrophobic polymer/molecules and the drugs used. Therefore, to improve 
the loading capacity of this system, a variety of hydrophobic 
polymers/molecules, ranging from long linear ones like C12 alky chains, or 
small compact hydrophobic molecules like phenylalanine and aromatic 
molecules, can be tested to solubilize the drugs within the micelles core. 
This work can be very tedious but with the right hydrophobic 






 As for hastening the DOX release rate, similarly the hydrophobic content 
of the amphiphilic polymer can be altered. Either grafting lesser number of 
cholesterol or substitute cholesterol with slight lesser hydrophobic 
molecules like C8 alky chain. This reduced in hydrophobicity might 
decrease the attraction of DOX and allow faster release. 
Although the above suggestions might overcome the issue of low drug 
loading capacity and slow DOX release, the change in the hydrophobic 
component might also alter the degradation characteristic of the system which 
is the formation of aggregate upon degradation, a property that can be useful 
in killing cancer cells. 
 
The hyperbranched poly(BAC2-AMPD1)-PEG based delivery system 
in chapter 5 has a higher DOX loading capacity and can release all of its 
loaded DOX in a considerable rate but the cytotoxicity of the system is not 
ideal. 
 Since the cytotoxicity of a system depends heavily both on the drug release 
profile and cellular uptake of the system, improvement can be made in this 
area. Clearly shown in the result in chapter 5, the DOX loaded micelles 
upon stimulated is able to fully release its loaded DOX in 72 h. Thus, the 
likely possible reason for its low cytotoxicity is its poor cellular uptake and 
this can be improved by conjugating the system with targeting ligands and 
cell penetrating peptides. For example, arginine-glycine-aspartic acid 
(RGD) peptide is well known for its high and specific affinity for αvβ3-
integrin which are over-expressed in endothelial cells during angiogenesis 





to be rapidly taken by tumor due to its over-expressed glucose transporters 
while cell penetrating peptides facilitate the endocytosis of the 
nanoparticles by the cells. With numerous primary amines available, 
conjugation processes like using NHS esters and imidoesters reaction or 
even condensation with carboxylic acids to form amide bonds can be done 
easily. 
 Furthermore, it also interesting to investigate how the amphiphilic 
polymers, which are very unlike conventional linear diblock polymers in 
term of structure, conform to form micelles with core/shell structure. 
 For the hyperbranched poly(amido amine)s, besides self-assembling into 
micelles, it is possible to form unimolecular micelles. Unlike conventional 
micelles where many polymer chains self-assemble to form one micelle, 
unimolecular micelles do not face stability/dissociation issue which is 
commonly associated to polymeric or surfactant micelles under certain 
conditions like high salt and low polymer concentration. As the 
hyperbranched poly(amido amine)s is insoluble in water, the 
hydrophilicity of the polymer must be improved via reaction with water 
soluble monomer like N,N-methylenebis(acrylamide). With well-
proportioned ratio, the resulting hyperbranched poly(amido amine)s is 
water soluble and still degradable. Making use of the plentiful surface 
amines, moieties with different functions like targeting ligands (as 
mentioned above), cell penetrating peptides, fluorescence dyes and Gd(III) 
chelates can be conjugated. Furthermore, with structural voids present, 
drugs still can be loaded, thus achieving multiple functional capabilities. 





hyperbranched poly(amido amine)s synthesized. More optimum 
polymerization conditions must be explored to narrow the polydispersity 
of the polymer. 
 
The redox-induced biodegradable macromolecular MRI contrast agent 
in chapter 6 has shown to be able to degrade in the biological extracellular 
conditions. However, to improve the system, more works can be done. 
 The r1 value of this system is not high enough when compared with many 
macromolecular MRI contrast agent. A possible reason is the 
complexation of the cationic AMPD and the anionic DTPA might have 
repel water molecules from the Gd(III) ions. Therefore, different methods 
can be employed to ensure the Gd-DTPA is located on the surface of the 
micelles instead of within the micelles. One such method is via 
nanoprecipitation. With hydrophobic interaction as the driving force for 
the self-assembly, the Gd-DTPA which is water soluble will be forced to 
the outer region of the micelles. 
 In chapter 6.3.5, the redox-induced biodegradable macromolecular MRI 
contrasat agent has shown to have redox-responsive relaxivity. However, 
the increase in relaxivity is not sufficient. Therefore to improve this, a 
practical approach is to lower the initial r1 of the contrast agent and a 
possible way is to increase the hydrophobicity of the polymer to expel 
more water molecules out of the micellar core where most of the Gd(III) 
ions are located. Thus, reducing the number of water molecules 






Although the redox-responsive bioimaging agent mentioned in chapter 
7 can enhance imaging contrast and has to potential to differentiate redox 
environment, the wavelengths that it can be excited and it emits is not suitable 
to in vivo imaging.  
 For maximum tissue penetration, radiation in the near infra-red (NIR) 
region is often mentioned and used in in vivo fluorescence imaging. 
Therefore, to make this system for practical for clinical use, like imaging 
of sub-surface tissue, the encapsulation of suitable dye to form NIR 
bioimaging agent is needed. 
 Furthermore, like mentioned earlier the redox-responsive bioimaging agent 
can also be conjugated with targeting ligand or cell-penetrating peptides to 
improve cellular uptake. This allows high concentration of fluorescent 
nanoparticles to accumulate in targeted tissue and thus can further improve 
imaging contrast. 
 
More applications of poly(amido amine)s can also be explored in the 
area of gene delivery. A popular and common approach to delivery gene is to 
complex negatively charged gene to positively charged polymers, an prime 
example is poly(ethylenimine) (PEI). Since poly(amido amine)s have 
numerous amount of amine groups, the polymers might be a suitable polymer 
candidate for gene delivery. Furthermore, the presence of disulfide bonds in 
the polymers can aid in the release of gene in nucleus where the level of GSH 
is significant high. 
Besides gene delivery, the anti-bacterial properties of poly(amido 





helps the polymers to get adsorbed and diffuse through the bacterial cell wall 
which are usually negatively charged. Then, the polymers can reach the cell 
membrane and disrupt its integrity. 
Here, the poly(amido amine)s developed  have been demonstrated in 
both drug delivery and imaging applications. On the basis of these 
understanding, theranostic systems which combine diagnosis and treatment in 
one platform can also be developed. A theranostic system from linear, 
branched and hyperbranched poly(BAC-AMPD) can be fabricated by 
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